INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND Complete Specifications Accepted 57 by jizhen1947

VIEWS: 128 PAGES: 49

									                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


            Complete Specifications Accepted                                   (57) Disclosed is a pharmaceutical composition including about 2.5 mg
                                                                                loratadine, or a corresponding amount in the form of a suitable salt thereof,
                                                                                together with a hydroxy-alpha-[(methylamino)methyl]-benzenemethanol
Copies of the specification and drawings (if any) can be obtained               such as phenylephrine, or a suitable salt thereof, for use in a method of
from the IPONZ website www.iponz.govt.nz.                                       treating upper respiratory/mucosal congestion by administering to a pa-
                                                                                tient four times a day. Also disclosed is a container containing a syrup
At any time within 3 months from the date of issue of this Journal, any         including loratadine and phenylephrine, or suitable salts thereof, at con-
person interested may give notice of opposition to the grant of a patent on     centrations suitable for administration of about 2.5 mg loratadine and
any of the applications relating to the accepted complete specification         about 8 to 10 mg phenylephrine per unit dose, the container including
shown hereunder, by filing form 15 in duplicate accompanied by a state-         instructions to administer an amount of syrup that will deliver about 2.5
ment of the case in duplicate and a fee of $300 plus GST where applica-         mg loratadine and about 8 to 10 mg phenylephrine per unit dose 4 times
ble, provided that if an application for extension on form 16 is made within    a day. Also disclosed theuse of the above in the treatment of upper
the said 3 months, the Commissioner may extend the prescribed period            respiratory mucosal congestion.
for opposition to 4 months from the date of issue of this Journal. The
                                                                               Divisional filed as 582107
grounds for giving notice of opposition are specified in section 21 of the
Act, and prospective opponents should also refer to regulations 48 to 56
of the Patents Regulations 1954.
                                                                               (21) 541972       (22) 26 Feb 2004
                                                                               (54) A furnace, its method of operation and control
                                                                               (86) PCT/GB2004/000781            (87) WO2004/076924
(21) 530775      (22) 1 Aug 2002                                               (51) IPC2010.01:F27B7/12,42,20,06,36; C22B9/16; F23G5/20
(54) Frozen product of unleached or little leached minced fish meat            (71) PLATINUM CONTROLS LIMITED
(86) PCT/JP2002/07866            (87) WO2003/013280                            (72) Evans, Thomas Hudson;
(51) IPC2010.01:A23L1/325; A23B4/08,20; A23L3/3409                             (31) 03 0304306           (32) 26 Feb 2003        (33) GB
(71) Nippon Suisan Kaisha, Ltd.                                                (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
(72) Mizuguchi, Toru; Okita, Takaaki; Mori, Takashi; Onuki, Hiroyuki;          Wellington 6011, New Zealand
(31) 01 237368 (32) 6 Aug 2001          (33) JP                                (57) A furnace (10), its method of operation and control. The furnace over-
(74) Freehills Patent & Trade Mark Attorneys, Level 43, 101 Collins Street,     comes problems associated with existing furnaces by improving the re-
Melbourne, Victoria 3000, Australia                                             covery rate of waste metal. In a preferred embodiment the furnace com-
(57) The disclosure relates to a method to provide a frozen product of          prises a cylindrical body of constant internal diameter. The furnace body
 unleached or little leached meat of a fish which has been usually taken        (12) is mounted on a frame (15) pivoted to a ground members (16a,
 after leaching. Also disclosed is fish meat in which iron in vivo, iron-       16b), the furnace body is adapted to be reclined or inclined or at various
 containing substances and/or reductants in vivo have been oxidized.            angles; a burner (30) to heat the furnace, and a door (19a, 19b) for seal-
 Additionally disclosed is a frozen product of unleached or little leached      ing an open end (14). As the internal walls of the furnace body are of a
 fish meat prepared by using minced fish meat or minced and dehydrated          constant diameter, it is no longer necessary to incline the furnace to such
 fish meat as a starting material, adding one or more freeze-denaturation       a degree in order to pour molten metal, because there is no narrow neck
 inhibitors thereto and preventing the decomposition of trimethylamine-N-       (which previously acted like a weir). In a preferred embodiment combus-
 oxide due to oxidation. The disclosure also relates to a frozen product of     tion air is routed through the door hinge to the burner. As a result the air/
 unleached or little leached fish meat which is prepared by bringing the        fuel delivery system has gas tight rotary and elbow joints is attached to
 above-described fish meat into contact with oxygen by stirring to thereby      the furnace and tilts and moves with the furnace. An artificial intelligence
 prevent the decomposition of trimethylarnine-N-oxide and adding a freeze       system monitors process variables and controls the operation of the fur-
 denaturation inhibitor followed by freezing and a frozen product of            nace.
 unleached or little leached fish meat prepared by adding a salt and stir-
 ring in the stirring stage also the ground fish meat products prepared
 therefrom.


(21) 541921      (22) 2 Feb 2004
(54) Polymer conjugates of mutated neublastin
(86) PCT/US2004/002763          (87) WO2004/069176
(51) IPC2010.01:C07K1/00; C07K14/475
(71) Biogen Idec MA Inc.
(72) Sah, Dinah Wen-Yee; Pepinsky, R Blake; Boriack-Sjodin, Paula Ann;
Miller, Stephan S; Rossomando, Anthony; Silvian, Laura;
(31) 03 356264 (32) 31 Jan 2003         (33) US
(74) CULLEN & CO, Level 32, 239 George Street, Brisbane, QLD 4001,
Australia
(57) Disclosed is a neublastin polypeptide which is at least 80% identical
 to amino acids 8-113 of SEQ ID NO:1 and which contains a substitution
 of one or more of the arginine at positions 48, 49, or 51 with a glutamic
 acid residue.
Divisional filed as 581460


(21) 541960      (22) 17 Jun 2005
(54) Novel pharmaceutical composition and its use in a method for treat-
ment of patients with upper respiratory mucosal congestion
(86) PCT/NZ2005/000132          (87) WO2006/135254
(51) IPC2010.01:A61K31/445,135; A61P11/02
(71) AFT Pharmaceuticals Limited                                               (21) 542174     (22) 5 Feb 2004
(72) Atkinson, Hartley Campbell;                                               (54) Quality control method for article and oxygen detecting agent for use
(31)     (32) 17 Jun 2005       (33) NZ                                        therein
(74) A J PIETRAS & CO, Level 2, Gibson Sheat Centre, 1 Margaret Street,        (86) PCT/JP2004/001216          (87) WO2004/077049
Lower Hutt, New Zealand                                                        (51) IPC2010.01:G01N31/00,22




PATENT OFFICE JOURNAL 1567                                      29 January 2010                                 Page 58 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(71) POWDERTECH CO., LTD.                                                        (21) 544048       (22) 29 Jun 2004
(72) Kodama, Ryuichi; Tamura, Minoru; Shinohara, Kazuhiko; Endo,                 (54) Improved stopper capsules and method for production thereof
Hiroshi; Wada, Toshitaka; Tanaka, Shigeru;                                       (86) PCT/FR2004/001667             (87) WO2005/012126
(31) 03 031409 (32) 7 Feb 2003              (33) JP                              (51) IPC2010.01:B65D41/62,34,04; B21D51/50; B65D49/04
(31) 03 392517 (32) 21 Nov 2003             (33) JP                              (71) ALCAN PACKAGING CAPSULES
(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-                     (72) Granger, Jacques;
tre, 342 Lambton Quay, Wellington 6011, New Zealand                              (31) 03 0308027            (32) 2 Jul 2003 (33) FR
(57) Disclosed is a quality control method for an article, characterized in      (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
  that it comprises forming a set of an article and an oxygen detecting          Wellington 6011, New Zealand
  agent having a specific sensitivity corresponding to the kind of the article   (57) Method for manufacturing a capsule 1 designed as a screw stopper
  and conditions for quality control, and carrying out the quality control of     for a container, comprising two parts fixed together in rotation and axially
  the article by utilizing the change in the colour of the an oxygen detecting    by an assembly means an insert 3, made of plastic material and a shell
  agent caused by the detection of the concentration of the oxygen enter-         4 comprising an outer head and a metallic or metal based outer skirt 41
  ing into the oxygen detecting agent by the elapse of a specific period of       having height H, the outer skirt 41 comprising at least a substantially
  time corresponding to the kind of the article and conditions for quality        cylindrical part having a height HI, a diameter D1 adapted to the neck 2
  control; and an oxygen detecting agent, characterized in that it com-           of the container, and at least a radially expanded part with height H2,
  prises a main part thereof and a film which seals and covers said main          inscribed in a circle with diameter D2 > Dl, wherein a blank of the outer
  part and has a specific oxygen permeability and/or carbon dioxide per-          part is formed from a metallic strip material, the blank comprising a skirt
  meability corresponding to the kind of the article to be controlled with        with diameter D1 and height H' > H, the blank is transformed into the
  respect to its quality and conditions for quality control.                      shell 4 by making the radially expanded part, wherein the skirt of the
                                                                                  blank is locally radially expanded over the height H2, by following the
                                                                                  following steps a) the blank is placed in a shaping die forming a radial
(21) 542719      (22) 2 Apr 2004                                                  cavity with a profile similar to the profile of the radially expanded part, b)
(54) Ultraviolet-responsive thin film photocatalyst and application thereof       an expandable punch is introduced in the blank and is axially compressed
(86) PCT/JP2004/004874             (87) WO2004/089544                             by an axial displacement of a slide, in such a manner that the expandable
(51) IPC2010.01:B01J35/02,04; B01J19/12; A61L9/00; F24F1/00; A61L9/               punch radially expands and forces a part of the skirt radially into contact
20                                                                                with the inner wall of the radial cavity, the expandable punch having a
(71) Photo-Catalytic Materials Inc.                                               sloping wall, such that the local radial expansion progressively extends
(72) Taoda, Hiroshi; Kato, Shigekazu;                                             in the axial direction, the expandable punch starting to apply its action at
(31) 03 102343 (32) 4 Apr 2003(33) JP                                             the bottom part of the blank closest to the outer head.
(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
tre, 342 Lambton Quay, Wellington 6011, New Zealand
(57) Disclosed is a transparent thin film titanium dioxide photocatalyst,
  wherein: the titanium dioxide photocatalyst forming the thin film is com-
  prised of crystals of a size of 5 nm to 50 nm, the crystals include spindle-
  shaped crystals, the adsorption wavelength peak of the photocatalyst is
  in the range of 200 nm to 300 nm, and the film thickness is 0.1 to 1.0
  microns.


(21) 543533      (22) 21 May 2004
(54) Method and device for the maintenance of a lift or escalator installa-
tion
(86) PCT/CH2004/00307             (87) WO2004/106211
(51) IPC2010.01:B66B5/00,02
(71) INVENTIO AG
(72) Engel, Werner; Weiss, Markus;
(31) 03 03405388         (32) 28 May 2003         (33) EP
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
(57) Disclosed is a method and a device for the maintenance of a lift or
  escalator installation (12), the device comprising an interface (14) for
  connecting to a control system (19) of the installation, a display and op-
  erating device (21) for displaying operating parameters or for inputting
  control commands, and a data connection device (15, 17) for establish-
  ing a data connection (16) to a central maintenance unit (13). Data and
  parameters of the installation stored in the central maintenance unit can
  be transmitted to the display and operating unit by means of the data
  connection, following an identification check. A failure log specifying op-
  erating errors and/or the replacement parts necessary for correcting the
  operating error can be produced according to a comparison between
  operating parameters and transmitted data and parameters.
                                                                                 (21) 544112     (22) 19 May 2004
                                                                                 (54) Novel pyridopyrazines and use thereof as kinase modulators
                                                                                 (86) PCT/EP2004/005388          (87) WO2004/104003
                                                                                 (51) IPC2010.01:C07D471/04; A61K31/4985; A61P17/14; A61P9/10;
                                                                                 A61P35/00
                                                                                 (71) Zentaris GmbH
                                                                                 (72) Gunther, Eckhard; Claus, Eckhard; Seipelt, Irene; Rapp, Ulf R; Wixler,
                                                                                 Ludmilla;
                                                                                 (31) 03 0323345         (32) 23 May 2003       (33) DE
                                                                                 (31) 04 04022383        (32) 6 May 2004        (33) DE
                                                                                 (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
                                                                                 tre, 342 Lambton Quay, Wellington 6011, New Zealand




 PATENT OFFICE JOURNAL 1567                                        29 January 2010                                  Page 59 |BACK TO CONTENT
                                  INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(57) The disclosure relates to pyrido[2,3-b]pyrazine derivatives of general    closed is the use of the compound as an inhibitor of a serine protease,
 formula (I), the production thereof and the use thereof as medicaments,       such as HCV NS3 protease. Also disclosed is a method of eliminating or
 especially for the treatment of malignant and other diseases based on         reducing HCV contamination of a biological sample or medical or labora-
 pathological cell proliferations, wherein the variables shown in formula      tory equipment comprising contacting the object with a composition con-
 (I) are as defined in the specification.                                      taining the compound.




(21) 544304      (22) 6 Jul 2004
(54) 2-Methylene-19-nor-20(S)-25-methyl-1alpha-hydroxycalciferol and its
uses
(86) PCT/US2004/021563           (87) WO2005/011706
(51) IPC2010.01:A61K31/59; C07C401/00; A61P3/14; A61P19/10;
A61P35/02,00; A61P17/06; C07C13/45
(71) Wisconsin Alumni Research Foundation
(72) Deluca, Hector F; Grzywacz, Pawel K;
(31) 03 613201 (32) 3 Jul 2003 (33) US
(31) 03 657533 (32) 8 Sep 2003          (33) US                               (21) 545186     (22) 16 Jul 2004
(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-                  (54) Process for treating waste water containing soluble phosphorous
tre, 342 Lambton Quay, Wellington 6011, New Zealand                           (86) PCT/AU2004/000965           (87) WO2005/007585
(57) Disclosed is a compound of formula (I) where Y1 and Y2, which may        (51) IPC2010.01:C02F1/58,52
  be the same or different, are each selected from the group consisting of    (71) Magnesium Tech Pty Ltd
  hydrogen and a hydroxy-protecting group.                                    (72) O’Brien, Errol William;
Also disclosed is the use of the above compound in the manufacture of a       (31) 03 903646 (32) 16 Jul 2003           (33) AU
  medicament for treating metabolic bone disease where it is desired to       (74) JAMES & WELLS, Level 12, KPMG Centre, 85 Alexandra Street,
  maintain or increase bone mass, treating psoriasis, or treating a cancer-   Hamilton, New Zealand
  ous disease.                                                                (57) A process for treating waste water which contains soluble phospho-
                                                                               rous and which comprises a solid component and a liquid component is
                                                                               disclosed, wherein the process includes the step of reacting soluble phos-
                                                                               phorous from the solid and liquid components with a source of magne-
                                                                               sium ions under reaction conditions to produce a phosphorous contain-
                                                                               ing precipitate. Preferably, the step of reacting the soluble phosphorous
                                                                               with a source of magnesium ions may be carried out in the presence of
                                                                               greater than 20ppm ammonia.


                                                                              (21) 545231      (22) 25 Aug 2004
                                                                              (54) Antioxidant sensor, methods and compositions
                                                                              (86) PCT/US2004/027644            (87) WO2005/022116
                                                                              (51) IPC2010.01:G01N21/64
                                                                              (71) MANNATECH, INC.
                                                                              (72) Mcanalley, Bill H; Vennum, Eileen P; Mcanalley, Shayne A; Koepke,
                                                                              Michael C;
                                                                              (31) 03 648047 (32) 26 Aug 2003           (33) US
                                                                              (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                              Wellington 6011, New Zealand
(21) 544789       (22) 16 Jul 2004                                            (57) The disclosure relates to an apparatus and method for detecting di-
(54) Dithia-azaspiro-nonane and decane derivatives as inhibitors of ser-       rectly the antioxidant activity of both lipophobic anti-oxidants that uses
ine proteases                                                                  an oxygen radical sensitive molecule in fluid communication with a sam-
(86) PCT/US2004/023054            (87) WO2005/007681                           ple in a solvent/water/surfactant mixture; wherein the oxygen sensor con-
                                                                               currently detects the effect of both lipophilic and lipophobic anti-oxidants
(51) IPC2010.01:C07K5/10; A61K38/04; A61P31/12; C07D207/12,16;                 in the solvent/water/surfactant mixture on the oxygen sensor.
C07D403/12; C07D241/24; A61K31/401; C07D495/10; A61K31/385,407
                                                                              Divisional filed as 577993
(71) Vertex Pharmaceuticals Incorporated
(72) Britt, Shawn D; Cottrell, Kevin M; Perni, Robert B; Pitlik, Janos;
(31) 03 488535 (32) 18 Jul 2003          (33) US                              (21) 545397     (22) 26 Aug 2004
(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-                  (54) Oxygen scavenger compositions derived from isophthalic acid and/or
tre, 342 Lambton Quay, Wellington 6011, New Zealand                           terephthalic acid monomers or derivatives thereof
(57) Disclosed is a compound of formula I, or a pharmaceutically accept-      (86) PCT/US2004/025597         (87) WO2005/030854
  able salt thereof, wherein X and X’ may form a ring as shown, and wherein
                                                                              (51) IPC2010.01:C08K5/09; C09K15/04; A23L3/3436; B32B27/18;
  the other substituents are as described in the specification. Also dis-
                                                                              C08L67/02




PATENT OFFICE JOURNAL 1567                                      29 January 2010                                Page 60 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(71) CRYOVAC, INC.
(72) Ebner, Cynthia Louise; Matthews, Andrew E; Millwood, Terry O;
(31) 03 649703 (32) 28 Aug 2003          (33) US
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand
(57) Disclosed is an oxygen scavenger composition that includes mer units
  that have at least one cycloalkenyl group or functionality and, further,       (21) 545542      (22) 9 Aug 2004
  has mer units de-rived from isophthalic acid or terephthalic acid or cer-      (54) Entrapped stem cells and uses thereof
  tain derivatives thereof, wherein the mer units are as defined in the speci-   (86) PCT/US2004/025713           (87) WO2005/026320
  fication. The oxygen scavenger composition has been found to act as an         (51) IPC2010.01:A61K48/00; C12N5/071; A01N63/02; A61K9/14; C12N5/
  oxygen scavenger under both ambient and refrigeration conditions, to           00,02
  be compatible with conventional film forming packaging materials, to in-       (71) THE ROGOSIN INSTITUTE
  hibit undesirable oligomer formation and oxidation by-product formation,       (72) Conn, Bryan; Smith, Barry; Rubin, Albert L; Stenzel, Kurt;
  and to be readily formable and processable using conventional film form-       (31) 03 655275 (32) 4 Sep 2003           (33) US
  ing equipment. A film and laminated product having said oxygen scaven-         (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
  ger composition are also disclosed.                                            Wellington 6011, New Zealand
                                                                                 (57) Provided is a method for inhibiting proliferation of at least a portion of
                                                                                   a non-entrapped cell population, comprising culturing said cell popula-
(21) 545398      (22) 26 Aug 2004                                                  tion in the presence of a composition of matter comprising a sample of
(54) Oxygen scavenger block copolymers and compositions                            human stem cells entrapped in a biocompatible, selectively permeable
(86) PCT/US2004/025596           (87) WO2005/023911                                structure, wherein the human stem cells are selected from the group
(51) IPC2010.01:C08J5/18; B01J20/26                                                consisting of non-embryonic human stem cells, pluripotent human stem
(71) CRYOVAC, INC.                                                                 cells and non-totipotent human stem cell lines. The cells to be treated
(72) Ebner, Cynthia L; Berrier, Authur L;                                          may be stem cells or cancer cells of various types and from the same or
(31) 03 649747 (32) 28 Aug 2003         (33) US                                    different species than the entrapped cell population. Further provided is
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,           a method of use of a conditioned medium obtained by a similar process.
Wellington 6011, New Zealand                                                     Divisional filed as 577865
(57) Disclosed is an oxygen scavenger composition comprising a transi-
 tion metal salt, compound or complex and a block co-polymer having at
 least one block including a polyester condensation polymer segment              (21) 545549       (22) 12 May 2004
 having cycloalkenyl group(s) or functionality directly or indirectly bonded     (54) Diffuser disk for LCD applications, method for the production and use
 to the polymer chain of said block, and having at least one second block        thereof
 including a polymer segment of a thermoplastic, film forming material.          (86) PCT/EP2004/005058             (87) WO2005/022245
 The block copolymer has been found to act as an oxygen scavenger                (51) IPC2010.01:G02F1/1335; G02B5/02; G03B21/62,60
 agent under both ambient and refrigerated conditions, to be compatible          (71) Evonik Rohm GmbH
 with conventional film forming packaging materials, and to provide com-         (72) Parusel, Markus; Schmidt, Jann; Groothues, Herbert;
 positions exhibiting low tack which can be readily formed and processed         (31) 03 0336130           (32) 4 Aug 2003           (33) DE
 using conventional film forming equipment. A packaging material, such
 as a film or laminated product suitable for packaging applications, can         (74) SPRUSON & FERGUSON, St Martins Tower, Level 35, 31 Market
 include the oxygen scavenger composition.                                       Street, Sydney, New South Wales 2000, Australia
                                                                                 (57) The disclosure relates to a process for producing a diffuser sheet for
                                                                                   LCD applications, comprising at least one light-diffusing polymethyl meth-
                                                                                   acrylate layer, which has a polymethyl methacrylate matrix and 0.5 % by
(21) 545495        (22) 2 Sep 2004
                                                                                   weight to 59.5 % by weight, with regard to the weight of the light-diffusing
(54) Use of modified cyclosporins for the treatment of Hepatitis C and             polymethyl methacrylate layer, of spherical diffusing particles (A), which
HCV disorders                                                                      have an average particle size V50 ranging from 0.1 to 40 micrometer
(86) PCT/EP2004/009804             (87) WO2005/021028                              and a refractive index difference from the polymethyl methacrylate ma-
(51) IPC2010.01:A61K38/13; A61P31/14                                               trix ranging from 0.02 to 0.2, and 0.5 % by weight to 59.5 % by weight,
(71) Novartis AG                                                                   with regard to the weight of the light-diffusing polymethyl methacrylate
(72) Hijikata, Makoto; Shimotohno, Kunitada; Watashi, Koichi;                      layer, of spherical particles (B), which have an average particle size V50
(31) 03 0320638            (32) 3 Sep 2003       (33) GB                           ranging from 10 to 150 micrometer and a refractive index difference from
(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-                       the polymethyl methacrylate matrix ranging from 0 to 0.2, whereby the
tre, 342 Lambton Quay, Wellington 6011, New Zealand                                total concentration of the spherical diffusing particles (A); and particles
(57) Disclosed is the use of a cyclosporin in the preparation of a pharma-         (B) ranges from 1 to 60 % by weight with regard to the weight of the light-
  ceutical composition for preventing or treating Hepatitis C infections or        diffusing polymethyl methacrylate layer, and the spherical diffusion parti-
  HCV induced disorders, wherein the cyclosporin (i) binds to human                cles (A) and the spherical particles (B) have a different average particle
  recombinant cyclophilin with a binding ratio of less than 0.7; and (ii) has      size V50, wherein the transmittance of the diffuser sheet is in the range
  an activity in the Mixed Lymphocyte Reaction of not more than 5% that of         and its diffusion coefficient factor (scattering power) is greater than 0.3,
  cyclosporin A. The cyclosporin is a compound of formula 1a in which:             wherein the ratio of the square of the average surface roughness of the
                                                                                   polymethyl methacrylate layer Rz to the third power of the size of the
W’       is MeBmt, dihydro-MeBmt or 8'-hydroxy-MeBmt;
                                                                                   spherical particles (B) RZ2 /DPB3 is in the range of 0.0009 to 0.0900
X        is alpha-Abu, Val, Thr, Nva or O-methyl threonine (MeOThr);               (micrometer)-1, wherein said process comprises the step of extruding a
R'       is Sar, (D)-MeSer, (D)-MeAla, or (D)-MeSer(Oacetyl);                      moulding composition encompassing 20 polymethyl methacrylate, spheri-
Y'       is MeLeu, y-hydroxy-MeLeu, Melle, MeVal, MeThr, MeAla, Mealle,            cal scattering particles (A) and spherical particles (B).
  MeaThr; N-ethyIVal, N-ethyille, N-ethyIThr, N-ethyIPhe, N-ethylTyr, N-
  ethyIThr(Oacetyl)
Z        is Val, Leu, MeVal or MeLeu; and                                        (21) 545657     (22) 21 Aug 2004
Q'       is MeLeu, y-hydroxy-MeLeu or MeAla.                                     (54) 5-substituted-alkylaminopyrazole derivatives as pesticides
or a pharmaceutically acceptable salt thereof. Further disclosed is the use      (86) PCT/EP2004/009376          (87) WO2005/023775
  of the cyclosporin as described above in combination with a co-agent           (51) IPC2010.01:C07D231/44; C07D401/04; A01N43/56
  selected from an agent having anti-HCV properties, an anti-viral agent,        (71) MERIAL LIMITED
  an inhibitor of HCV-encoded factors, an anti-fibrotic agent, an immune
                                                                                 (72) Chou, David Teh-Wei; Knauf, Werner; Doller, Uwe; Seeger, Karl;
  modulating agent or a S1P receptor agonist in the preparation of a phar-
  maceutical composition.                                                        (31) 03 03019619        (32) 4 Sep 2003        (33) EP
                                                                                 (74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand




 PATENT OFFICE JOURNAL 1567                                        29 January 2010                                  Page 61 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(57) Disclosed are 5-substiuted-alkylaminopyrazole derivatives of
 formula (I) that are useful as pesticides for controlling pests, wherein:
 R1 is CSNH2;
 W is C-halogen, or Cl;
 R2 is H or Cl;
 R3 is CF3, OCF3 or SF4;
 X is F or Cl;
 and wherein the remaining substituents are as defined in the specifica-
 tion.
 Also disclosed are processes for their preparation, compositions
 thereof, and their use for the control of pests (including arthropods and
 helminths).




(21) 545720      (22) 8 Jul 2005
(54) Anti-glypican 3 antibody
(86) PCT/JP2005/013103           (87) WO2006/006693
(51) IPC2010.01:C07K16/18; C12N15/09; A61K39/395; A61P1/16;                     (21) 545862     (22) 18 Aug 2004
A61P35/00; C07K14/47; C12P21/08                                                 (54) 2-Methylene-19-nor-vitamin D2 compounds
(71) CHUGAI SEIYAKU KABUSHIKI KAISHA                                            (86) PCT/US2004/026925           (87) WO2005/018658
(72) Nakano, Kiyotaka; Yoshino, Takeshi; Nezu, Jun-ichi; Tsunoda, Hiroyuki;     (51) IPC2010.01:A61K31/59; A61K38/00; A61P37/00; A61P35/02; A61P19/
Igawa, Tomoyuki; Konishi, Hiroko; Tanaka, Megumi; Sugo, Izumi; Kawai,           08; A61P17/06; C07C13/465
Shigeto; Ishiguro, Takahiro; Kinoshita, Yasuko;                                 (71) Wisconsin Alumni Research Foundation
(31) 04 203637 (32) 9 Jul 2004 (33) JP                                          (72) Deluca, Hector F; Sicinski, Rafal R; Gowlugari, Sumithra;
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,        (31) 03 496415 (32) 20 Aug 2003         (33) US
Wellington 6011, New Zealand                                                    (74) SPRUSON & FERGUSON, St Martins Tower, Level 35, 31 Market
(57) Provides are specified anti-glypican 3 antibodies, corresponding           Street, Sydney, New South Wales 2000, Australia
  polynucleotides, which are useful as anticancer agents. Also provided         (57) Disclosed is a compound of formula (IA) or (IB), a pharmaceutically
  are methods of producing the antibodies.                                        acceptable salt of the compound, or a mixture thereof.
Divisional filed as 579543                                                      Also disclosed is the use of the above compound in the manufacture of a
                                                                                  medicament for the treatment of bone diseases, psoriasis, leukaemia,
                                                                                  colon cancer, breast cancer or prostate cancer or automimmune dis-
(21) 545739      (22) 17 Sep 2004                                                 eases or disorders.
(54) Process for enantioselective synthesis of single enantiomers of
modafinil by asymmetric oxidation
(86) PCT/IB2004/003026           (87) WO2005/028428
(51) IPC2010.01:C07C315/02; C07C327/28
(71) CEPHALON FRANCE
(72) Rebiere, Francois; Duret, Gerard; Prat, Laurence;
(31) 03 507089 (32) 1 Oct 2003          (33) US
(31) 03 03292312         (32) 19 Sep 2003        (33) EP
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand
(57) Disclosed is a method for preparing a sulphoxide compound of for-
 mula (I) either as a single enantiomer or in an enantiomerically enriched
 form wherein the substituents are disclosed in the specification compris-
 ing the steps of contacting a pro-chiral sulphide of formula (II) wherein
 the substituents are disclosed in the specification with a metal chiral lig-
 and complex, selected from a titanium, zirconium, manganese or vana-
 dium chiral ligand complex, an organic base and an oxidising agent in an
 organic solvent; and optionally isolating the obtained sulphoxide of for-
 mula (I).



PATENT OFFICE JOURNAL 1567                                       29 January 2010                               Page 62 |BACK TO CONTENT
                                  INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


                                                                              (31) 04 0407538           (32) 7 Jul 2004 (33) FR
                                                                              (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                              Wellington 6011, New Zealand
                                                                              (57) A process for forming part of an anode for the production of aluminium
                                                                                by fused bath electrolysis is disclosed. This forms an anode material that
                                                                                has improved thermo-mechanical properties. The part is made from a
                                                                                cermet comprising at least one metallic oxide with spinel structure and at
                                                                                least one metallic phase. A powder containing at least one mixed oxide
                                                                                with spinel structure and a metal, present in the form of cations, is pre-
                                                                                pared. The metal is wholly or partly reduced, so as to form all or part of
                                                                                the metallic phase. The reduction operation is carried out at least partly
                                                                                using a powder of a carbonaceous material. A mixture containing the
                                                                                prepared powder and a binder is then shaped to form the part by
                                                                                compaction of the mixture, which then goes through a debinding opera-
                                                                                tion, then a sintering operation.


                                                                              (21) 546070       (22) 23 Aug 2004
                                                                              (54) Mitoquinone derivatives used as mitochondrially targeted antioxidants
                                                                              (86) PCT/NZ2004/000196              (87) WO2005/019232
                                                                              (51) IPC2010.01:C07F9/54; A61K33/42
(21) 545884      (22) 13 Sep 2004                                             (71) ANTIPODEAN PHARMACEUTICALS, INC.
(54) Treating and/or preventing urinary incontinence using prodrugs of        (72) Taylor, Kenneth Martin; Smith, Robin;
GABA analogs
                                                                              (31) 03 527800 (32) 22 Aug 2003              (33) NZ
(86) PCT/US2004/029944           (87) WO2005/025562
                                                                              (31) 03 529153 (32) 23 Oct 2003              (33) NZ
(51) IPC2010.01:A61K31/195
                                                                              (31) 04 533556 (32) 14 Jun 2004              (33) NZ
(71) XENOPORT, INC.
                                                                              (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
(72) Barrett, Ronald W;                                                       Wellington 6011, New Zealand
(31) 03 502585 (32) 11 Sep 2003           (33) US                             (57) Disclosed is a compound comprising a lipophilic cationic moiety se-
(31) 03 505210 (32) 22 Sep 2003           (33) US                               lected from the group consisting of triphenylphosphonium,
(31) 03 512288 (32) 17 Oct 2003           (33) US                               tribenzylammonium and phosphonium, linked by a linking moiety which
(31) 04 538748 (32) 22 Jan 2004           (33) US                               comprises (C)n wherein n is an integer from 2 to 20 to an antioxidant
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,        moiety selected fro the group consisting of a quinine or a quinol, vitamin
Wellington 6011, New Zealand                                                    E or a vitamin E derivative, a fullerene, butylated hydroxyanisole, butylated
(57) Disclosed herein is the use of 1-{[(a-isobutanoyloxyethoxy)carbonyl]-      hydroxytoluene, 5,5dimethylpyrroline-N-oxide, tert-butylnitrosobenzene,
  aminomethyl}-1-cyclohexane acetic acid in the preparation of a medica-        tert-nitrosobenzene and alpha-phenyl-tert-butylnitrone and an anionic
  ment for treating or preventing urinary incontinence in a patient. The        complement is not (i) an alkyl sulfonate, (ii) an aryl sulfonate, (iii)
  medicament is formulated as a sustained release oral dosage form to           hexafluroantimonate, hexafluoroarsenate or hexafluorophosphate, (iv)
  provide an amount of from 300 to 3600 mg gabapentin equivalents/day,          trifluoromethanesulfonate, tetraphenylborate, tetra(perfluorophenyl)borate
  and wherein the sustained release oral dosage form is formulated to           or another tetrafluoroborate or (v) a halide, wherein the cationic species
  release 1-{[(a-isobutanoyloxyethoxy)carbonyl]-aminomethyl}-1-                 is capable of mitochondrially targeting the antioxidant species, and the
  cyclohexane acetic acid gradually over a period of at least about 6 hours     salt form is chemically stable and/or the anionic complement does not
  after administration of the dosage form, thereby providing a therapeutic      exhibit reactivity against the antioxidant moiety, the cationic moiety or the
  concentration of gabapentin in the plasma of the patient.                     linking moiety.
Divisional filed as 579392
                                                                              (21) 546156       (22) 20 Sep 2004
(21) 545968     (22) 17 Sep 2004                                              (54) Methods and systems for improving a search ranking using location
(54) KID3 and KID3 antibodies that bind thereto                               awareness
(86) PCT/US2004/030676           (87) WO2005/028498                           (86) PCT/US2004/030982             (87) WO2005/031613
(51) IPC2010.01:C07K16/00; A61K39/395; C07H21/04; G01N33/53                   (51) IPC2010.01:G06F17/30
(71) Raven biotechnologies, inc.                                              (71) Google Inc.
(72) Liang, Tony W; Loo, Deryk T; Xu, Xiaolin;                                (72) Ge, Xianping; Parmar, Abhishek; Singhal, Amitabh K; Smith, Adam;
(31) 03 504441 (32) 18 Sep 2003           (33) US                             Egnor, Daniel; Hamon Reid, Elizabeth;
(74) F B RICE & CO, Level 23, 44 Market Street, Sydney, New South             (31) 03 505095 (32) 22 Sep 2003            (33) US
Wales 2000, Australia                                                         (31) 03 748656 (32) 31 Dec 2003            (33) US
(57) Provided is a substantially purified immunoglobulin polypeptide or an    (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
 epitope-binding fragment thereof that specifically binds to an epitope on    tre, 342 Lambton Quay, Wellington 6011, New Zealand
 the surface of a cancer cell, wherein the epitope is recognized by the       (57) A method for ordering documents, comprises receiving a search query;
 monoclonal antibody expressed by the hybridoma having ATCC Deposit             determining a geographic location associated with the query; determin-
 No. PTA-4860. Further provided are uses of the polypeptide in the manu-        ing a topic associated with the query; identifying a set of documents based,
 facture of medicaments for various cancers.                                    at least in part, on the query; determining a location sensitivity factor
                                                                                associated with the topic and determining a topical score for each docu-
                                                                                ment in the set of documents. The topical score is based at least in part
(21) 546066      (22) 5 Oct 2004                                                on the query. The method further comprises for each document in the
(54) Inert anode produced using metal oxides and a binder that goes though      set of documents determining a measure of distance between a geo-
a debinding step and a sintering step                                           graphic location associated with the document and the geographic loca-
                                                                                tion associated with the query and then generating a distance score based,
(86) PCT/FR2004/002509           (87) WO2005/035813
                                                                                at least in part, on the measure of distance and the location sensitivity
(51) IPC2010.01:C22C29/12; B22F3/00; C25C3/12                                   factor for each document in the set of documents. The location sensitiv-
(71) ALUMINIUM PECHINEY                                                         ity factor controls an amount that the distance score changes as a func-
(72) Tailhades, Phillippe; Rousset, Abel; Gabriel, Armand; Baco-Carles,         tion of the measure of distance. The method further comprises ordering
Valerie; Laurent, Veronique; Lamaze, Airy-Pierre;                               the set of documents as a function of both the topical scores for the set
(31) 03 0311700          (32) 7 Oct 2003       (33) FR




 PATENT OFFICE JOURNAL 1567                                     29 January 2010                                  Page 63 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


 of documents and the distance scores for the set of documents. Also
 disclosed is a system comprising means such as a server operable to
 execute the above described method. A method for presenting adver-
 tisements relevant to a target document comprises analyzing a target
 document to identify a topic for the target document and a geographic
 location associated with the target document; identifying targeting infor-
 mation for a plurality of advertisements; comparing the targeting infor-
 mation to the topic to identify a set of potential advertisements; determin-
 ing a distance score for at least one advertisement in the set of potential
 advertisements using a geographic location of an advertiser location
 associated with the one advertisement and the geographic location as-
 sociated with the target document; ordering the set of potential adver-
 tisements based, at least in part, on the distance score of the at least
 one advertisement; and presenting at least some of the ordered set of
 potential advertisements within the target document.




                                                                                (21) 546309     (22) 1 Oct 2004
                                                                                (54) Arylalkylcarbamate derivatives, preparation method thereof and use
                                                                                of same in therapeutics
                                                                                (86) PCT/FR2004/002486            (87) WO2005/033066
                                                                                (51) IPC2010.01:C07C271/48; C07D271/10; C07C271/42; A61K31/27
                                                                                (71) SANOFI-AVENTIS
                                                                                (72) Abouabdellah, Ahmed; Almario Garcia, Antonio;
                                                                                (31) 03 0311615         (32) 3 Oct 2003             (33) FR
                                                                                (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                                Wellington 6011, New Zealand
                                                                                (57) Disclosed are compounds of formula (I), wherein the substituents are
                                                                                 as defined in the specification. The compounds are useful for the pre-
                                                                                 vention or treatment of acute or chronic pain, dizziness, vomiting, nau-
                                                                                 sea, eating disorders, neurological and psychiatric pathologies, acute or
                                                                                 chronic neurodegenerative diseases, epilepsy, sleep disorders, cardio-
                                                                                 vascular diseases, renal ischemia, cancers, immune system disorders,
                                                                                 allergic diseases, parasitic, viral or bacterial infectious diseases, inflam-
                                                                                 matory diseases, osteoporosis, ocular conditions, pulmonary conditions,
                                                                                 gastrointestinal diseases or urinary incontinence.




(21) 546291      (22) 20 Sep 2004
(54) Polyether brevetoxin derivatives as a treatment for cystic fibrosis,       (21) 546333       (22) 29 Oct 2004
mucociliary dysfunction, and pulmonary diseases                                 (54) A lifting assembly for a shutter to allow continuous casting
(86) PCT/US2004/030637            (87) WO2005/028482                            (86) PCT/AU2004/001497            (87) WO2005/042876
(51) IPC2010.01:C07D493/22; A61K31/366,352; A61P11/12                           (51) IPC2010.01:E04G11/28,22,24; E04G17/00
(71) UNIVERSITY OF NORTH CAROLINA AT WILMINGTON                                 (71) FORMULA ONE SELF DRIVING SCREENS PTY LTD
(72) Baden, Daniel G; William, Abraham M; Bourdelais, Andrea J;                 (72) Brazis, Paul; Totsenberger, Rudiger; Rosati, Emilio;
(31) 03 504665 (32) 19 Sep 2003          (33) US                                (31) 03 905947 (32) 29 Oct 2003           (33) AU
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,        (74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
Wellington 6011, New Zealand                                                    (57) A lifting assembly which comprises a pair of support frames (10), a
(57) Disclosed is a compound of formula (I), or a pharmaceutically accept-       shutter (21) slidably engaged to and between the support frames and a
 able salt thereof, wherein A is CH=CH, CH2-CH2, or epoxide, Y is C=CH2,         hoist (15, 20) operatively connected between at least one of the support
 C(O), CH(CH3), or CH2, R1 is H or C(O)CH3, OR2 and OR3 may to-                  frames and the shutter to cause movement of the shutter with respect to
 gether be a six membered ring, and wherein the other substituents are           the support frames. In use, when the support frames are fixed, opera-
 as described in the specification.                                              tion of the hoist causes movement of the shutter, and when the shutter is
Also disclosed is the use of the compound for treating diseases associ-          fixed, operation of the hoist causes movement of the support frames.
 ated with decreased mucus transport, chronic airway obstruction, asthma,        The assembly is suited to the continuous casting of a structure by the
 pulmonary disease, pulmonary infection, or cystic fibrosis.                     shutter as it provides means for separately and independently moving
                                                                                 the shutter in relation to the support frame or moving the support frame
                                                                                 in relation to a stationary shutter.




PATENT OFFICE JOURNAL 1567                                       29 January 2010                                 Page 64 |BACK TO CONTENT
                                  INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


                                                                               pha-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic
                                                                               acid has characteristic absorption peaks at 7.0 deg. ± 0.3 deg., 8.2deg. ±
                                                                               0.3 deg.., 10.5 deg. ± 0.3 deg., 12.8 deg. ± 0.3 deg., 14.9 deg. ± 0.3 deg.,
                                                                               and 16.4 deg. ± 0.3 deg. in an X-ray powder diffractogram using Cu Ka
                                                                               radiation. This crystalline form of a gamma-aminobutyric acid analog may
                                                                               be suitable for treating epilepsy, pain, depression, anxiety, psychosis,
                                                                               faintness attacks, hypokinesia, cranial disorders, neurodegenerative dis-
                                                                               orders, panic, inflammatory disease, insomnia, gastrointestinal disorders,
                                                                               hot flashes, restless legs syndrome, urinary incontinence or ethanol with-
                                                                               drawal syndrome.
                                                                              Divisional filed as 582040


                                                                              (21) 546557      (22) 15 Oct 2004
                                                                              (54) Therapeutic agent for mesothelioma comprising interleukin-6
                                                                              (86) PCT/JP2004/015674           (87) WO2005/037315
                                                                              (51) IPC2010.01:A61K45/00; A61K39/395; A61P35/00
                                                                              (71) CHUGAI SEIYAKU KABUSHIKI KAISHA
                                                                              (72) Nishimoto, Norihiro; Kishimoto, Tadamitsu; Adachi, Yasuo; Takayama,
                                                                              Koichi;
                                                                              (31) 03 358152 (32) 17 Oct 2003            (33) JP
                                                                              (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                              Wellington 6011, New Zealand
                                                                              (57) Provided is the use of an anti-interleukin-6 (IL-6) receptor antibody for
                                                                                production of a medicament for treating mesothelioma. Further provided
                                                                                are uses of specified similar antibodies.
(21) 546365       (22) 8 Oct 2004
(54) Modulators of ATP-binding cassette transporters containing cycloalkyl    (21) 546634      (22) 4 Nov 2004
or pyranyl groups                                                             (54) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
(86) PCT/US2004/033367           (87) WO2005/035514                           (86) PCT/EP2004/012475           (87) WO2005/047284
(51) IPC2010.01:C07D307/87; C07D213/82; C07D231/14; C07D209/42;               (51) IPC2010.01:C07D471/04; A61P29/00; A61K31/519; C07D239:00;
C07D215/56; C07D333/32; C07D237/28; C07D231/56; C07C307/00;                   C07D221:00
A61K31/335,38,435,495,40,41                                                   (71) F. Hoffmann-La Roche AG
(71) Vertex Pharmaceuticals Incorporated                                      (72) Goldstein, David Michael;
(72) Hadida Ruah, Sara S; Miller, Mark T; Hamilton, Matthew; Grootenhuis,     (31) 03 519789 (32) 13 Nov 2003           (33) US
Peter D J; Singh, Ashvani K;
                                                                              (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
(31) 03 509642 (32) 8 Oct 2003           (33) US                              Wellington 6011, New Zealand
(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-                  (57) Disclosed is a compound of formula (I), wherein the substituents are
tre, 342 Lambton Quay, Wellington 6011, New Zealand                            as defined in the specification. Also disclosed are processes for prepar-
(57) Disclosed is a compound of formula II wherein A is C(O) or SO2, RC        ing the compounds which are p38 kinase modulators useful in the treat-
  and RD taken together form a 3-6 membered cycloalkyl ring; RB is (C1-        ment of arthritis, Crohn’s disease, irritable bowel syndrome, adult respi-
  C4)alkoxy, Z is a substituent of formula I and wherein the rest of the       ratory distress syndrome, chronic obstructive pulmonary disease and
  substituents are disclosed within the specification.                         Alzheimer's disease.
Also disclosed is the modulating ARP- Binding Cassette (ABC) transporter
  activity of the compound of formula II.




                                                                              (21) 546663      (22) 8 Oct 2004
                                                                              (54) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
                                                                              (86) PCT/US2004/033238           (87) WO2005/037860
                                                                              (51) IPC2010.01:A61K38/07; C07K5/08,10
(21) 546381      (22) 14 Oct 2004                                             (71) Vertex Pharmaceuticals Incorporated
(54) Crystalline form of gamma-aminobutyric acid analog                       (72) Cottrell, Kevin M; Perni, Robert B; Pitlik, Janos;
(86) PCT/US2004/033979          (87) WO2005/037784                            (31) 03 510156 (32) 10 Oct 2003           (33) US
(51) IPC2010.01:A61K9/20,22,26; C07C271/22                                    (31) 03 513768 (32) 23 Oct 2003           (33) US
(71) XENOPORT, INC.                                                           (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
(72) Estrada, Tono; Raillard, Stephen P.; Frauenfelder, Christine; Zacher,    tre, 342 Lambton Quay, Wellington 6011, New Zealand
Uwe;                                                                          (57) Disclosed is a compound of formula I or a pharmaceutically accept-
(31) 03 511287 (32) 14 Oct 2003        (33) US                                  able salt or mixture thereof wherein the substituents are disclosed within
                                                                                the specification.
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand                                                  Also disclosed is the use of the above compound in the production of a
                                                                                composition for inhibiting the activity of a serine protease such as HCV
(57) A pharmaceutical composition comprising crystalline 1-{[(alpha-
                                                                                NS3 protease.
 isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid
 and a pharmaceutically acceptable vehicle wherein the crystalline 1-{[(al-   Divisional filed as 582190




 PATENT OFFICE JOURNAL 1567                                     29 January 2010                                 Page 65 |BACK TO CONTENT
                                  INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


                                                                               resin, at least one hardener and one or more accelerators, said formula-
                                                                               tion having elongation properties in excess of glass fiber elongation prop-
                                                                               erties, and a plurality of longitudinally extending fibers of one or more
                                                                               fiber types embedded in the matrix material to form a fiber/resin matrix,
                                                                               wherein, the fiber/resin matrix is cured to form the composite core.




(21) 546760     (22) 22 Oct 2004
(54) Alcoholic beverage dispensing appliance with gas connection
(86) PCT/IB2004/003476           (87) WO2005/040035
(51) IPC2010.01:B67D1/04; F16L37/127
(71) INBEV S.A.
(72) Grimwade, Stephen J; Halket, Andrew R B;
(31) 03 0324905          (32) 24 Oct 2003         (33) GB
(74) P L BERRY & ASSOCIATES, AEQ Building, 61 Cambridge Terrace,
Christchurch 8013, New Zealand                                                (21) 546823      (22) 4 Nov 2004
(57) Disclosed is an alcohol beverage dispensing appliance. The appli-        (54) Inkjet ink composition exhibiting low gloss
 ance has an alcoholic beverage container housed within, and a tap adapter    (86) PCT/EP2004/012467            (87) WO2005/049740
 (38) mounted to the container for dispensing beverage from the con-          (51) IPC2010.01:C09D11/00
 tainer. The tap adapter has a first gas connector (88) and a gas line (56)   (71) SICPA Holding S.A.
 adapted for connection with the container for charging the container with    (72) Tiller, Thomas; Marguerettaz, Xavier;
 pressurized gas to facilitate beverage dispensing. The tap adapter has       (31) 03 03025903          (32) 12 Nov 2003       (33) EP
 at least one gas connecting locating member (90). The appliance has a
                                                                              (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
 gas supply line (58) housed in the container that has a second gas con-
                                                                              tre, 342 Lambton Quay, Wellington 6011, New Zealand
 nector (86) adapted for sealing engagement with the first gas connector.
 The appliance has a guideway (64) for locating the second gas connec-        (57) Disclosed is the use of at least one hydrocarbon compound having a
 tor that is adapted for receiving the gas connecting locating member of        carbon chain of two to six carbon atoms carrying two or three hydroxyl
 the tap adapter in sliding and guiding relation to permit movement of the      groups in an inkjet printing ink composition as a non-particulate matting
 first gas connector into sealing relation with the second gas connector.       compound for adapting the gloss of a printed marking to the gloss of a
 The appliance has a locking member (96) moveable in the guideway               substrate carrying the marking, such that the marking is not discernible
 between an unlocked position permitting movement of the locating mem-          by an unaided eye.
 ber along the guideway and a locked position engaging the locating mem-
 ber to prevent reversing movement of the gas connecting locating mem-
 ber out of the guideway.                                                     (21) 546824      (22) 14 Oct 2004
                                                                              (54) Aqueous aerosol preparation
                                                                              (86) PCT/EP2004/011571            (87) WO2005/037246
                                                                              (51) IPC2010.01:A61K9/00,107,12
                                                                              (71) PARI Pharma GmbH
                                                                              (72) Jauernig, Jurgen; Lintz, Frank-Christophe; Keller, Manfred;
                                                                              (31) 03 0347994           (32) 15 Oct 2003         (33) DE
                                                                              (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
                                                                              tre, 342 Lambton Quay, Wellington 6011, New Zealand
                                                                              (57) Disclosed is a sterile aqueous preparation for the application as aero-
                                                                                sol, wherein the preparation contains an active agent, a non-ionic sur-
                                                                                factant and a pure phospholipid, wherein the active agent is not a sur-
                                                                                factant, wherein the preparation is a single-phase liquid system, which
                                                                                optionally contains colloidal particles with an average particle size of not
                                                                                more than about 1 micrometer, and wherein the active agent is a corti-
                                                                                costeroid.


                                                                              (21) 546827      (22) 4 Nov 2004
                                                                              (54) Device for controlling spray channels in dishwasher machines
                                                                              (86) PCT/EP2004/052797            (87) WO2005/044071
                                                                              (51) IPC2010.01:A47L15/16,42
(21) 546772      (22) 22 Oct 2004                                             (71) BSH Bosch und Siemens Hausgerate GmbH
(54) A composite core for a reinforced aluminium cable                        (72) Jerg, Helmut; Nannt, Hans-Peter;
(86) PCT/US2004/035201          (87) WO2005/040017                            (31) 03 0351785           (32) 6 Nov 2003          (33) DE
(51) IPC2010.01:B05D1/18; B05D3/02; B32B27/04; D04H3/08                       (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
                                                                              tre, 342 Lambton Quay, Wellington 6011, New Zealand
(71) CTC CABLE CORPORATION
(72) Bryant, David; Hiel, Clement; Korzeniowski, George;                      (57) The aim of the invention is to provide a dishwasher machine with a
                                                                                compact device for spraying items to be rinsed. The rinsing liquid is regu-
(31) 03 691447 (32) 22 Oct 2003        (33) US                                  larly sprayed in the rinsing container (1) and the spray jets created by the
(31) 03 692304 (32) 23 Oct 2003        (33) US                                  spray device can be varied. The rinsing device includes at least one
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,        spray channel (3) which guides a rinsing liquid and, on an inside face of
Wellington 6011, New Zealand                                                    the rinsing container (1), openings (4) for the rinsing liquid and two open
(57) A composite core 302 comprised of a matrix material, the matrix ma-        ends via which rinsing liquid can be supplied in a pressurised manner. At
 terial further comprising a chemical formulation comprising at least a




PATENT OFFICE JOURNAL 1567                                      29 January 2010                                Page 66 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


 least one distributor (5) is provided, for regulating the supply of rinsing     (57) Disclosed is a compound of formula (1) or a salt thereof, wherein M1
 liquid to the spray channel (3). The distributor is driven by means of a         and M2 are the same or different and are individually selected from a
 drive, the drive including a rotary disk (7) and a cam (8); the rotary disk      platinum complex, a palladium complex, a ruthenium complex, and a
 (7) engages in a drive slot (9) formed in the distributor. The distributor       rhodium complex, wherein at least one of M1 and M2 is capable of inter-
 can be driven to a periodic motion by means of the drive. In this way,           acting with a major groove or minor groove of a polynucleotide, P1 and
 mobile components, such as spray arms, are no longer required for dis-           P2 are the same or different and are each a sequence selective pyrrole-
 tributing the rinsing liquid in the rinsing container (1). Various spray pat-    imidazole polyamide wherein each pyrrole-imidazole polyamide (P1, P2)
 terns can be produced by means of the distributor (5), as a result of the        independently comprises a plurality of heterocyclic rings selected from
 regulation of the rinsing liquid supplied to the spray channel (3), improv-      the group consisting of optionally substituted N-methylimidazole (Im),
 ing the cleaning action of the dishwasher machine.                               optionally substituted N-methylpyrrole (Py) and optionally substituted 3-
                                                                                  hydroxy N-methylpyrrole (Hp) and wherein the rest of the substituents
                                                                                  are disclosed within the specification.
                                                                                 Also disclosed is a compound of formula (3) wherein the substituents are
                                                                                  disclosed within the specification.
                                                                                 Also disclosed is the use of the above compounds of formula (1) and
                                                                                  formula (3) in the manufacture of a medicament for treating a disease
                                                                                  selected from cancer, HIV and Hepatitis C.


                                                                                 (21) 546904     (22) 4 Nov 2004
                                                                                 (54) Diazaindole-dicarbonyl-piperazinyl antiviral agents
                                                                                 (86) PCT/US2004/037213         (87) WO2005/054247
                                                                                 (51) IPC2010.01:A61K31/5025,519; A61P31/12,18; C07D487/04
                                                                                 (71) BRISTOL-MYERS SQUIBB COMPANY
                                                                                 (72) Bender, John A; Yang, Zhong; Kadow, John F; Meanwell, Nicholas A;
                                                                                 (31) 03 525624 (32) 26 Nov 2003        (33) US
                                                                                 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                                 Wellington 6011, New Zealand
                                                                                 (57) Disclosed are compounds of formula (I), wherein Q is as pictured, T
                                                                                  is –C(O) – or –CH(CN)– and the remaining substituents are as defined in
                                                                                  the specification. The compounds are useful in the treatment of HIV.




(21) 546836     (22) 5 Nov 2004
(54) Liquid cleaning composition containing an anionic polyacrylamide
copolymer
(86) PCT/US2004/036811           (87) WO2005/047443
(51) IPC2010.01:C11D1/14,22,29,72,83; C11D3/37
(71) COLGATE-PALMOLIVE COMPANY
(72) Mondin, Myriam; Bessemans, Frederic; Massaux, Jean;
(31) 03 702276 (32) 6 Nov 2003           (33) US
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand                                                     (21) 546916      (22) 5 Oct 2004
(57) Disclosed is a cleaning composition comprising approximately by             (54) Method for producing N-substituted 3-beta-aminonortropanes
 weight: (a) 0.1 wt. % to 8 wt. % of an anionic surfactant selected from the     (86) PCT/EP2004/011094            (87) WO2005/037831
 group consisting of sulfonates surfactants and sulfated surfactants;(b)         (51) IPC2010.01:C07D451/04
 0.025% to 2% of a sodium salt of an olefin maleic acid copolymer; and           (71) BOEHRINGER INGELHEIM INTERNATIONAL GMBH
 (c) 0.001 % to 0.5% of an anionic polyacrylamide copolymer; and (d)             (72) Sobotta, Rainer; Ignatow, Hans-Peter;
 water. Another embodiment discloses a cleaning composition compris-             (31) 03 0348112           (32) 16 Oct 2003       (33) DE
 ing approximately by weight: (a) 0.5% to 8% of an ethoxylated nonionic          (31) 04 013227 (32) 18 Mar 2004           (33) DE
 surfactant; (b) 0.025% to 2% of a sodium salt of an olefin maleic acid          (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
 copolymer; (c) 0. 001 % to 0.5% of an anionic polyacrylamide copoly-            tre, 342 Lambton Quay, Wellington 6011, New Zealand
 mer; and (d) water. These cleaning compositions may further include
                                                                                 (57) Disclosed is a method for producing, on the basis of the correspond-
 fatty acids and perfumes.
                                                                                   ing 3-oxonortropane or the corresponding 3alpha-aminonortropane, N-
                                                                                   substituted 3beta-aminonortropanes of formula (I), wherein R1 is as de-
                                                                                   fined in the specification. The starting compounds are converted to the
(21) 546896      (22) 7 Oct 2004                                                   corresponding imines by means of an arylmethylamine or an arylaldehyde,
(54) Sequence selective pyrrole and imidazole polyamide                            said imines are tautomerized or isomerized and then hydrolyzed. Also
metallocomplexes                                                                   disclosed are novel compounds of formula (V), wherein R1 and Ar are as
(86) PCT/AU2004/001368           (87) WO2005/033077                                defined in the specification.
(51) IPC2010.01:A61K31/40,4164; A61P31/12,18; A61P35/00; C07D207/
34; C07D209/56; C07D233/90
(71) University of Western Sydney
(72) Jaramillo, David; Brodie, Craig; Howard, Warren; Taleb, Robin; Aldrich-
Wright, Janice;
(31) 03 905512 (32) 7 Oct 2003           (33) AU
(74) SPRUSON & FERGUSON, St Martins Tower, Level 35, 31 Market
Street, Sydney, New South Wales 2000, Australia




 PATENT OFFICE JOURNAL 1567                                        29 January 2010                               Page 67 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND




(21) 546931     (22) 18 Nov 2004
(54) Method for synthesis of perindopril and the pharmaceutically accept-
able salts thereof
(86) PCT/FR2004/002936           (87) WO2005/054276
(51) IPC2010.01:C07C229/36; C07C309/73; C07K5/06
(71) LES LABORATOIRES SERVIER
(72) Dubuffet, Thierry; Langlois, Pascal;
(31) 03 03292864         (32) 19 Nov 2003       (33) EP
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand
(57) The disclosure relates to a method for synthesis of perindopril of
 formula (I) and the pharmaceutically-acceptable salts thereof.




                                                                                (21) 546991       (22) 18 Nov 2004
                                                                                (54) 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-
                                                                                quinoxalinones as PARP inhibitors
                                                                                (86) PCT/EP2004/013163             (87) WO2005/054201
                                                                                (51) IPC2010.01:A61K31/498,4704; C07D241/44; C07D403/06; C07D401/
                                                                                06; A61P1/04; A61P13/12; A61P19/02; A61P21/00; A61P25/28; C07D215/
                                                                                227; C07D405/06,14; C07D407/06,12
                                                                                (71) Janssen Pharmaceutica N.V.
                                                                                (72) Mabire, Dominique Jean-Pierre; Guillemont, Jerome Emile Georges;
                                                                                Van Dun, Jacobus Alphonsus Josephus; Somers, Maria Victorina
                                                                                Francisca; Wouters, Walter Boudewijn Leopold;
(21) 546934     (22) 5 Nov 2004                                                 (31) 03EP 13028           (32) 20 Nov 2003          (33) EP
(54) Method and system for injecting a treatment fluid into a well              (31) 03 03078860          (32) 5 Dec 2003           (33) EP
(86) PCT/EP2004/052829           (87) WO2005/045183                             (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
(51) IPC2010.01:E21B34/10; E21B37/06; E21B41/02; E21B43/25                      tre, 342 Lambton Quay, Wellington 6011, New Zealand
(71) SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.                            (57) The disclosure relates to substituted 2-quinolinones and 2-
(72) Van Eljden, Gerbrand Jozef Maria; Lugtmeir, Lubbertus;                       quinoxalinones of formula (I), the N-oxide forms, the addition salts and
                                                                                  the stereo-chemically isomeric forms thereof, wherein the variables are
(31) 03 03104119         (32) 7 Nov 2003          (33) EP
                                                                                  defined in the specification. Also disclosed is the preparation of said com-
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,          pounds and their use as PARP inhibitors in the treatment of cancer and
Wellington 6011, New Zealand                                                      arthritis.
(57) A system for injecting a treatment fluid into a well comprising a sur-
 face controlled subsurface safety valve 5, which is controlled by varying
 fluid pressure in a valve control conduit 8 which extends from the safety
 valve 5 to a wellhead of the well, the system comprising a valve control
 conduit 8 and at least one treatment fluid injection opening for discharg-
 ing treatment fluid into the well; and which system further comprises a
 treatment fluid-injection conduit 12 for injecting treatment fluid into the
 well, which treatment fluid injection conduit 12 is connected to the valve
 control conduit 8, and which treatment fluid injection conduit 12 com-
 prises the at least one treatment fluid injection opening and a one way
 check valve 13 which prevents fluid flow from each treatment fluid injec-
 tion opening via the treatment fluid injection conduit 12 into the valve       (21) 547119     (22) 10 Nov 2004
 control conduit 8, wherein the treatment fluid injection conduit is arranged   (54) Catalytic calcination process for making rutile pigments from aque-
 to extend into a section of the well which is located below the safety         ous titanium solutions
 valve 5 such that at least one treatment fluid injection opening is located
                                                                                (86) PCT/US2004/037421          (87) WO2005/049496
 below the safety valve 5.
                                                                                (51) IPC2010.01:C01G23/053; C09C1/36
                                                                                (71) ALTAIR NANOMATERIALS INC.




PATENT OFFICE JOURNAL 1567                                       29 January 2010                                 Page 68 |BACK TO CONTENT
                                     INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(72) Prochazka, Jan; Spitler, Timothy Malcome; Sabacky, Bruce J;                    ses, various forms of anxiety, panic attacks, phobias, obsessive-com-
(31) 03 712768 (32) 13 Nov 2003           (33) US                                   pulsive disorders, various forms of depression, of disorders due to alco-
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,            hol abuse or to withdrawal from alcohol, sexual behaviour disorders, food
Wellington 6011, New Zealand                                                        intake disorders, and migraine.
(57) A low-temperature process for producing pigment-grade rutile tita-
  nium dioxide from an aqueous solution is disclosed, wherein the process
  comprises the following sequential steps:
(a) preparing an aqueous feed solution comprising one or more titanium
  compounds;
 (b) adding a catalyzing salt selected from the group of alkali metal salts to
  the solution in an amount from 3 weight % of the equivalent amount of
  TiO2 present in the feed solution to the amount corresponding to the
  saturation point of the catalyzing salt in the feed solution;
  (c) evaporating the solution to produce a dry amorphous intermediate
  that includes a mixture of titanium compounds; and
 (d) calcining the intermediate at a temperature less than 500 Deg C to
  form TiO2 rutile pigment base.


(21) 547163       (22) 15 Oct 2004
(54) Derivatives of N-heterocyclylmethylbenzamides, preparation method
thereof and application of therapeutics as glycine transport inhibitors
(86) PCT/FR2004/002643              (87) WO2005/037783
(51) IPC2010.01:C07D471/08; C07D487/08; A61P25/00; A61P29/00                       (21) 547165       (22) 15 Oct 2004
(71) SANOFI-AVENTIS                                                                (54) Derivatives of N-[heteroaryl(piperidine-2-yl)methyl]benzamide, prepa-
(72) Dargazanli, Gihad; Estenne-Bouhtou, Genevieve; Magat, Pascale;                ration method thereof and application of same in therapeutics
Marabout, Benoit; Roger, Pierre;                                                   (86) PCT/FR2004/002641            (87) WO2005/037781
(31) 03 0312165            (32) 17 Oct 2003          (33) FR                       (51) IPC2010.01:C07D401/06; C07D409/06; C07D417/06
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,           (71) SANOFI-AVENTIS
Wellington 6011, New Zealand
                                                                                   (72) Dargazanli, Gihad; Estenne-Bouhtou, Genevieve; Medaisko, Florence;
(57) Disclosed is a compound corresponding to general formula (I) in which         Renones, Maria-Carmen;
R represents a hydrogen atom or a vinyl group; n represents 0 or 1 or 2            (31) 03 0312142           (32) 17 Oct 2003         (33) FR
  when R represents a hydrogen atom and n represents 1 when R repre-
                                                                                   (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
  sents a vinyl group;
                                                                                   Wellington 6011, New Zealand
X represents a group of formula CH or a nitrogen atom when R represents
                                                                                   (57) The disclosure relates to compounds having general formula (I),
  a hydrogen atom and X represents a group of formula CH when R repre-
                                                                                     wherein: R1 represents H or an alkyl, cycloalkyl, cycloalkylalkyl,
  sents a vinyl group;
                                                                                     phenylalkyl, alkenyl, alkynyl group; R2 represents a pyridinyl, furanyl,
R1 represents either a phenyl or naphthyl group optionally substituted with          thienyl, thiazolyl or oxazolyl group, said group being optionally substi-
  one or more substituents chosen from halogen atoms, linear or branched             tuted; and R3 represents H, one or more substituents selected from among
  (C1-C6) alkyl, hydroxyl and (C1-C6)alkoxy groups, the trifluoromethyl              the halogen atoms and the trifluoromethyl, alkyl, cycloalkyl, alkoxy, phe-
  group, or a cyclohexyl group, or a heteroaryl group chosen from the thienyl,       nyl, cyano, acetyl, benzoyl, thioalkyl, alkylsulfonyl, carboxy or
  pyridinyl, oxazolyl, furanyl, thiazolyl, quinolinyl, and isoquinolinyl groups;     alcoxycarbonyl groups, or a group having general formula NR4R5 or
R2 represents either a hydrogen atom, or one or more substituents cho-               SO2NR4R5 or CONR4R5 in which R4 and R5 each represent H or an
  sen from halogen atoms and the trifluoromethyl, (C1-C6) alkyl, (C1-C6)             alkyl group or, together with the nitrogen atom bearing same, form a
  alkoxy, thienyl, phenyloxy, hydroxyl, mercapto, thio (C1-C6) alkyl and             pyrrolidine, piperidine or morpholine ring, said compound taking the form
  cyano groups or a group of general formula -NR4R5 SO2NR4R5, –SO2                   of a base, an acid addition salt, a hydrate or a solvate. The disclosure
  (C1-C6) alkyl, -SO2-phenyl, -CONR4R5 , -COOR7, -CO- (C1-C6) alkyl,                 also relates to the use of the compound in therapeutics.
  -CO-phenyl, -NHCOR8 , -NHSO2- (C1-C6)alkyl, -NHSO2-phenyl and -
  NHSO2NR4R5 or a group of formula -OCF2O- attached at the 2- and 3-
  positions of the phenyl group; the groups (C1-C6) alkyl, (C1-C6) alkoxy,
  -SO2- (C1-C6) alkyl, -CO-(C1-C6)alkyl and -NHSO2-(C1-C6)alkyl being
  optionally substituted with one or more groups R3; the groups phenyl, -
  SO2-phenyl, -CO-phenyl and –NHSO2 phenyl being optionally substi-
  tuted with a group R6;
R3 represents a halogen atom, or a phenyl, (C1-C6) alkoxy or -NR4R5
  group; R4 and R5 represent, independently of each other, a hydrogen
  atom or a (C1-C6) alkyl group or R4 and R5 form with the nitrogen atom
  bearing them a pyrrolidine ring, a piperidine ring or a morpholine ring; R6
  represents a hydrogen atom, a halogen atom, a trifluoromethyl group, a
  cyano group, a hydroxyl group, a mercapto group, a (C1-C6)alkyl or (C1-
  C6)alkoxy group; R7 represents a hydrogen atom or a (C1-C6) alkyl
  group optionally substituted with one or more groups R3, or a phenyl
  group optionally substituted with a group R6; R8 represents a (C1-C6)
  alkyl group optionally substituted with one or more groups R3, or a (C1-
  C6) alkoxy group, or a phenyl group optionally substituted with a group
  R6, in the form of a free base or of an addition salt with an acid, of a
  hydrate or of a solvate. Also disclosed is the use of a compound of
  formula (I) for the preparation of a medicament intended for the treat-
  ment of contractures, of pain, of Parkinson's disease and of Parkinso-
                                                                                   (21) 547196       (22) 12 Nov 2004
  nian symptoms, of epilepsy, of mixed forms and other epileptic syndromes
  as a supplement to another antiepileptic treatment, or in monotherapy, of        (54) Electrically propulsed vehicle steered using differential driving of wheels
  sleep apnea, and for neuroprotection. Also disclosed is the use of a com-        where the rear wheels always follow in the tracks of the front wheels
  pound of formula (I) for the preparation of a medicament intended for the        (86) PCT/SE2004/001662            (87) WO2005/047042
  treatment of behavioural disorders associated with dementia, psycho-




 PATENT OFFICE JOURNAL 1567                                          29 January 2010                                  Page 69 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(51) IPC2010.01:B60K17/356; B60K7/00; B62D11/02; B62D12/00;                    (57) Disclosed is a compound of formula (I), or an N-oxide form, addition
B62D13/02; B62D6/00; B62D115/00                                                 salt, or stereoisomer thereof, wherein n is 0 or 1, s is 0 or 1, X is –N= or
(71) El-Forest AB                                                               –CR4=, Y is –N< or –CH<, Q is –NH–, –O–, –C(=O) –, –CH2-CH2–, or –
(72) Lundstrom, Lennart;                                                        CHR5–, R1 is C1-6alkyl or thienyl, R2 is hydrogen, and wherein the rest
(31) 03 0303007          (32) 14 Nov 2003          (33) SE                      of the substituents are defined in the specification. Also disclosed is the
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand               use of the compounds as chemosensitization or radiosensitization agents
                                                                                for the treatement of cancer. Also disclosed is a process for making the
(57) A vehicle (100) with at least three drive axles (A, B, C), whose wheels    compound.
 essentially follow the same wheel tracks is disclosed. Each drive axle (A,
 B, C) has a pair of drive wheels. The steering system controls the relive
 rotational speed of the wheels on each side with respect to an overall
 speed control signal. When the angle between the first set of axles (A, B)
 is changed, a steering angle sensor modifies the drive signal controlling
 the relative speed the wheels on each side of those axels. This differen-
 tial compensating means (20a, 20b) is arranged to register the relative
 steering angle for each consecutive pair of drive axles, respectively, so
 that the speed for each of the wheels there after is controlled only by the
 overall speed of the vehicle and the steering angle for that axle (C) rela-
 tive to the previous axle (B). The differential compensating means may        (21) 547295       (22) 16 Nov 2004
 be achieved with a potentiometer arranged to decreases the speed sig-         (54) 3-Aminopyrrolidone derivatives
 nal controlling the wheels on the inside of the turn.                         (86) PCT/EP2004/012957            (87) WO2005/054190
Divisional filed as 577125                                                     (51) IPC2010.01:A61K31/4015,4412,55; C07D207/273; C07D211/76;
                                                                               C07D223/12
                                                                               (71) NEWRON PHARMACEUTICALS S.p.A.
                                                                               (72) Thaler, Florian; Sabido David, Cibele Maria; Maestroni, Sara; Raveglia,
                                                                               Luca Francesco; Salvati, Patricia;
                                                                               (31) 03 03026779          (32) 21 Nov 2003        (33) EP
                                                                               (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                               Wellington 6011, New Zealand
                                                                               (57) Disclosed is the use of 3-aminopyrrolidone derivatives of the general
                                                                                 formula I wherein:
                                                                               m is an integer from 1 to 3
                                                                               X is methylene, oxygen, sulphur or a NR6 group;
                                                                               R1 is a straight or branched C1-C8 alkyl or C3-C8 alkenylene or C3-C8
                                                                                 alkynylene chain, optionally substituted with CF3, phenyl, phenoxy or
                                                                                 naphthyl or phenyl, the aromatic rings optionally substituted by one or
                                                                                 more C1-C4 alkyl, halogens, trifluoromethyl, hydroxy or C1-C4 alkoxy
                                                                                 groups;
                                                                               R2, R3 are independently hydrogen, a C1-C3 alkyl chain, halogen,
                                                                                 trifluoromethyl, hydroxy or C1-C4 alkoxy groups;
                                                                               R4, R5, R6 are independently hydrogen or C1-C6 alkyl;
                                                                               and the pharmaceutically acceptable salts thereof for the preparation of a
                                                                                 medicament for the treatment of pain, migraine, cognitive disorders, in-
                                                                                 flammation, gastrointestinal tract disorders, disorders of the genitor-uri-
                                                                                 nary tract, ophthalmic diseases, obesity.




(21) 547278      (22) 18 Nov 2004
(54) Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-
quinoxalinones as PARP inhibitors for chemosensitization or
radiosensitization                                                             (21) 547438     (22) 17 Dec 2004
(86) PCT/EP2004/013165           (87) WO2005/058843                            (54) Monovalent antibody fragments useful as therapeutics
(51) IPC2010.01:C07D241/44; C07D401/06; A61K31/498; A61P43/00                  (86) PCT/US2004/042619          (87) WO2005/063816
(71) Janssen Pharmaceutica N.V.                                                (51) IPC2010.01:C07K16/28
(72) Mabire, Dominique Jean-Pierre; Van Dun, Jacobus Alphonsus                 (71) GENENTECH, INC
Josephus; Somers, Maria Victorina Francisca; Wouters, Walter Boudewijn         (72) Huang, Arthur Jyh-Yen; Schwall, Ralph H; Yansura, Daniel G;
Leopold;
                                                                               (31) 03 531409 (32) 19 Dec 2003        (33) US
(31) 03 03078918         (32) 10 Dec 2003     (33) EP
                                                                               (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-                   Wellington 6011, New Zealand
tre, 342 Lambton Quay, Wellington 6011, New Zealand
                                                                               (57) Provided is an antibody fragment comprising a single antigen binding
                                                                                arm and an Fc region that increases stability of said antibody fragment
                                                                                compared to a Fab molecule comprising said antigen binding arm, wherein




PATENT OFFICE JOURNAL 1567                                      29 January 2010                                 Page 70 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


 the Fc region comprises a complex of a first and a second Fc polypep-           the proteins and corresponding nucleic acids in modifying tolerance of
 tide, wherein one but not both of the Fc polypeptides is an N-terminally        freezing in plants.
 truncated heavy chain, wherein the antibody fragment does not specifi-
 cally bind a T cell surface antigen. Further provided are corresponding
 nucleic acids and methods of making the antibodies.                            (21) 547625     (22) 19 Nov 2004
                                                                                (54) Method for producing (3-oxo-2,3-dihydro-1H-isoindol-1-
                                                                                yl)acetylguanidine derivatives
(21) 547456       (22) 3 Dec 2004                                               (86) PCT/EP2004/013153           (87) WO2005/054195
(54) Process for increasing the refiner production rate and/or decreasing       (51) IPC2010.01:C07C233/66; C07D209/46
the specific energy of pulping wood by applying a lubricant solution or a       (71) Sanofi-Aventis Deutschland GmbH
carrier/frictionizer solution                                                   (72) Schubert, Gerrit; Rieke-Zapp, Joerg; Keil, Johannes; Kleemann, Heinz-
(86) PCT/US2004/040571            (87) WO2005/056916                            Werner; Hanna, Reda; Huang, Bao-Guo; Wu, Xiao-Dong; Gouraud, Yves;
(51) IPC2010.01:D21B1/02,16                                                     (31) 03 0356717          (32) 2 Dec 2003          (33) DE
(71) HERCULES INCORPORATED                                                      (74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
(72) Laurint, Mark Edward; Fernandez, Eric Oswaldo;                             (57) Disclosed are methods for producing (3-oxo-2,3-dihydro-1H-isoindol-
(31) 03 527121 (32) 4 Dec 2003            (33) US                                 1-yl) acetylguanidine derivatives of formula (I) using 3-hydroxy-2,3-
(31) 04 614170 (32) 29 Sep 2004           (33) US                                 dihydro-1H-isoindol-1-one derivatives or 3-(2-carbamoyl-phenyl) acrylic
(31) 04 002594 (32) 2 Dec 2004            (33) US                                 acid ester derivatives as intermediates, a method for the resolution of
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,          racemates and intermediates for use therein.
Wellington 6011, New Zealand
(57) Disclosed is a process for increasing the production rate and/or re-
  ducing specific energy of a refiner for a freeness target comprising: (a)
  applying a lubricant solution to an amount of wood chips prior to delivery
  into a refining area; and (b) delivering the wood chips to a refiner.
Divisional filed as 581995


(21) 547460      (22) 3 Nov 2004
(54) Longitudinally reinforced cured in place liner
(86) PCT/US2004/036621            (87) WO2005/046973
(51) IPC2010.01:B29C63/06; F16L55/165; B29C63/00
(71) INA ACQUISITION CORP.
(72) Driver, Franklin Thomas; Wang, Weiping;
(31) 03 704487 (32) 7 Nov 2003           (33) US
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand
(57) A cured in place liner 21, comprising a first tubular member of a resin
 impregnable material in lay flat condition having, a reinforcing scrim 33
 having greater strength in the warp direction positioned on at least a
 portion of one surface of the flattened first tubular member so as not to
 interfere with radial expansion of the liner 21, and an outer resin imper-     (21) 547646      (22) 24 Nov 2004
 meable layer 31 disposed about the tubular member and scrim 33.                (54) Reformer exercise apparatus anchor bar and carriage stop assembly
                                                                                (86) PCT/US2004/039530            (87) WO2005/051496
                                                                                (51) IPC2010.01:A63B21/055; A63B23/035,04
                                                                                (71) Balanced Body, Inc.
                                                                                (72) Endelman, Ken; Janowski, Brian; Barnard, Edward D;
                                                                                (31) 03 723407 (32) 25 Nov 2003          (33) US
                                                                                (31) 04 920741 (32) 17 Aug 2004          (33) US
                                                                                (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                                Wellington 6011, New Zealand
                                                                                (57) A reformer exercise apparatus has a head end and a foot end and a
                                                                                 pair of spaced apart parallel track members, a movable carriage mounted
                                                                                 on the track members for movement between the head and foot end.
                                                                                 One or more springs are connected between the carriage and an elastic
                                                                                 member anchor bar and carriage stop assembly at the foot end. The
                                                                                 anchor bar and carriage stop assembly adjustably positions the carriage,
(21) 547506     (22) 24 Nov 2004                                                 the anchor bar and the elastic members on the tracks to accommodate a
(54) Ice recrystallisation inhibition protein or antifreeze proteins from        wide range of user heights. Each end of the anchor bar is disposed in an
deschampsia, lolium and festuca species of grass                                 elongated slot formed in each track member. The elongated slot has
(86) PCT/AU2004/001633           (87) WO2005/049835                              spaced gear teeth shaped openings defining spaced anchor bar stop or
(51) IPC2010.01:C07K14/415; C12N15/29                                            lock portions. The anchor bar can be moved between lock portions only
(71) Agriculture Victoria Services Pty Ltd.                                      when rotated to an unlocked position wherein the bar, coupled to the
(72) Spangenberg, German; John, Ulrik Peter; Polotonianka, Renata                carriage, can slide along the track within the slot.; In addition, the assem-
Martina;                                                                         bly maintains the carriage and anchor bar a predetermined distance apart
                                                                                 when the anchor bar is in the unlocked position and maintains a mini-
(31) 03 906477 (32) 24 Nov 2003          (33) AU
                                                                                 mum distance between the anchor bar and the carriage when the anchor
(74) PHILLIPS ORMONDE FITZPATRICK, 367 Collins Street, Melbourne,                bar is in the locked position.
Victoria 3000, Australia
(57) Provided is an isolated ice recrystallisation inhibition protein derived
  from a plant wherein said protein includes an IRIP domain including 3 to
  32 repeats of a specified amino acid sequence and an amino acid resi-
  due motif of another specified sequence. Further provided are uses of




 PATENT OFFICE JOURNAL 1567                                       29 January 2010                                 Page 71 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


                                                                                 (21) 547908     (22) 2 Dec 2004
                                                                                 (54) Pre-metered dry powder inhaler for moisture-sensitive medicaments
                                                                                 (86) PCT/SE2004/001794          (87) WO2005/053648
                                                                                 (51) IPC2010.01:A61J1/00; A61K31/46; A61K9/14,72; A61M15/00;
                                                                                 A61P11/06,08
                                                                                 (71) BOEHRINGER INGELHEIM INTERNATIONAL GMBH
                                                                                 (72) Nilsson, Thomas; Myrman, Mattias; Calander, Sven; Niemi, Alf;
                                                                                 (31) 03 0303269         (32) 3 Dec 2003          (33) SE
                                                                                 (31) 03 0303569         (32) 22 Dec 2003         (33) SE
                                                                                 (31) 04 933219 (32) 3 Sep 2004          (33) US
                                                                                 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                                 Wellington 6011, New Zealand
                                                                                 (57) A pre-metered dry powder inhaler provided with a dry powder dose of
                                                                                  tiotropium and excipient(s) loaded into a container comprising a dry, high
                                                                                  barrier seal, which prevents ingress of moisture so that the fine particle
                                                                                  structure of the powder dose is preserved. The dry powder dose has
                                                                                  been formed by either volumetric or electric field dose forming methods.
                                                                                  Also disclosed is a dry powder dose of tiotropium loaded into a container
                                                                                  as described above. The dry powder inhaler and the dry powder dose is
(21) 547699       (22) 23 Nov 2004                                                intended for use in the treatment of asthma and other respiratory disor-
(54) Fluid purifier having magnetic field generation                              ders.
(86) PCT/US2004/039553            (87) WO2005/061390
(51) IPC2010.01:C02F1/48
(71) D2O, LLC
(72) Naito, Harusuke;
(31) 03 736091 (32) 15 Dec 2003           (33) US
(31) 04 959717 (32) 6 Oct 2004            (33) US
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand
(57) A fluid purifier includes a filter having a chamber of reduced cross
 section formed either between an inner wall and an outer wall or within
 the inner wall. A ceramic layer of granular ceramic particles and at least
 a pair of magnetic layers each comprising an annular magnet and mag-
 netite pieces are provided above or below the ceramic layer in the cham-
 ber. The annular magnets are arranged in such a way that the same
 polarities of adjacent annular magnets are facing each other, and the
 direction of the magnetic lines of force is parallel to the direction of flow
 of the fluid. Fluid molecules are activated while passing through the mag-
 netic field produced by the magnetic layers of annular magnets and mag-
 netite pieces which are magnetized by the annular magnets. In other
 embodiments the magnets may be differently and irregularly shaped
 magnet pieces, magnetite pieces may also be present and the magnet
 pieces and/or the magnetite pieces may be coated with the ceramic.




                                                                                 (21) 547938     (22) 15 Nov 2004
                                                                                 (54) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
                                                                                 (86) PCT/GB2004/004784          (87) WO2005/049033
                                                                                 (51) IPC2010.01:C07D401/14; C07D403/12,14; C07D409/14; C07D417/
                                                                                 04; C07D471/04; C07D487/04; C07D495/04
                                                                                 (71) AstraZeneca AB
                                                                                 (72) Block, Michael Howard; Han, Yongxin; Josey, John Anthony; Lee,
                                                                                 John W; Scott, David; Wang, Bin; Wang, Haixia; Wang, Tao; Yu, Dingwei;
                                                                                 (31) 03 520581 (32) 17 Nov 2003          (33) US
                                                                                 (31) 04 556213 (32) 25 Mar 2004          (33) US
                                                                                 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                                 Wellington 6011, New Zealand
                                                                                 (57) Disclosed is a compound of formula (I), wherein A is a direct bond, C
                                                                                  is a carbocyclic or heterocyclic ring, R2 is C1-6alkyl, optionally substi-
                                                                                  tuted by one or more R10, R3 is fluoro and n is 1, R5 is H or C1-6alkyl
                                                                                  optionally substituted by one or more R14, R6 and R7 may together form
                                                                                  a 5 or 6 membered ring, and wherein the other substituents are as de-
                                                                                  fined in the specification.




PATENT OFFICE JOURNAL 1567                                        29 January 2010                                Page 72 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


Also disclosed is a process for preparing the compound, and the use of
 the compound for treating cancer, for inhibiting Trk activity, or for an anti-
 proliferative effect.




                                                                                  (21) 548271      (22) 27 Dec 2004
                                                                                  (54) Prostaglandin nitrooxyderivatives
                                                                                  (86) PCT/EP2004/014820            (87) WO2005/068421
                                                                                  (51) IPC2010.01:C07C405/00; A61P27/06; A61K31/5575
                                                                                  (71) Nicox, S.A.
                                                                                  (72) Ongini, Ennio; Benedini, Francesca; Chiroli, Valerio; Del Soldato, Piero;
                                                                                  (31) 04 04100001          (32) 5 Jan 2004         (33) EP
                                                                                  (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
                                                                                  tre, 342 Lambton Quay, Wellington 6011, New Zealand
                                                                                  (57) Prostaglandin nitrooxyderivatives having improved pharmacological
                                                                                    activity and enhanced tolerability are disclosed. These prostaglandin
                                                                                    nitrooxyderivatives can be employed for the treatment of glaucoma and
                                                                                    ocular hypertension. These compounds are particularly suitable for the
                                                                                    reduction of intraocular pressure in patients with open-angle glaucoma
                                                                                    or with chronic angle-closure glaucoma who underwent peripheral
                                                                                    iridotomy or laser iridoplasty.
(21) 548028       (22) 17 Dec 2004
(54) Pharmaceutical composition of vinflunine which is intended for               (21) 548276       (22) 3 Dec 2004
parenteral administration preparation method thereof and use of same              (54) Methods for treating prostate cancer with herbal compositions
(86) PCT/FR2004/003287            (87) WO2005/070425                              (86) PCT/US2004/040568            (87) WO2005/056032
(51) IPC2010.01:A61K31/4375,475; A61K47/12; A61K9/00,08; A61P35/                  (51) IPC2010.01:A61K35/78
00                                                                                (71) NEW CHAPTER, INC.
(71) PIERRE FABRE MEDICAMENT                                                      (72) Newmark, Thomas; Schulick, Paul; Katz, Aaron;
(72) Leverd, Elie; Bougaret, Joel; Ibarra, Marie-Dominique;                       (31) 03 728087 (32) 5 Dec 2003            (33) US
(31) 03 0315312           (32) 23 Dec 2003         (33) FR                        (74) COLLISON & CO, 117 King William Street, Adelaide, South Australia
(74) PHILLIPS ORMONDE FITZPATRICK, 367 Collins Street, Melbourne,                 5001, Australia
Victoria 3000, Australia                                                          (57) Provided is the use of a composition in the preparation of a medica-
(57) Disclosed is a vinflunine pharmaceutical composition, wherein it is in         ment for the treatment of prostate neoplasia in a subject, said composi-
  the form of a stable and sterile aqueous solution of a water-soluble              tion comprising therapeutically effective amounts of supercritical carbon
  vinflunine salt at a pH of between 3 and 4 and in that it does not contain        dioxide extracts of rosemary, turmeric, oregano and ginger; and thera-
  any preservatives. In one embodiment the preferred vinflunine salt is             peutically effective amounts of ethanol extracts of holy basil, ginger, tur-
  vinflunine ditartrate and no buffer solution is added to the composition.         meric, Scutellaria baicalensis, rosemary, green tea, huzhang, Chinese
  The disclosure also relates to the method of preparing said composition           goldthread, and barberry, provided that said prostate neoplasia is not
  and to the use thereof as a parenterally-administered medicament for              prostatic intraepithelial neoplasia.
  the treatment of cancer.


(21) 548048      (22) 15 Dec 2004                                                 (21) 548317      (22) 21 Dec 2004
(54) Means for protecting technical materials                                     (54) Spirocyclic cyclohexane derivatives with affinity for the ORL1-receptor
(86) PCT/EP2004/014287            (87) WO2005/063023                              (86) PCT/EP2004/014539           (87) WO2005/066183
(51) IPC2010.01:A01N47/40                                                         (51) IPC2010.01:C07D471/10; C07D491/10; C07D495/10; C07D491/04;
(71) Lanxess Deutschland GmbH                                                     A61K31/407; A61P29/00
(72) Jaetsch, Thomas; Bruns, Rainer; Spetmann, Peter;                             (71) Grunenthal GmbH
(31) 03 0360836           (32) 23 Dec 2003         (33) DE                        (72) Hinze, Claudia; Sundermann, Bernd; Schick, Hans; Henkel, Birgitta;
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand                 Englberger, Werner; Oberborsch, Stefan; Friderichs, Elmar; Frormann,
(57) Disclosed is a use of the 1-(2-chloro-5-pyridylmethyl)-2-                    Sven; Kogel, Babette-Yvonne; Linz, Klaus; Merla, Beatrix; Saunders, Derek;
  cyanoiminothiazolidine (thiacloprid) compound of the formula (I) its metal      Schroder, Wolfgang; Sonnenschein, Helmut;
  salts or acid addition compounds thereof and a boron compound as an             (31) 03 10360792         (32) 23 Dec 2003        (33) DE
  insecticide for protecting industrial materials against attack and/or de-       (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
  struction by insects. Also disclosed are compositions for protecting            tre, 342 Lambton Quay, Wellington 6011, New Zealand
  industrial materials (such as wood or plastic), which comprise a thiacloprid    (57) The disclosure relates to spirocyclic cyclohexane derivatives of for-
  compound of the formula (I) or metal salts or acid addition compounds             mula (I), wherein the substituents are as defined in the specification.
  thereof, a boron compound, a quaternary ammonium compound and at                  Also disclosed is a method for the production thereof, to medicaments
  least one solvent or diluent.                                                     containing said derivatives and to the use of spirocyclic cyclohexane
Divisional filed as 582106                                                          derivatives for the production of medicaments.




 PATENT OFFICE JOURNAL 1567                                         29 January 2010                                 Page 73 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND




(21) 548346       (22) 23 Dec 2004
(54) Combination therapies employing a composition comprising a HMG
Co A reductase inhibitor and a vitamin B6 related compound
(86) PCT/CA2004/002196            (87) WO2005/060975                              (21) 548497     (22) 10 Mar 2005
(51) IPC2010.01:A61K31/366,4355,4412,4415,675; A61P9/00                           (54) Fungal lipolytic enzymes
(71) MEDICURE INTERNATIONAL INC.                                                  (86) PCT/IB2005/000875            (87) WO2005/087918
(72) Friesen, Albert; Khalil, Ahmad; Zettler, Marjorie;                           (51) IPC2010.01:C12N9/00; A21D8/04; C12N9/18,20
(31) 03 531605 (32) 23 Dec 2003             (33) US                               (71) DANISCO A/S
(31) 04 586215 (32) 9 Jul 2004 (33) US                                            (72) Brunstedt, Janne; Mikkelsen, Jorn Dalgaard; Pedersen, Henrik; Soe,
(74) PIPERS, Level 1, 5A Pacific Rise, Mt Wellington, Auckland, New Zea-          Jorn Borch;
land                                                                              (31) 04 0405637          (32) 12 Mar 2004       (33) GB
(57) The present disclosure provides pharmaceutical compositions com-             (31) 04 559149 (32) 2 Apr 2004(33) US
  prising a HMG CoA reductase inhibitor and a vitamin B6 related com-             (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
  pound wherein the HMG CoA reductase inhibitor is selected from a group          Wellington 6011, New Zealand
  consisting: pravatstatin, lovastatin, fluvastatin, atorvastatin, simvastatin,   (57) Disclosed is a fungal lipolytic enzyme wherein the enzyme comprises
  rosuvastatin, velostatin, fluindostatin, and a mixture thereof; and wherein      an amino acid sequence as shown in SEQ ID No. 1 or SEQ ID No. 2 or
  the vitamin B6 related compound is selected from a group consisting:             SEQ ID No. 4 or SEQ ID No. 6 or an amino acid sequence which has at
  pyridoxal, pyridoxal-5'-phosphate, pyridoxamine, a 3-acylated analogue           least 90% identity to anyone of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No.
  of pyridoxal, a 3-acylated analogue of pyridoxal-4,5-aminal, a pyridoxine        4 or SEQ ID No. 6. The enzymes disclosed have a higher ratio of activity
  phosphate analogue, and a mixture thereof, wherein these analogues               on polar lipids compared with triglycerides and can be used to prepare
  are defined as in the specification. Also disclosed are the methods for          lyso-phospholipids and food products.
  using the pharmaceutical compositions for reducing the risk of cardio-
  vascular and other diseases.
                                                                                  (21) 548531       (22) 7 Jan 2005
                                                                                  (54) Acylaminothiazole derivatives, preparation method thereof and use
(21) 548446      (22) 25 Jan 2005                                                 of same in therapeutics
(54) Optical inspection for container lean                                        (86) PCT/FR2005/000032            (87) WO2005/073226
(86) PCT/US2005/002422          (87) WO2005/073699                                (51) IPC2010.01:C07D277/48,46; C07D417/12,06; A61K31/427,426
(51) IPC2010.01:G01B11/24,26,27; G01N21/90                                        (71) SANOFI-AVENTIS
(71) OWENS-BROCKWAY GLASS CONTAINER INC.                                          (72) Baltzer, Sylvie; Van Dorsselaer, Viviane;
(72) Juvinall, John W; Ringlien, James A; Graff, Stephen M; Chen, Jie;            (31) 04 0400387           (32) 16 Jan 2004       (33) FR
Anderson, William H;
                                                                                  (31) 04 0408115           (32) 22 Jul 2004       (33) FR
(31) 04 765801 (32) 26 Jan 2004          (33) US
                                                                                  (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,          Wellington 6011, New Zealand
Wellington 6011, New Zealand
                                                                                  (57) Disclosed is a compound of formula (I), wherein one of R4 and R5
(57) An apparatus (20) for inspecting lean of a container includes a light         represents a group (Z), and the other represents a group –C(X)R6, and
 source (50) positioned beneath a container (34) for directing light energy        the remaining substituents are as defined in the specification. The com-
 (60) onto the container bottom (62) as the container is held in position          pounds are inhibitors of the beta-amyloid (beta-A4) peptide and are use-
 and rotated around an axis (A). A light sensor (54) positioned beneath            ful in the treatment of senile dementia, Alzheimer's disease, Down's syn-
 the container receives portions of the light energy from the source re-           drome, Parkinson's disease, amyloid angiopathy, cerebrovascular disor-
 flected from the container bottom. An information processor (56) is cou-          ders, frontotemporal dementia and Pick's disease, post-traumatic de-
 pled to the light sensor for determining, as a combined function of the           mentia, pathologies associated with neuroinflammatory processes, Hunt-
 reflected light energy and container rotation, departure of the container         ington’s disease and Korsakov’s syndrome.
 bottom from a plane perpendicular to the axis. The container preferably
 is held in position and rotated around an axis by a drive roller (24) that
 urges the container against axially spaced backup rollers (26, 28), so as
 to define an average axis of rotation as a function of the geometry of the
 container and spacing between the backup rollers.




PATENT OFFICE JOURNAL 1567                                         29 January 2010                                Page 74 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND




(21) 548535      (22) 21 Jan 2005
(54) Realeasably-securable one-piece adjustable gastric band
(86) PCT/US2005/001620             (87) WO2005/072195
(51) IPC2010.01:A61B17/08,10
(71) Allergan Sales, LLC
(72) Birk, Janel;
(31) 04 538595 (32) 23 Jan 2004           (33) US
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,       (21) 549235      (22) 4 Mar 2005
Wellington 6011, New Zealand                                                   (54) Adenosine receptor agonists
(57) A releasably-securable gastric band having a tail end and a head end      (86) PCT/GB2005/000800           (87) WO2005/084653
  for receiving the tail end is disclosed. The gastric band also includes a    (51) IPC2010.01:A61K31/7076; A61P29/00; A61P9/00; C07H19/16
  releasable locking means that releasably secures the head and tail ends
                                                                               (71) Cambridge Biotechnology Limited
  together. The tail end includes a tooth and the head end includes a notch
  for engaging the tooth. Upon insertion of the tail end into the head end,    (72) Pritchard, Martyn Clive; Ouzman, Jacqueline Valerie Anne; Savory,
  the tooth mates with the notch and releasably locks the tail end in the      Edward Daniel; Brown, Giles Albert;
  head end. The releasably-securable gastric band also includes a release      (31) 04 0405012          (32) 5 Mar 2004         (33) GB
  tab. When force is applied to the release tab in a direction perpendicular   (31) 04 0412262          (32) 2 Jun 2004         (33) GB
  to a central axis of the gastric band, the tooth is disengaged from the      (31) 04 0412261          (32) 2 Jun 2004         (33) GB
  notch to allow the gastric band to be released.                              (31) 04 0413627          (32) 18 Jun 2004        (33) GB
                                                                               (31) 04 0419718          (32) 6 Sep 2004         (33) GB
                                                                               (31) 04 0420063          (32) 9 Sep 2004         (33) GB
                                                                               (31) 04 0420615          (32) 16 Sep 2004        (33) GB
                                                                               (31) 04 0405009          (32) 5 Mar 2004         (33) GB
                                                                               (31) 04GB 04000902 (32) 5 Mar 2004               (33) GB
                                                                               (74) Shelston IP, Level 21, 60 Margaret Street, Sydney, NSW 2000, Aus-
                                                                               tralia
                                                                               (57) Disclosed are compounds of formula (I), wherein X is OH and R1 is
                                                                                 selected from the group consisting of OCH2CHF2, OCH2cyclopropyl,
                                                                                 O-(4-cyano)Ph, O-(3-Ph)Ph, O-(2,5-F2)Ph, O-(2,4-F2)Ph, O-(3,4-F2)Ph,
                                                                                 O-(2,3,5-F3)Ph, O-(3-Me,4-F)Ph, O-(2-Me)Ph, O-(3-Br)Ph, O-(4-Me)Ph,
                                                                                 5-indanyloxy, O-(3-CH(CH3)2)Ph, OCH2cyclopentyl and O-(2,2,3,3-
                                                                                 tetrafluoro-cyclobutyl), or wherein X is H; and R1 is O(CH2)5CH3, or a
                                                                                 pharmaceutically acceptable salt thereof. The compounds are useful for
                                                                                 the treatment of pain or inflammation.




(21) 548751       (22) 27 Dec 2004
(54) Two layer breathable waterproof sole for shoes with the lower layer
forming the tread and the upper layer having a waterproof coating ob-
tained by a plasma deposition treatment
(86) PCT/EP2004/014717             (87) WO2005/063069
(51) IPC2010.01:A43B7/06,12; A43B13/12; B05D7/24
(71) GEOX S.p.A.
(72) Polegato Moretti, Mario; Ferrarese, Antonio; Mattioni, Bruno;
(31) 03 PD A 0312         (32) 30 Dec 2003         (33) IT
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
(57) A waterproof breathable sole 10 for shoes, comprising, for at least
  part of its extension, at least two structural layers, a lower one 14 pro-   (21) 549358      (22) 16 Feb 2005
  vided with a supporting structure so as to form the tread, and an upper
                                                                               (54) Skin lightening agents, compositions and methods, and synthesis
  microporous one 15 that is permeable to water vapour, the lower layer
                                                                               from coumarin derivatives
  14 having portions 14a that are open onto the upper layer 15, the sole 10
  being characterized in that at least one of the two surfaces of the upper    (86) PCT/EP2005/001595           (87) WO2005/085169
  layer 15 has a coating obtained by means of a plasma deposition treat-       (51) IPC2010.01:C07C59/52; C07C69/732; A61K7/48
  ment for waterproofing.                                                      (71) Unilever PLC
Divisional filed as 582263                                                     (72) Harichian, Bijan; Rosa, Jose Guillermo; Barratt, Michael James; Bosko,
                                                                               Carol Annette; Bajor, John Steven;
                                                                               (31) 04 789293 (32) 27 Feb 2004          (33) US
                                                                               (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                               Wellington 6011, New Zealand




 PATENT OFFICE JOURNAL 1567                                      29 January 2010                                Page 75 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(57) Disclosed is a compound of formula (I), wherein R1 and R2 are both          (21) 549605     (22) 4 Feb 2005
 H, and wherein the other substituents are as defined in the specification.      (54) Use of glufosfamide to treat chemotherapy-refractory pancreatic can-
 Also disclosed is a cosmetic composition comprising the compound and            cer
 a cosmetically acceptable carrier. Also disclosed is a method of lighten-       (86) PCT/US2005/003370           (87) WO2005/076888
 ing skin comprising applying the composition to skin. Also disclosed is a       (51) IPC2010.01:A61K31/70; A61P35/00
 process for preparing a compound of formula (I).                                (71) Threshold Pharmaceuticals, Inc.
                                                                                 (72) Tidmarsh, George;
                                                                                 (31) 04 542494 (32) 6 Feb 2004          (33) US
                                                                                 (74) SPRUSON & FERGUSON, St Martins Tower, Level 35, 31 Market
                                                                                 Street, Sydney, New South Wales 2000, Australia
                                                                                 (57) Disclosed is the use of glufosfamide for the manufacture of a medica-
                                                                                  ment for use in the treatment of a chemotherapy-refractory pancreatic
                                                                                  cancer, particularly a gemcitabine-refractory pancreatic cancer.


                                                                                 (21) 549675           (22) 21 Mar 2005
                                                                                 (54) Metof injecting lift gas into a production tubing of an oil well and gas
                                                                                 lift flow control device for use in the method
                                                                                 (86) PCT/EP2005/051298                (87) WO2005/093209
                                                                                 (51) IPC2010.01:E21B43/12
(21) 549556       (22) 17 Mar 2005                                               (71) SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.
(54) Method and separator for cyclonic separation of a fluid mixture             (72) Hall, James William; Johnson, Joseph Larry; Nettleship, Gary; Gallo-
(86) PCT/EP2005/051227            (87) WO2005/089950                             way, Arthur William;
(51) IPC2010.01:B04C5/14,181                                                     (31) 04 04101175              (32) 22 Mar 2004        (33) EP
(71) SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.                             (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
(72) Tee, Lih-Der; Verbeek, Paulus Henricus Johannes;                            Wellington 6011, New Zealand
(31) 04101155 (32) 19 Mar 2004            (33) EP                                (57) A method is disclosed for injecting lift gas or other fluid into a produc-
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,            tion conduit of an oil well via one or more wear resistant downhole gas lift
Wellington 6011, New Zealand                                                        flow control devices which each comprise: a tubular valve housing (1)
(57) A method for cyclonic separation of gaseous and liquid fractions from          comprising a flow passage (2) having an upstream end (9) which is con-
 a multiphase fluid mixture comprises: providing a cyclonic separation              nected to a lift gas supply conduit and a downstream end (10) which is
 vessel (1) having a bottom section (4), a top section (3) and a tubular            connected to the interior of the production conduit; a flapper type valve
 mid-section (2), which is co-axial to a central axis (5); injecting the            body (3) which is pivotally connected to the valve housing and is ar-
 multiphase fluid mixture into the vessel via an inlet conduit (6) which has        ranged in the flow passage such that if the valve body is pivoted in the
 a substantially tangential orientation relative to the central axis; inducing      open position the valve body is oriented substantially parallel to the flow
 the fluid mixture to swirl within the tubular mid-section of the vessel at         passage and that if the valve body is pivoted in the closed position the
 such a speed that liquid and gaseous fractions are separated by cyclonic           valve body is oriented substantially perpendicular to the flow passage
 separation and gravity forces induce the liquid fraction to drop to the            and is pressed against a ring shaped valve seat (4), thereby blocking
 bottom section of the vessel; removing the gaseous fraction from the               passage of lift gas through the flow passage; a valve protection sleeve
 interior of the top section of the vessel via a gas outlet conduit (8) which       (5) which is slidably arranged in the flow passage between a first position
 has an entrance opening which is located at or near the central axis;              wherein the sleeve extends through the ring-shaped valve seat, whilst
 removing the liquid fraction from the interior of the bottom section of the        the valve body is pivoted in the open position thereof, thereby protecting
 vessel via a plurality of liquid outlet openings (21) that are located at          the valve body and seat against wear by the flux of lift gas or other fluid
 different vertical levels and through which liquid is discharged into a liq-       and a second position wherein the sleeve extends through the section of
 uid outlet conduit (10) such that liquid components with different densi-          the flow passage upstream of the valve seat, whilst the valve body is
 ties are mixed into a substantially homogeneous liquid fraction and the            pivoted in the closed position thereof; and a flow restrictor (8) forming
 formation of high density and low density liquid slugs in the conduit is           part of the valve protection sleeve, which is dimensioned such that the
 mitigated.                                                                         flux of lift gas flowing through the flow restrictor creates a pressure differ-
                                                                                    ence which induces the sleeve to move towards the first position.




PATENT OFFICE JOURNAL 1567                                        29 January 2010                                   Page 76 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


                                                                                (21) 549780       (22) 25 Jan 2005
                                                                                (54) Kinase inhibitors
                                                                                (86) PCT/US2005/000025            (87) WO2005/075478
                                                                                (51) IPC2010.01:C07D471/04; A61K31/4188; A61P29/00
                                                                                (71) ELI LILLY AND COMPANY
                                                                                (72) Bonjouklian, Rosanne; Hamdouchi, Chafiq Hamdouchi; Shih, Chuan;
                                                                                De Dios, Alfonso; Del Prado, Miriam Filadelfa; Jaramillo Aguado, Carlos;
                                                                                Kotiyan, Pramila; Mader, Mary Margaret; Selgas, Sheila Pleite; Sanchez-
                                                                                Martinez, Concepcion;
                                                                                (31) 04 540830 (32) 30 Jan 2004          (33) US
                                                                                (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                                Wellington 6011, New Zealand
                                                                                (57)
                                                                                Disclosed is a compound of formula (I), wherein W is defined by formulae
                                                                                  (i) – (vii)
                                                                                X is N or C-R1;
                                                                                R is C1-C7 alkyl, C3-C7 cycloalkyl, (C1-C7 alkylene)-(C3-C7 cycloalkyl), -
                                                                                  SO2-(C1- C7 alkyl), or -SO2-NR5R6;
                                                                                R1 is hydrogen, amino, methyl, or -N=CH(NMe)2;
                                                                                R2 is phenyl optionally substituted with one or two substituents independ-
                                                                                  ently selected from halo;
                                                                                R3 is hydrogen, C1-C7 alkyl, C3-C7 cycloalkyl, or phenyl optionally substi-
                                                                                  tuted with one or two substituents independently selected from halo and
                                                                                  trifluoromethyl;
                                                                                R4 is hydrogen or C1-C7 alkyl;
                                                                                R5 and R6 are independently selected from the group consisting of C1-C7
                                                                                  alkyl; or a pharmaceutically acceptable salt thereof.
                                                                                Also disclosed is the use of this compound for treatment of cancer by
                                                                                  inhibition of p-38 kinase activity.



(21) 549756       (22) 6 Apr 2005
(54) Fluid ejection device and print head die with address generator for
actuating firing cells
(86) PCT/US2005/011729           (87) WO2005/105456
(51) IPC2010.01:B41J2/045,05
(71) Hewlett-Packard Development Company, L.P.
(72) Benjamin, Trudy L; Axtell, James P;
(31) 04 827163 (32) 19 Apr 2004          (33) US
(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
tre, 342 Lambton Quay, Wellington 6011, New Zealand
(57) A fluid ejection device comprises firing cells (70), signal lines (106a,
  106b, …) configured to receive a series of pulses, and an address gen-
  erator (not shown) configured to receive pulses from the series of pulses
  and generate a set of address signals in response to the received pulses,
  wherein the set of address signals is adapted to enable the firing cells
  (70) for activation.




                                                                                (21) 549839      (22) 10 Mar 2005
                                                                                (54) Formamide derivatives useful as adrenoceptor
                                                                                (86) PCT/IB2005/000619            (87) WO2005/092840
                                                                                (51) IPC2010.01:C07C217/60; C07C233/43; A61P11/00
                                                                                (71) PFIZER INC.
                                                                                (72) Brown, Alan Daniel; Bunnage, Mark Edward; Glossop, Paul Alan;
                                                                                James, Kim; Lane, Charlotte Alice Louise; Lewthwaite, Russell Andrew;
                                                                                Price, David Anthony;
                                                                                (31) 04 04290767          (32) 23 Mar 2004        (33) EP
                                                                                (31) 04 0425054           (32) 12 Nov 2004        (33) GB
                                                                                (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                                Wellington 6011, New Zealand
                                                                                (57) Disclosed is a beta2 agonist of general formula (1) wherein the (CH2)n-
                                                                                  C(=O)Q1 group is in the meta or para position and wherein the substituents
                                                                                  are disclosed within the specification or pharmaceutically acceptable salts
                                                                                  and/or steroisomers, tautomers, solvates or isotropic variations thereof.




 PATENT OFFICE JOURNAL 1567                                       29 January 2010                                 Page 77 |BACK TO CONTENT
                                     INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND




(21) 549862       (22) 18 Mar 2005
(54) Progesterone receptor modulators
(86) PCT/EP2005/051265            (87) WO2005/092912
(51) IPC2010.01:C07J43/00; C07J53/00; A61K31/58; A61P15/18
(71) N.V. ORGANON
(72) Hamersma, Johannes Antonius Maria; Rewinkel, Johannes Bernardus
Maria;
(31) 04 04101241          (32) 25 Mar 2004        (33) EP
(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-                        (21) 550180       (22) 19 Mar 2005
tre, 342 Lambton Quay, Wellington 6011, New Zealand                                 (54) Use of PDE III inhibitors for the reduction of heart size in mammals
(57) Disclosed are progesterone receptor modulating steroids of formula             suffering from heart failure
  (I) which have both agonistic and antagonistic modulating activities to-          (86) PCT/EP2005/002957             (87) WO2005/092343
  wards the progesterone receptor, processes for their preparation, and             (51) IPC2010.01:A61K31/4166,4412,4427,444,501
  their use in therapy, wherein the variables shown in formula (I) are as           (71) Boehringer Ingelheim Vetmedica GmbH
  defined in the specification. These compounds of formula (I) are suit-            (72) Daemmgen, Juergen; Jons, Olaf; Kleemann, Rainer;
  able for the treatment of endometriosis, for hormone replacement therapy
                                                                                    (31) 04 04007179          (32) 25 Mar 2004          (33) EP
  or for the treatment of a gynaecological disorder, and as a contraceptive.
                                                                                    (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
                                                                                    tre, 342 Lambton Quay, Wellington 6011, New Zealand
                                                                                    (57) The disclosure relates to the use of a phosphodiesterase type III
                                                                                      (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically ac-
                                                                                      ceptable salt or functional derivative thereof for the preparation of a medi-
                                                                                      cation for the reduction of the heart size of a patient suffering from heart
                                                                                      failure.


                                                                                    (21) 550417        (22) 15 Apr 2005
                                                                                    (54) Multi-phase contraceptive preparation based on a natural estrogen
                                                                                    (86) PCT/EP2005/004022            (87) WO2005/102247
                                                                                    (51) IPC2010.01:A61K31/00,56,57; A61P15/18
                                                                                    (71) Bayer Schering Pharma Aktiengesellschaft
                                                                                    (72) Endrikat, Jan; Dusterberg, Bernd;
                                                                                    (31) 04 019743 (32) 20 Apr 2004            (33) DE
                                                                                    (74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
                                                                                    (57) Provided is a multiphase product and method of for contraception
                                                                                     based on a natural estrogen with a synthetic progestogen, characterized
                                                                                     in that the first phase consists of 2 daily dose units of 3 mg of the natural
                                                                                     estrogen estradiol valerate, a second phase consists of 2 groups of daily
(21) 550154        (22) 29 Mar 2005                                                  dose units, where the first group is formed by 5 daily dose units of a
                                                                                     combination of 2 mg estradiol valerate and at least twice or three times
(54) Method and apparatus for controlling at least one ventilation param-
                                                                                     the ovulation-inhibitory dose of dienogest or drospirenon and the second
eter of an artificial ventilator for ventilating the lung of a patient in accord-
                                                                                     group is formed by 17 daily dose units of a combination of 2 mg estradiol
ance with a plurality of lung positions
                                                                                     valerate and at least three times or four times the ovulation-inhibitory
(86) PCT/US2005/010741               (87) WO2005/094369                              dose of dienogest or drospirenon, a third phase consists of 2 daily dose
(51) IPC2010.01:A61M16/00; A61H31/00                                                 units with 1 mg estradiol valerate, and a further phase consists of 2 daily
(71) KCI LICENSING, INC.                                                             dose units of a pharmaceutically acceptable placebo.
(72) Bohm, Stephan; Johnson, Royce W;
(31) 04 04007580            (32) 29 Mar 2004          (33) EP
(31) 05 05005418            (32) 11 Mar 2005          (33) EP                       (21) 550442    (22) 22 Apr 2005
(74) PIPERS, Level 1, 5A Pacific Rise, Mt Wellington, Auckland, New Zea-            (54) Reducing viscosity of oil for production from a hydrocarbon contain-
land                                                                                ing formation
(57) Positioning apparatus 101 for controlling the change of the position of        (86) PCT/US2005/013891           (87) WO2005/106194
  an artificially ventilated lung of a patient 105 lying in a nursing bed, com-     (51) IPC2010.01:E21B43/12,24
  prising a) a position actuator 103 for changing the position of the artifi-       (71) SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.
  cially ventilated lung, b) means for providing a periodical controlling sig-      (72) Pastor-Sanz, Guillermo; Vinegar, Harold J;
  nal having a distribution of a plurality of position periods and/or of a plu-     (31) 04 565077 (32) 23 Apr 2004         (33) US
  rality of amplitudes, and c) means for controlling 104 the position actua-
                                                                                    (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
  tor 103 by the periodical controlling signal.
                                                                                    Wellington 6011, New Zealand




PATENT OFFICE JOURNAL 1567                                           29 January 2010                                  Page 78 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(57) A method for treating a hydrocarbon containing formation (104), com-        (21) 550682       (22) 30 Jan 2006
  prises applying electrical current to one or more electrical conductors        (54) Method of producing a material of oxide superconductor with reduced
  (106) located in an opening in the formation to provide an electrically        impurities
  resistive heat output; allowing the heat to transfer from the electrical       (86) PCT/JP2006/301399            (87) WO2006/082767
  conductors to a part of the formation containing hydrocarbons so that a        (51) IPC2010.01:H01B13/00; H01L39/24; C01G1/02; H01B12/10
  viscosity of hydrocarbons in the part and at or near the opening in the        (71) SUMITOMO ELECTRIC INDUSTRIES, LTD.
  formation is reduced; providing gas at one or more locations in the open-
  ing to reduce the density of the hydrocarbons so that the hydrocarbons         (72) Ayai, Naoki;
  are lifted in the opening towards the surface of the formation by the for-     (31) 05 026466 (32) 2 Feb 2005              (33) JP
  mation pressure; and producing the hydrocarbons through the opening.           (31) 05 372553 (32) 26 Dec 2005             (33) JP
At least one of the electrical conductors comprises an electrically resistive    (74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
  ferromagnetic material and provides a reduced heat above or near a             (57) A method of producing an oxide for the manufacture of an oxide su-
  Curie temperature of the ferromagnetic material, and the produced hy-            perconductor is disclosed. The method comprises the steps ionizing a
  drocarbons have an API gravity of 20 degrees or less.                            solution (21) of the oxide, removing the solvent by spraying (12) the so-
                                                                                   lution (21) in a first atmosphere (14) to produce a powder (1a) and then
                                                                                   cooling the powder in a second atmosphere (16) into which a cooling gas
                                                                                   is introduced. The concentration of carbon dioxide in the second atmos-
                                                                                   phere (16) is lower than that in the first atmosphere (14). The concentra-
                                                                                   tion of nitrogen oxide in the second atmosphere (16) is lower than that in
                                                                                   the first atmosphere (14). The concentration of water vapour in the sec-
                                                                                   ond atmosphere (16) is lower than that in the first atmosphere (14). This
                                                                                   results in an oxide (1) substantially free of impurities.




(21) 550610       (22) 12 Apr 2005
(54) Method and auxiliary device for the underwater disassembly/assem-
bly of a tunnel thruster
(86) PCT/SE2005/000520           (87) WO2005/100151
(51) IPC2010.01:B63H25/42
(71) ROLLS-ROYCE AKTIEBOLAG
(72) Andersson, Lars-Goran;
(31) 040 1006 (32) 19 Apr 2004            (33) SE
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand
(57) A method in connection with disassembly and/or assembly of a tunnel
  thruster unit 2 by using an auxiliary device 1 for guiding the thruster unit
  2 and its movement during disassembly/ assembly inside the tunnel, the
  method comprising transporting the thruster unit 2 through the tunnel,
  and irremovably fixing the auxiliary device 1 at the thruster unit 2 before
  final disassembly/assembly, such that the auxiliary device 1 controls the
  movement during disassembly/assembly, mainly by compressive forces.
Divisional filed as 581536
                                                                                 (21) 550694      (22) 25 Apr 2005
                                                                                 (54) Coating material for highly corrosion-resistant zinc alloy-plated steel
                                                                                 member and steel structure having coating film made of such coating
                                                                                 material
                                                                                 (86) PCT/JP2005/008330           (87) WO2005/105934
                                                                                 (51) IPC2010.01:B32B15/08; C09D5/10; C09D7/12; C23C26/00
                                                                                 (71) NIPPON STEEL CORPORATION
                                                                                 (72) Yamamoto, Masahiro;
                                                                                 (31) 04 132315 (32) 28 Apr 2004           (33) JP
                                                                                 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                                 Wellington 6011, New Zealand
                                                                                 (57) Disclosed is a coating material for highly corrosion-resistant zinc-
                                                                                  alloy coated steel members, containing zinc-alloy powder at not less than
                                                                                  60 mass% and a resin, characterized in that said powder contains alu-
                                                                                  minium at not less than 10 mass% and less than 30 mass% and the
                                                                                  remainder comprising zinc and unavoidable impurities, the shape of pow-
                                                                                  der particles is spherical or oval and the ratio between the maximum and
                                                                                  minimum diameters (maximum diameter/minimum diameter) is 1 to 1.5.
                                                                                  Also disclosed is a steel structure having a coating film which is formed
                                                                                  by using such a coating material.




 PATENT OFFICE JOURNAL 1567                                        29 January 2010                                Page 79 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(21) 550718      (22) 19 Apr 2005                                               (21) 550782       (22) 24 Apr 2007        (23) 3 Jul 2008
(54) Placement system for a flying kite-type wind-attacked element in a         (54) Children’s stroller transporter
wind-powered watercraft                                                         (51) IPC2010.01:B60R9/06; B62B7/00; B62B9/00
(86) PCT/EP2005/004186            (87) WO2005/100150                            (71) KYLE ALEXANDER BURNETT
(51) IPC2010.01:B63H9/06                                                        (72) Burnett, Kyle Alexander;
(71) Skysails GmbH & Co. KG                                                     (74) JAMES & WELLS, Level 11, PricewaterhouseCoopers Centre, 119
(72) Wrage, Stephan; Bohm, Johannes;                                            Armagh Street, Christchurch, New Zealand
(31) 04 018814 (32) 19 Apr 2004           (33) DE                               (57) A support including: an attachment for attaching the support to a ve-
(74) Pizzeys Patent and Trade Mark Attorneys, Level 2, Woden Plaza               hicle; a first arm connected to the attachment; and a second arm pivot-
Offices, Woden Town Square, Woden, ACT 2606, Australia                           ally connected to the first arm and including a support coupling fitting
(57) A deployment system for a freely flying kite-like element 101 for a         configured to engage with a container coupling fitting located on a con-
 watercraft which is acted on by the wind and includes a hawser 1.1 by           tainer to be attached to the second arm. The range of relative pivotal
 which the element 101, which has a wing shaped profile, is connected to         movement of the second arm with respect to the first arm is between
 the craft body and can be moved from a rest position on-board the water-        zero and approximately 150 degrees. The attachment includes a cou-
 craft to a raised launch position, which is free of obstructions at the same    pling including a vehicle coupling fitting for fixing to a tow bar of the vehi-
 level or a higher level than the watercraft, by a pivotable holder 182. The     cle and an attachment coupling fitting fixed to the support attachment,
 holder 182, which moves the element 101 to a position in which it is            the coupling capable of being reversibly engaged to releasably secure
 subject to sufficient wind effect, and also allows it to be stowed away has     the support to the vehicle.
 a docking receptacle apparatus 186 which forms a detachable connec-
 tion to a docking adapter 187 of the element 101 on the side facing away
 from the wind.




                                                                                (21) 550831      (22) 14 Apr 2004
                                                                                (54) 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione or CC-4047
(21) 550732     (22) 21 Apr 2005                                                for the treatment and management of myelodysplastic syndromes
(54) Polyamide multilayer film                                                  (86) PCT/US2004/011630            (87) WO2005/110408
(86) PCT/US2005/013799          (87) WO2005/110747                              (51) IPC2010.01:A61K31/445; A61K38/16,18,19,20; C07D401/04;
                                                                                C07K14/435,52,53,54,55; A61K45/06; A61P7/00
(51) IPC2010.01:B32B27/34; C08G69/48
                                                                                (71) CELGENE CORPORATION
(71) CRYOVAC, INC.
                                                                                (72) Zeldis, Jerome B;
(72) Bekele, Solomon; Esakov, Michael D;
                                                                                (74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
(31) 04 835792 (32) 30 Apr 2004          (33) US
                                                                                (57) Disclosed is the use of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                                  1,3-dione or CC-4047 in the manufacture of a composition for treating
Wellington 6011, New Zealand
                                                                                  myelodysplastic syndrome.
(57) The disclosure relates to a multilayer film comprising:
A first layer comprising at least about 40% of one or more modified
 polyamides, based on the weight of the first layer;
A second layer comprising at least about 40% of one or more unmodified
 polyamides, based on the weight of the second layer;
and a third layer comprising at least about 40% of one or more tie poly-
 mers selected from ethylene/vinyl acetate copolymer, ethylene/
 (meth)acrylic acid copolymer, ethylene/C1-C12 alkyl (meth)acrylate co-
 polymer, and anhydride-modified polyolefin, based on the weight of the
 third layer; wherein the second layer is directly adhered to the first and
 third layers.




PATENT OFFICE JOURNAL 1567                                       29 January 2010                                  Page 80 |BACK TO CONTENT
                                      INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(21) 550840       (22) 24 May 2005                                                   (21) 550970      (22) 27 May 2004
(54) Use of substituted quinoline derivatives for the treatment of drug re-          (54) Medical adhesive and methods of tissue adhesion
sistant mycobacterial diseases                                                       (86) PCT/US2004/016767           (87) WO2005/118011
(86) PCT/EP2005/052371              (87) WO2005/117875                               (51) IPC2010.01:C08G18/00; A61L24/04
(51) IPC2010.01:A61K31/47; A61P31/06                                                 (71) University of Pittsburgh
(71) Janssen Pharmaceutica N.V.                                                      (72) Beckman, Eric J; Buckley, Michael; Agarwal, Sudha; Zhang, Jianying;
(72) Andries, Koenraad Jozef Lodewijk Marcel; Van Gestel, Jozef Frans                (31)     (32) 27 May 2004        (33) US
Elisabetha;                                                                          (74) Mallesons Stephen Jaques, Level 50 Bourke Place, 600 Bourke Street,
(31) 04 04102402           (32) 28 May 2004             (33) EP                      Melbourne VIC 3000, Australia
(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-                         (57) Disclosed is the use of a moisture-curable, isocyanate-functional com-
tre, 342 Lambton Quay, Wellington 6011, New Zealand                                    position in the manufacture of an adhesive for adhering tissue, the
(57) Disclosed is the use of a substituted quinoline derivative of formula             isocyanate-functional composition comprising the reaction product of a
  (Ia) or (Ib), wherein p is 1 to 4, q is 0 to 4, r is 1 to 5, two R6 radicals may     reaction mixture consisting essentially of:
  be taken together to form a bivalent radical of formula -CH=CH-CH=CH-              (a) a stoichiometric excess of multi-isocyanate functional molecules de-
  , R9 is O, or R8 and R9 may together form the radical =N-CH=CH-, and                 rived from multi-functional amino acid precursors; and
  wherein the other substituents are as described in the specification, for          (b) a multi-functional reactant selected from the group consisting of a sac-
  treating infections of drug resistant Mycobacterium strains.                         charide, a polysaccharide, a steroid, glycerol, ascorbic acid, an amino
Also disclosed is a combination of a compound of formula (Ia) or (Ib) as               acid, and combinations thereof, the multi-functional reactant having at
  defined above and at least one other antimycobacterial agent.                        least two isocyanate-reactive functional groups, wherein the reaction
                                                                                       product has an average isocyanate functionality of at least 2.1.
                                                                                     Divisional filed as 581865


                                                                                     (21) 551199        (22) 6 Jun 2005
                                                                                     (54) Methods of reducing nematode damage
                                                                                     (86) PCT/EP2005/006057               (87) WO2005/120232
                                                                                     (51) IPC2010.01:A01N37/44; A01N43/90
                                                                                     (71) Syngenta Participations AG
                                                                                     (72) Angst, Max; Kerber, Elmar; Morcos, Adel;
                                                                                     (31) 04013338 (32) 7 Jun 2004                (33) EP
                                                                                     (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
                                                                                     tre, 342 Lambton Quay, Wellington 6011, New Zealand
                                                                                     (57) Disclosed is a method of reducing damage to a plant or plant propa-
                                                                                       gation material or plant organs which grow during the life of a plant, by a
                                                                                       representative of the class of Nematoda, which method comprises (i)
                                                                                       treating the plant or plant propagation material with (A) a chelating agent
                                                                                       before the plant or the material is sown or planted, or (ii) applying (A) a
                                                                                       chelating agent to the locus of the plant, the material or the treated mate-
                                                                                       rial defined in (i) before its planting, and/or at its planting and/or during its
                                                                                       growth, wherein the chelating agent is polycarboxylic acid and provided,
                                                                                       when the chelating agent is metallated, the metal is selected from Cr,
                                                                                       Mn, Fe, Co, Ni, Cu and Zn.


                                                                                     (21) 551430     (22) 6 Jun 2005
                                                                                     (54) Diagnosing or predicting the course of breast cancer
                                                                                     (86) PCT/US2005/019616          (87) WO2005/118875
                                                                                     (51) IPC2010.01:C12Q1/68
                                                                                     (71) VERIDEX, LLC
                                                                                     (72) Atkins, David; Backus, John; Belly, Robert; Rosen, Steve; White,
                                                                                     Robert;
                                                                                     (31) 04 577155 (32) 4 Jun 2004          (33) US
(21) 550926     (22) 13 May 2005                                                     (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
(54) Hydrogel interferon formulations                                                Wellington 6011, New Zealand
(86) PCT/EP2005/052219          (87) WO2005/110466                                   (57) Provided is a method of diagnosing the presence or predicting the
(51) IPC2010.01:A61K38/19                                                             course of breast cancer comprising measuring the expression of a com-
(71) ARES TRADING S.A.                                                                bination of marker genes comprising at least one tissue specific gene
(72) Del Curto, Maria Dorly; Zambaldi, Ilaria; Pompili, Silvia; Esposito,             and at least one non-tissue-specific gene in a cell or tissue sample de-
Pierandrea;                                                                           rived from a patient; wherein the tissue-specific gene is selected from
(31) 04 04076496        (32) 17 May 2004         (33) EP                              the group consisting of mammaglobin, PIP and B30SD, and the non-
(31) 04 579218 (32) 14 Jun 2004          (33) US                                      tissue specific gene is selected from the group consisting of CK19 and
                                                                                      EPCAM. Further provided are corresponding PCR primer kits for said
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                                      assays.
Wellington 6011, New Zealand
(57) A pharmaceutical composition comprising an interferon-beta (IFN-
  beta), wherein said composition is a Poloxamer hydrogel and further
                                                                                     (21) 551443    (22) 24 May 2005
  comprises a methionine antioxidant and a solution-to-gel temperature
  transition modifier such as Trehalose or cyclodextrin. These pharma-               (54) Chimeric adenoviruses for use in cancer treatment
  ceutical preparations are useful for the treatment of multiple sclerosis.          (86) PCT/US2005/018301        (87) WO05/118825
                                                                                     (51) IPC2010.01:A61K48/00; C12N15/861; C12N7/01,02
                                                                                     (71) SCHERING AG
                                                                                     (72) Harden, Paul; Herminston, Terry; Kuhn, Irene;




 PATENT OFFICE JOURNAL 1567                                            29 January 2010                                   Page 81 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(31) 04 574 851         (32) 26 May 2004       (33) US                            (21) 551638      (22) 20 Jun 2005
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand                 (54) Microbial glyphosate resistant 5-enolpyruvylshikimate-3-phosphate
(57) Provided is a recombinant chimeric adenovirus having a genome com-           synthases
 prising an E2B region, which said region comprises nucleic acid se-              (86) PCT/US2005/021725            (87) WO2006/012080
 quences derived from two different adenoviral serotypes, wherein the             (51) IPC2010.01:C12N15/82; C12N9/10
 said chimeric adenovirus is oncolytic and demonstrates an enhanced               (71) MONSANTO TECHNOLOGY LLC
 therapeutic index for a tumor cell.                                              (72) Alibhai, Murtaza F; Chay, Cathy; Flasinski, Stanislaw; Lu, Maolongs;
                                                                                  Stallings, Williams; Sammons, Douglas;
                                                                                  (31) 04582658 (32) 20 Jun 2004           (33) US
(21) 551566     (22) 14 Jun 2005                                                  (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
(54) Providing freezing and thawing resistance to cementitious composi-           Wellington 6011, New Zealand
tions                                                                             (57) Provided is a chimeric DNA construct comprising a promoter mol-
(86) PCT/EP2005/006329          (87) WO2005/123624                                 ecule functional in a plant cell operably linked to an artificial polynucle-
(51) IPC2010.01:C04B28/02; C04B38/02,08                                            otide molecule encoding a Caulobacter glyphosate resistant 5-
(71) CONSTRUCTION RESEARCH & TECHNOLOGY GMBH                                       enolpyruvyl-3-phosphoshikimate synthase (EPSPS) polypeptide, wherein
(72) Christensen, Bruce J; Vickers, Thomas M;                                      said EPSPS polypeptide comprises the sequence domains G-D-K-S; S-
(31) 04 579975 (32) 15 Jun 2004        (33) US                                     A-Q-X2_K, in which X2 is I or V; and R-D-H-T-E, and N-E-L-R. Further
(31) 04 579691 (32) 15 Jun 2004        (33) US                                     provided are transgenic plants and seed comprising the DNA construct
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,           and a method of selectively killing weeds with glyphosate in a field planted
Wellington 6011, New Zealand                                                       with such transgenic plants.
(57) The disclosure relates to a cementitious freeze-thaw damage resist-          Divisional filed as 578809
  ant wet cast composition adapted to be exposed to freeze-thaw cycles
  comprising hydraulic cement, gas generating additives, and flexible poly-
  meric microspheres, wherein the flexible polymeric microspheres have            (21) 551808      (22) 14 Feb 2005
  an average diameter of about 100 micrometers or less.                           (54) Two-way architectural structural system and modular support mem-
                                                                                  ber
                                                                                  (86) PCT/US2005/004462           (87) WO2005/111329
(21) 551605       (22) 27 Jun 2005                                                (51) IPC2010.01:E04B1/24
(54) Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-               (71) DAVID HOVEY
methylpropyl)-phenol hydrochloride                                                (72) Hovey, David;
(86) PCT/EP2005/006884            (87) WO2006/000441                              (31) 04 840440 (32) 6 May 2004           (33) US
(51) IPC2010.01:A61K31/135; A61P13/00; C07C215/54; A61K31/137                     (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
(71) Grunenthal GmbH                                                              Wellington 6011, New Zealand
(72) Fischer, Andreas; Buschmann, Helmut; Gruss, Michael; Lischke,                (57) A structural connector 44 for an architectural structural system com-
Dagmar;                                                                            prising a plurality of transverse blades 16’ having opposed faces, a por-
(31) 04 04015091          (32) 28 Jun 2004         (33) EP                         tion of each of the transverse blades meeting at a juncture 48, each of
(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-                       the plurality of blades 16’ provided to connect to adjacently disposed
tre, 342 Lambton Quay, Wellington 6011, New Zealand                                pairs of c-beams in an architectural structural system one to the other on
(57) Disclosed is a crystalline form of (-)-(1R,2R)-3-(3-dimethylamino-1-          opposed faces of the blades, a first lower columnar blade 46 coplanar
  ethyl-2-methylpropyl)-phenol hydrochloride, with an X-ray diffraction pat-       with and extending from a lower edge of one of the plurality of transverse
  tern as described in the specification. Also disclosed is a process for          blades 16’ for connecting with a lower beam 22, and a first upper colum-
  preparing this crystalline form. Also disclosed is the use of the crystalline    nar blade 46 coplanar with and extending from an upper edge of one of
  form for treating pain or urinary incontinence.                                  the plurality of transverse blades 16’ for connecting with an upper beam
                                                                                   22.

(21) 551622      (22) 1 Jun 2005
(54) Treatment of esophageal cancer with lapatinib tosylate
(86) PCT/US2005/019053           (87) WO2005/120504
(51) IPC2010.01:A61K31/517; C07D239/94
(71) SMITHKLINE BEECHAM (CORK) LIMITED
(72) Berger, Mark S; El-Hariry, Iman; Gilmer, Tona Morgan; Rusnak, David;
Spector, Neil L; Pandite, Arundathy Nirmalini;
(31) 04 576825 (32) 3 Jun 2004           (33) US
(31) 04 606790 (32) 2 Sep 2004           (33) US
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
(57) Disclosed is the use of N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-
 [5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
 tosylate in the manufacture of a medicament for the treatment of an EGFR
 and/or erbB2 overexpressing esophageal cancer.




PATENT OFFICE JOURNAL 1567                                         29 January 2010                                 Page 82 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(21) 551832        (22) 9 Jun 2005                                                (21) 551940      (22) 22 Jun 2005
(54) Neural stem cells                                                            (54) Improvements in welding hollow flange members using resistance
(86) PCT/GB2005/002289               (87) WO2005/121318                           welding
(51) IPC2010.01:C12N5/06                                                          (86) PCT/AU2005/000897           (87) WO2006/000018
(71) The University Court of The University of Edinburgh                          (51) IPC2010.01:B21D19/02,04,06; B23K13/02
(72) Conti, Luciano; Pollard, Steven Michael; Smith, Austin Gerard;               (71) Smorgon Steel LiteSteel Products Pty Ltd
(31) 0412887 (32) 9 Jun 2004                 (33) GB                              (72) Bartlett, Ross John; Noller, Alexander; Yokoyama, Keiji;
(31) 0503044 (32) 14 Feb 2005                (33) GB                              (31) 04 903388 (32) 23 Jun 2004           (33) AU
(31) 0505510 (32) 17 Mar 2005                (33) GB                              (74) FISHER ADAMS KELLY, Level 29, Comalco Place, 12 Creek Street,
(74) Shelston IP, Level 21, 60 Margaret Street, Sydney, NSW 2000, Aus-            Brisbane, Queensland 4000, Australia
tralia                                                                            (57) A process for In-line welding of hollow flange steel members (30) in a
(57) Provided is a method of obtaining and maintaining a transfected               cold forming mill is disclosed. The process forms the hollow flange steel
  population of symmetrically dividing neural stem cells, the method com-          member (30) from a metal strip whose edges are formed into a con-
  prising: (a) transfecting ES cells with a construct encoding a selectable        toured surface having a free edge and then welding the free edge to the
  marker A, wherein said ES cells are not totipotent human ES cells and            surface of the metal strip by an ERW process. The free edges are aligned
  wherein said selectable marker A is expressible under the control of a           linearly with a predetermined weld axis on the surface of the strip by one
  neural stem cell-specific promoter; (b) promoting differentiation of the         or more seam guide rolls (68, 68a), each of which has a circumferential
  ES cells to neural stem cells; (c) selecting for cells that express the          shoulder (70). The free edge is urged into abutment with the shoulder by
  selectable marker A, wherein at least 80% of the selected cells are sym-         a contoured guide roll (66, 66a) and is guided through a predetermined
  metrically-dividing neural stem cells and wherein no more than I% of the         linear trajectory along an incidence axis of the subsequent weld junction
  selected cells are positive for the expression of markers for mature             between the free edge and the surface. Energy is then focussed by a
  astrocytes, neurons or oligodendrocytes; and (d) culturing the selected          proximity effect along the predetermined weld axis prior to fusing the free
  cells attached to a substrate in a medium containing: (i) an activator of a      edge to the surface.
  signalling pathway downstream from a receptor of the EGF family; and
  (ii) an activator of a signalling pathway downstream from an FGF receptor.
  Further provided are neural stem cell lines obtained by the method.


(21) 551865       (22) 18 May 2005
(54) Container and blank with a window foil
(86) PCT/EP2005/005406            (87) WO2005/113347
(51) IPC2010.01:B65D3/06,28
(71) SEDA S.P.A.
(72) D’Amato, Gianfranco;
(31) 04 04007969          (32) 18 May 2004         (33) DE
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand
(57) Container 1 for receiving food with a container wall 5 comprising at
  least a paper layer and a further layer, the container 1 having a container
  opening 7 at its upper end and being closed at its end opposite to the
  container opening 7, wherein at least the container wall 5 is formed by a
  two dimensional blank, the blank being connected to itself to form a con-
  tinuous container wall 5, and wherein the container wall 5 has at least
  one window 10, which is closed by a transparent or translucent window
  foil, wherein the container wall 5 is curved at least partially in the region
  of the window 10 and the window foil is hot sealed to the paper layer for
  sealing the window 10.                                                          (21) 551970       (22) 20 Jun 2005
                                                                                  (54) New process for the preparation of crystal modifications for use in the
                                                                                  preparation of esomeprazole sodium salt
                                                                                  (86) PCT/SE2005/000954            (87) WO2006/001753
                                                                                  (51) IPC2010.01:A61K31/4439; C07D401/12
                                                                                  (71) ASTRAZENECA AB
                                                                                  (72) Bohlin, Martin; Noreland, Ursula;
                                                                                  (31) 04 582 617           (32) 24 Jun 2004      (33) US
                                                                                  (74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
                                                                                  (57) Disclosed is a process for preparing an esomeprazole sodium salt,
                                                                                     comprising:
                                                                                  i) Dissolving esomeprazole neutral form in toluene,
                                                                                  ii) Adding an addition solvent selected from methanol, ethanol, and isopro-
                                                                                     pyl alcohol,
                                                                                  iii) Adding about 1 molar equivalents of a sodium salt of a suitable base B,
                                                                                  iv) Allowing the esomeprazole sodium salt to crystallize and isolating the
                                                                                     formed salt.
                                                                                  Also disclosed is an esomeprazole sodium salt obtained by the process.
                                                                                     Also disclosed are three esomeprazole sodium salt, each with X-ray dif-
                                                                                     fraction patterns as described herein.


                                                                                  (21) 551974     (22) 1 Jul 2005
                                                                                  (54) Alpha-helical minetics
                                                                                  (86) PCT/AU2005/000968          (87) WO2006/002474
                                                                                  (51) IPC2010.01:A61K31/17; A61P29/00; A61P35/00,02; C07C275/50,54




 PATENT OFFICE JOURNAL 1567                                         29 January 2010                                Page 83 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(71) The Walter and Eliza Hall Institute of Medical Research                   (21) 552150      (22) 14 Jun 2005
(72) Lessene, Guillaume Laurent; Baell, Jonathan;                              (54) MULTIPLEXING FOR A MULTI-CARRIER CELLULAR COMMUNI-
(31) 04 584473 (32) 2 Jul 2004 (33) US                                         CATION SYSTEM
(74) DAVIES COLLISON CAVE - MELBOURNE, 1 Nicholson Street, Mel-                (86) PCT/US2005/021056           (87) WO2006/009715
bourne, Victoria, Australia                                                    (51) IPC2010.01:H04J13/06; H04L5/02; H04B1/713,69; H04J13/02
(57) Disclosed is a compound of formula (I) wherein R1 is selected from        (71) Qualcomm Incorporated
 CO2H or a carboxylic acid or carboxylate bioisostere and wherein the          (72) Sutivong, Arak; Agrawai, Avneesh;
 rest of the substituents are disclosed in the specification and               (31) 04 580810 (32) 18 Jun 2004          (33) US
 pharmaceutically acceptable salts and prodrugs thereof.                       (31) 04 887710 (32) 8 Jul 2004 (33) US
Also disclosed is a conjugate of formula (I) and a cell targeting moiety.      (74) JAMES & WELLS, Level 12, KPMG Centre, 85 Alexandra Street,
Also disclosed is the use of a compound of formula (I) in the manufacture      Hamilton, New Zealand
 of a medicament for treating and/or preventing a disease or condition         (57) An apparatus in a communication system comprises means for de-
 characterized by the inappropriate persistence or proliferation of unwanted    termining L sets of traffic channels to use for U terminals selected for
 or damaged cells or for treating or preventing a pro-survival BCl-2 family     data transmission to a base station where L is greater than one and U is
 member-mediated disease or condition.                                          one or greater and means for assigning the U terminals with the traffic
                                                                                channels in the L sets. Each set includes multiple traffic channels that
                                                                                are orthogonal to one another, and the traffic channels in each set are
(21) 552063     (22) 30 Jun 2005                                                not orthogonal to the traffic channels in each of the L-1 other sets. Each
(54) Chimeric and humanised monoclonal antibodies against inteleukin-           traffic channel is associated with one or more frequency subbands to
13                                                                              use for data transmission in each transmission interval, and wherein data
                                                                                transmissions for the U terminals are sent using the traffic channels as-
(86) PCT/GB2005/002581           (87) WO06/003407
                                                                                signed to the U terminals. An apparatus in a communication system
(51) IPC2010.01:A61K39/06; A61P37/02,08; C07K16/24                              comprises means for obtaining a traffic channel to use for data transmis-
(71) GLAXO GROUP LIMITED                                                        sion and means for mapping data modulation symbols onto the one or
(72) Ashman, Claire; Cassidy, Martin John; Ellis, Jonathan Henry; Wattam,       more frequency subbands belonging to the traffic channels. The traffic
Trevor Anthony Kenneth;                                                         channel is selected from among L sets of traffic channels for a base
(31) 04 0414799          (32) 1 Jul 2004 (33) GB                                station where L is greater than one and each set includes multiple traffic
(31) 04 0423675          (32) 25 Oct 2004        (33) GB                        channels that are orthogonal to one another. The traffic channels in each
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,        set are not orthogonal to the traffic channels in each of the L-1 other
Wellington 6011, New Zealand                                                    sets, and the traffic channel is associated with one or more frequency
(57) Provided is a therapeutic antibody or antigen binding fragment thereof     subbands to use for data transmission in each transmission interval. The
 which specifically binds hIL-13 and modulates the interaction between          means for obtaining a traffic channel is a controller and the means for
 hIL-13 and hIL-13R and comprises a specified sequence of CDRH3.                mapping data modulation symbols is a mapping unit. The apparatus can
 Further provided are methods of producing the antibody and use of the          be either a terminal or a base station.
 antibody in the manufacture of medicaments.


(21) 552103     (22) 23 Jun 2005
(54) Inhaler device counter
(86) PCT/SE2005/000995          (87) WO2006/004497
(51) IPC2010.01:G06M3/02; A61M15/00; G06M1/22,24
(71) ASTRAZENECA AB
(72) Hodson, Darren; Treneman, William; Bunce, Martin;
(31) 0401787 (32) 5 Jul 2004 (33) SE
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
(57) Inhaler 10 device counter 20 for displaying the number of remaining
 doses in an inhaler 10 device, comprising a counter mechanism and a
 display arrangement 60, characterized in the display arrangement 60 is
 of pointer-gauge type with a static display section provided as an inte-
 grated part of a transparent display containing part of a counter housing
 70.



                                                                               (21) 552219     (22) 19 Oct 2004
                                                                               (54) Handle-fixing system for a hand tool or utensil
                                                                               (86) PCT/ES2004/000449          (87) WO2006/030047
                                                                               (51) IPC2010.01:B25G3/12,28
                                                                               (71) PEDRO JOSE ZUBIAURRE ALBERDI; MANUEL MA ZUBIAURRE
                                                                                ALBERDI
                                                                               (72) Zubiaurre Alberdi, Pedro Jose; Zubiaurre Alberdi, Manuel Ma;
                                                                               (31) P-200402342        (32) 1 Oct 2004         (33) ES
                                                                               (31) P-200402343        (32) 1 Oct 2004         (33) ES
                                                                               (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                               Wellington 6011, New Zealand
                                                                               (57) A handle connection for a manual utensil or tool 2, comprising a) a
                                                                                handle for an implement 2, the handle having a non-metallic head 1, b)
                                                                                the implement 2 has a hole in which the head 1 of the handle is inset,
                                                                                thereby leaving the end surface of the handle head 1 free, c) a third,
                                                                                metallic and non-deformable element fastened to the top of the head 1 of
                                                                                the handle, hereby partially occupying a transversal section of the head
                                                                                1 of the handle and being completely contained within the head 1 of the




PATENT OFFICE JOURNAL 1567                                      29 January 2010                                Page 84 |BACK TO CONTENT
                                  INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


 handle, and d) a fastening screw 7, the body 16 of which is connected to
 the third element and the screw 7 has a head 9 that abuts against the
 implement, thereby establishing a male-female relationship, between the
 third element and the fastening screw 7 such that the third element can
 move longitudinally, thus pulling the head 1 of the handle with it and
 thereby inserting the handle into the hole of the implement.




                                                                             (21) 552390     (22) 4 Aug 2005
                                                                             (54) Novel fenofibrate formulations and related methods of treatment
                                                                             (86) PCT/US2005/027806             (87) WO2006/017692
                                                                             (51) IPC2010.01:A61K31/192; A61K9/00
                                                                             (71) TRANSFORM PHARMACEUTICALS, INC.
                                                                             (72) Guzman, Hector; Almarsson, Orn; Remenar, Julius;
                                                                             (31) 04 599320 (32) 6 Aug 2004             (33) US
                                                                             (31) 04 604861 (32) 27 Aug 2004            (33) US
                                                                             (31) 05 655762 (32) 24 Feb 2005            (33) US
                                                                             (31) 05 687704 (32) 6 Jun 2005             (33) US
                                                                             (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                             Wellington 6011, New Zealand
                                                                             (57) Provided is a liquid formulation comprising fenofibrate dissolved in a
                                                                              vehicle comprising an omega-3 fatty acid ethyl ester and an alcohol,
                                                                              wherein: the formulation comprises (i) about 5 % to about 20 % by weight
                                                                              of fenofibrate; (ii) about 55 % to about 85 % by weight of an omega-3
                                                                              fatty acid ethyl ester; (iii) about 5 % to about 20 % by weight of an alco-
                                                                              hol; and (iv) about 5 % to about 25 % by weight of a surfactant. Also
                                                                              provided are methods of increasing the solubility of fenofibrate and use
                                                                              of the composition in the manufacture of medicaments for treating
                                                                              hyperlipidemia.
(21) 552284      (22) 24 May 2005
(54) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1              (21) 552444      (22) 6 Jun 2005
(86) PCT/US2005/018081           (87) WO2005/116002                          (54) Methods and apparatuses for obtaining beverages
(51) IPC2010.01:A61K31/42,426; A61P19/10; A61P25/24,28; A61P29/00;           (86) PCT/EP2005/006045            (87) WO2006/010404
A61P3/00,04,06,10; A61P31/12; C07D263/48; C07D277/54                         (51) IPC2010.01:A47J31/30
(71) Amgen Inc; Biovitrum AB                                                 (71) ILLYCAFFE’ S.p.A
(72) Henriksson, Martin; Homan, Evert; Johansson, Lars; Vallgarda, Jerk;     (72) Navarini, Luciano; Mastropasqua, Luca; Dellapietra, Bruno; Suggi
Williams, Meredith; Bercot, Eric; Fotsch, Christopher H; Li, Aiwen; Cai,     Liverani, Furio;
Guolin; Hungate, Randall W; Yuan, Chester Chenguang; Tegley,
                                                                             (31) 04 202      (32) 30 Jul 2004         (33) IT
Christopher; St Jean, David; Han, Nianhe; Huang, Qi; Liu, Qingyian;
Bartberger, Michael D; Moniz, George A; Frizzle, Matthew J;                  (74) P L BERRY & ASSOCIATES, AEQ Building, 61 Cambridge Terrace,
                                                                             Christchurch 8013, New Zealand
(31) 04 0401324          (32) 24 May 2004        (33) SE
                                                                             (57) An apparatus for preparing a coffee beverage by imbibing a dose (W)
(31) 04 0402509          (32) 15 Oct 2004        (33) SE
                                                                              of coffee with an extraction fluid driven by heating through the dose (W),
(31) 05 650777 (32) 31 Jan 2005          (33) US                              comprises inhibition means arranged to inhibit the imbibing when the
(74) KNIGHTSBRIDGE PATENT ATTORNEYS, Level 14, 200 Queen                      fluid contains a prevalently steam phase. Also disclosed is a method for
Street, Melbourne, Victoria 3000, Australia                                   obtaining a coffee beverage comprises heating an extraction fluid so as
(57) The disclosure relates to compounds with the formula (III) wherein       to induce the passage of the extraction fluid through a dose (W) of coffee
  R5, R6, R7 are as defined in the specification. Also disclosed are phar-    to obtain the beverage and inhibiting the passing when the extraction
  maceutical compositions comprising the compounds, as well as meth-          fluid contains a prevalently steam phase, the inhibiting including avoid-
  ods of use of the compounds for treatment of disorders associated with      ing the formation of the prevalently steam phase.
  human hydroxysteroid dehydrogenase type 1 enzyme and for the prepa-        Divisional filed as 581483
  ration of a medicament which acts on the human 11-hydroxysteroid de-
  hydrogenase type 1 enzyme.




 PATENT OFFICE JOURNAL 1567                                     29 January 2010                               Page 85 |BACK TO CONTENT
                                  INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


                                                                              (21) 552528      (22) 7 Jul 2005
                                                                              (54) Food ingredients and food products treated with an oxidoreductase
                                                                              and methods for preparing such food ingredients and food products
                                                                              (86) PCT/US2005/023983           (87) WO2006/014487
                                                                              (51) IPC2010.01:A23C9/00,12; A61K35/20; A61K38/44
                                                                              (71) Leprino Foods Company
                                                                              (72) Merrill, Richard K; Singh, Mayank;
                                                                              (31) 04 586193 (32) 7 Jul 2004 (33) US
                                                                              (31) 05 176634 (32) 6 Jul 2005 (33) US
                                                                              (74) Freehills Patent & Trade Mark Attorneys, Level 43, 101 Collins Street,
                                                                              Melbourne, Victoria 3000, Australia
                                                                              (57) Disclosed is a process of making a cheese, the process comprising:
                                                                               mixing purified oxygen and an oxidoreductase enzyme with a milk prod-
                                                                               uct to form a mixture comprising an aldobionate product; combining the
                                                                               mixture with a cheese precursor to make an admixture; and heating,
                                                                               kneading and stretching the admixture to form a pasta filata cheese.
                                                                              Also disclosed is a process of making a cheese with a decreased concen-
                                                                               tration of reducing sugars, the method comprising: converting milk into
                                                                               cheese curds; heating, kneading and stretching the cheese curds into a
                                                                               cheese mass; adding an oxidoreductase enzyme to the cheese mass,
                                                                               wherein at least a portion of the reducing sugars in the cheese mass are
                                                                               converted into aldobionate products by the oxidoreductase enzyme; and
                                                                               forming the cheese mass into the cheese with the decreased concentra-
                                                                               tion of reducing sugars. Also disclosed is a process of making a cheese,
                                                                               the process comprising: forming a slurry comprising an oxidoreductase
                                                                               enzyme; mixing the slurry with a cheese precursor to form an admixture;
                                                                               and processing the admixture to form a cheese product, wherein the
                                                                               oxidoreductase enzyme catalyzes a reaction between oxygen and a re-
                                                                               ducing sugar in the slurry or the cheese precursor to form an aldobionate
                                                                               product.

(21) 552465      (22) 5 Jul 2005
(54) Breadmaking methods and products                                         (21) 552571       (22) 12 Jul 2005
(86) PCT/EP2005/007258           (87) WO2006/002985                           (54) Packaging and method for solid dose administration of an electronic
(51) IPC2010.01:A21D15/02; A21D2/18; A21D8/04,06                              identification chip and medicaments to an animal
(71) Lesaffre et Compagnie                                                    (86) PCT/US2005/024736           (87) WO2006/017308
(72) Desbuquois, Philippe; Grouet, Norbert; Maitre, Hubert; Muchembled,       (51) IPC2010.01:A61M37/00
Jean-Jacques;                                                                 (71) SOLIDTECH ANIMAL HEALTH, INC.
(31) 04 015795 (32) 5 Jul 2004 (33) EP                                        (72) Hansen, Richard D; Anderson, Mark L;
(74) Freehills Patent & Trade Mark Attorneys, Level 43, 101 Collins Street,   (31) 04 889558 (32) 12 Jul 2004           (33) US
Melbourne, Victoria 3000, Australia                                           (74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
(57) Disclosed is a process for making a frozen, pre-baked dough piece        (57) A method of inoculating non-human animals with an electronic identi-
 which is able to yield a totally baked bread product within 5 minutes or       fication microchip and at least one biologically active pellet comprising
 less. Further disclosed is a bread product obtained by the aforemen-           providing an implant apparatus 12 for implanting the chip and the pellet
 tioned disclosure.                                                             in an animal which can be operably coupled to a dosing magazine 22,
                                                                                the dosing magazine 22 comprising a series of loaded dosing pellet col-
                                                                                umns, each column loaded with a microchip having a convex surface
                                                                                which matingly abuts against a concave surface of a biologically active
(21) 552480     (22) 1 Aug 2005                                                 dosing pellet, arranged so that the chip is inoculated first, the pellet being
(54) Antibodies directed against amyloid-beta peptide and methods of us-        coded to represent a particular medicament, and thereafter, implanting
ing same                                                                        the chip and dosing pellet combination in an animal to be inoculated with
                                                                                a single injection.
(86) PCT/US05/027295            (87) WO06/036291
(51) IPC2010.01:C07K16/18; A61P25/00
(71) Rinat Neuroscience Corp.
(72) Rosenthal, Arnon; Pons, Jaume; Ho, Wei-Hsien; Grimm, Jan Markus;
(31) 04 592494 (32) 30 Jul 2004         (33) US
(31) 04 653197 (32) 14 Feb 2005         (33) US
(31) 04 676093 (32) 29 Apr 2005         (33) US
(74) Shelston IP, Level 21, 60 Margaret Street, Sydney, NSW 2000, Aus-
tralia
(57) Provided is the use of an antibody that specifically binds to a beta-
  amyloid peptide or an aggregated form of a beta-amyloid peptide, wherein
  the antibody comprises at least one CDR region selected from the group
  consisting of a specified amino acid sequence of heavy or light chain
  CDR1, CDR2 or CDR3 region for the manufacture of a medicament for
  the treatment of a disease characterized by aberrant deposition of beta-
  amyloid in a subject. Further provided are variants of the antibodies,
  polynucleotides encoding the antibodies and methods of making the an-
  tibodies.




PATENT OFFICE JOURNAL 1567                                      29 January 2010                                 Page 86 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(21) 552604      (22) 26 Jul 2005
(54) Device for Providing the Position of a Flaw Indication on the Exterior
of a Nozzle, a Pressure Vessel, and/or a Blend
(86) PCT/US2005/026479            (87) WO2006/086004
(51) IPC2010.01:G01B13/00; G21C17/00; G01B11/14,26
(71) Electric Power Research Institute, Inc.
(72) Donaldson, Teresa K; Abbott, John; Hall, Scott; Baucom, Darryl;
(31) 04 591232 (32) 26 Jul 2004           (33) US
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
(57) A measurement device capable of providing coordinates in at least
 two dimensions for a specified location on the exterior surface of a ves-
 sel is provided. The device includes: a base adapted to contact the exte-
 rior surface of the vessel, where the base is capable of being oriented at
 various positions on the exterior surface of the vessel; a rail extending
 from the base, which includes a measurement scale; an angle indicator
 for determining the angular position of the rail; a head slidably supported
 by the rail; and a laser carried by the head for projecting an image on the
 exterior surface of the vessel.


                                                                                (21) 552614     (22) 15 Jun 2005
                                                                                (54) Anther specific promoters and uses thereof
                                                                                (86) PCT/AU2005/000853          (87) WO2005/123920
                                                                                (51) IPC2010.01:C12N15/29
                                                                                (71) LA TROBE UNIVERSITY; GRAINS RESEARCH AND DEVELOP-
                                                                                  MENT CORPORATION
                                                                                (72) Li, Song; Parish, Roger;
                                                                                (31) 04 903245 (32) 15 Jun 2004         (33) AU
                                                                                (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
                                                                                tre, 342 Lambton Quay, Wellington 6011, New Zealand
                                                                                (57) Provided is an expression cassette comprising a specified sequence
                                                                                  of an anther-specific promoter nucleic acid sequence. Further provided
                                                                                  are transgenic plants containing the expression cassette to express a
                                                                                  desired gene in anther or pollen.


(21) 552608       (22) 24 Jun 2005                                              (21) 552737      (22) 11 Jul 2005
(54) Bung hole and tab assembly for small containers provided with at           (54) Compression connector for coaxial cable
least one positioning and holding means                                         (86) PCT/US2005/024407           (87) WO2006/19647
(86) PCT/FR2005/001606             (87) WO2006/013248                           (51) IPC2010.01:H01R9/05
(51) IPC2010.01:B65D77/06                                                       (71) John Mezzalingua Associates, Inc
(71) FLEXTAINER (SOCIETE ANONYME)                                               (72) Montena, Noah;
(72) Erb, Rene;                                                                 (31) 04 892645 (32) 16 Jul 2004           (33) US
(31) 04 07384 (32) 2 Jul 2004 (33) FR                                           (74) WATERMARK PATENT & TRADE MARK ATTORNEYS, Level 2, 302
(74) PHILLIPS ORMONDE FITZPATRICK, 367 Collins Street, Melbourne,               Burwood Road, Hawthorn, Victoria 3122, Australia
Victoria 3000, Australia                                                        (57) A compression connector 10 for the end of a coaxial cable includes a
(57) Bung hole and tap assembly for small flexible containers, in particular     body 18 having a first end and a second end and defining an internal
  for nutritious drinks, consisting of a bung hole (2) for mounting on a con-    passageway. The first end 56 of a tubular post is configured for insertion
  tainer, provided with an external ring (22), which is used for guiding and     between the conductive grounding sheath and the dielectric layer of the
  supporting the bung hole, and a tap for dispensing liquids inserted into       coaxial cable. A portion of the second end of the tubular post engages
  the bung hole and comprising a body (1) for the assembly of the tap into       the body at a portion of the internal passageway. The first end of a com-
  the bung hole and for dispensing liquid. Provided on the bung hole is at       pression member 12 includes an outer surface and a tapered inner sur-
  least one means (3) for positioning and holding the bung hole on the           face; the outer surface engages with a portion of the internal passage-
  container during the assembly and preparation of containers or the like        way at the first end of the body. The first end of a ring member 14 with a
  and/or a machine for filling and indexing the body for mounting the tap in     cylindrical inner surface engages the tapered inner surface of the com-
  the bung hole. The means consists of at least one flat surface provided        pression member 12. A mandrel 70 is disposed within the internal pas-
  on the external ring of the bung hole and designed to cooperate with the       sageway at the second end of the body and is adapted to receive and be
  guiding means of the preparation and/or filling machines.                      electrically connected with the centre conductor of the coaxial cable. A
                                                                                 spacer 72 is disposed between and engaged with the mandrel and the
                                                                                 body holding each apart from one another in a predetermined position so
                                                                                 that the centre conductor of the cable is electrically isolated from the
                                                                                 conductive grounding sheath of the cable and the body of the connector.
                                                                                Divisional filed as 580898




 PATENT OFFICE JOURNAL 1567                                       29 January 2010                                Page 87 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


                                                                               (71) CHUGAI SEIYAKU KABUSHIKI KAISHA
                                                                               (72) Matsuoka, Hiroharu; Sato, Tsutomu; Nishimoto, Masahiro; Shimma,
                                                                               Nobuo;
                                                                               (31) 04 217065 (32) 26 Jul 2004           (33) JP
                                                                               (31) 04 340104 (32) 25 Nov 2004           (33) JP
                                                                               (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
                                                                               tre, 342 Lambton Quay, Wellington 6011, New Zealand
                                                                               (57) Disclosed is a cyclohexane derivative represented by formula (I)
                                                                                 wherein:
                                                                               A is -O-, -CH2-, or -NH-;
                                                                               n is an integer selected from 0 and 1;
                                                                               R6 and R7 are each independently a hydrogen atom or a C1 – C6 alkyl
                                                                                 group
                                                                               m is an integer selected from 1 to 3;
                                                                               Q is selected from Q1 to Q5 represented by the following corresponding
                                                                                 formulae:
                                                                               Ar1 is optionally substituted arylene or optionally substituted heteroarylene,
                                                                                 provided that the heteroarylene may be bonded to an aromatic carbocycle
                                                                                 or aromatic heterocycle to form a fused ring;
                                                                               A2 is optionally substituted aryl or optionally substituted heteroaryl, or a
                                                                                 pharmaceutically acceptable salt. Also disclosed is a medicine, a me-
(21) 552743     (22) 27 Jul 2005                                                 dicinal composition each containing the compound for the treatment of
(54) Plugging device and method                                                  diseases attributable to hyperglycaemia.
(86) PCT/AU2005/002205           (87) WO2006/015406
(51) IPC2010.01:F16L55/134
(71) Neal Christopher Borland
(72) Borland, Neal Christopher;
(31) 05 9000830          (32) 23 Feb 2005        (33) AU
(31) 04 904485 (32) 10 Aug 2004         (33) AU
(31) 05 901178 (32) 11 Mar 2005         (33) AU
(74) DAVIES COLLISON CAVE - SYDNEY, 255 Elizabeth Street, Sydney,
New South Wales 2000, Australia
(57) A plugging device for impeding the flow of a first fluid in a pipe is
 provided. The device includes an expandable bladder to receive a sec-
 ond fluid; and, a flexible adaptor providing a fluid communication path-
 way for the second fluid between the bladder and a pump. At least part of
 the flexible adaptor is made from a substantially heat resistant material.




(21) 552756      (22) 28 Jul 2005
(54) Stabilised prostaglandin composition
(86) PCT/GB2005/002951           (87) WO2006/013335
(51) IPC2010.01:A61K31/5575; A61K47/48; A61K9/00
(71) CONTROLLED THERAPEUTICS (SCOTLAND) LTD
(72) Robertson, Steven;
(31) 04 0417401          (32) 5 Aug 2004          (33) GB
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand
(57) Disclosed is a pharmaceutical delivery device comprising synthetic
 prostaglandin PGE1 analogue in a polyurethane hydrogel, wherein the
 hydrogel has a water content of less than 1% by weight. Preferably the
 delivery device is in the form of a suppository, or vaginal pessary, a buc-
 cal insert or an implant.                                                     (21) 552766      (22) 9 May 2005
                                                                               (54) Wire tying implement where each the end of each jaw has a tie post
                                                                               and a hole
(21) 552761    (22) 26 Jul 2005                                                (86) PCT/ZA2005/000081         (87) WO2006/002442
(54) Novel cyclohexane derivative, prodrug thereof and salt thereof, and       (51) IPC2010.01:B25B25/00; B25B7/02,22
therapeutic agent containing the same for diabetes
                                                                               (71) CORNELIUS JOHANNES GRIESHABER
(86) PCT/JP2005/013634         (87) WO2006/011469
                                                                               (72) Grieshaber, Cornelius Johannes;
(51) IPC2010.01:A61K31/085,343,381,415,4409; A61P3/04,10; C07C217/
56; C07C235/42; C07C255/54; C07C317/22; C07C323/20; C07C43/                    (31) 04 5105 (32) 28 Jun 2004         (33) ZA
23,253; C07C65/26; C07C69/94; C07D209/12; C07D213/65; C07D231/                 (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
12; C07D307/80; C07D317/54; C07D333/56                                         tre, 342 Lambton Quay, Wellington 6011, New Zealand




PATENT OFFICE JOURNAL 1567                                      29 January 2010                                 Page 88 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(57) An implement for binding and clamping wire tightly around pipes or          (21) 552858        (22) 28 Jun 2005
 other objects is disclosed. The wire tying implement comprises a pair of        (54) Ready-made dish disposable packaging, equipped of vent device for
 handles that are pivotally connected by a pivot pin, with a jaw extending       inner vapors
 integrally from each handle beyond the pivot. Each jaw is on the same           (86) PCT/IT2005/000371             (87) WO2006/001048
 side of a longitudinally oriented plane, which is coincident with the axis of   (51) IPC2010.01:B65D81/32
 the pivot pin of the implement. The handle, from which the jaw extends,         (71) DevelPack Srl
 has a groove located at the end of each jaw. A tiepost and a hole is
 located at the end of each jaw where the groove of each jaw is aligned          (72) Palamara, Antonio; Cotronei, Mariantonia;
 with the groove of the other jaw.                                               (31) 05 CZ A 0011          (32) 27 Jun 2005        (33) IT
                                                                                 (31) 04 CS A 0006          (32) 28 Jun 2004        (33) IT
                                                                                 (74) Acacia Law, 16 Brasenose Place, Tawa, Wellington, 5028, New Zea-
                                                                                 land
                                                                                 (57) Ready made dish disposable packaging comprising a container (1)
                                                                                   which defines a first compartment (2) and at least one second compart-
                                                                                   ment (3). The container can have a bowl form and is closed in its upper
                                                                                   part by a superior sealing film (21) which is also an integral and substan-
                                                                                   tial part of a vent device of inner vapours. The second compartment is,
                                                                                   on the contrary, closed by means of a sliding sealing system comprising
                                                                                   a plug (14). In the closure position of the plug, it is impossible that the
                                                                                   component contained in the second compartment enters in contact with
                                                                                   the component contained in the first compartment, while in the opening
                                                                                   position of the plug, the component contained in the second compart-
                                                                                   ment can spill out through the lateral openings of the plug.




(21) 552801       (22) 25 Jul 2005
(54) Plastic bag for fine powders
(86) PCT/US2005/026232           (87) WO2006/023205
(51) IPC2010.01:B65B31/00; B65D33/01; B65D81/20; B65B31/04
(71) UNITED STATES GYPSUM COMPANY
(72) Doyle, Stanley B; Boggia, George W; Immordino, Salvatore C;
(31) 04 924314 (32) 23 Aug 2004             (33) US
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand                                                     (21) 552878       (22) 29 Jul 2005
(57) Disclosed is a method of making and filling a plastic bag. The method       (54) Tyrosine derivatives as PPAR-gamma-modulators
 includes the steps of providing or making from film, a bag having a plu-
                                                                                 (86) PCT/EP2005/053728            (87) WO2006/010775
 rality of laser microperforations; filling the bag with a fine powder having
 an average particle diameter of up to about 150ìm; securing the bag;            (51) IPC2010.01:A61K31/198,341,4406,47; A61P3/04,10; C07C229/36;
 removing at least a portion of entrapped air in the bag through the             C07C233/20,69,88; C07D213/56; C07D215/14; C07D307/54
 microperforations; and sealing the microperforations. In one embodiment         (71) LABORATORIOS SALVAT, S.A.
 the microperforations are sealed using a UV curable sealant. A pack-            (72) Serra Comas, Carmen; Fernandez Serrat, Anna; Balsa Lopez, Dolors;
 aged product made according to the method above is also claimed.                Masip Masip, Isabel; Catena Ruiz, Juan Lorenzo; Hidalgo Rodriguez, Jose;
                                                                                 Lagunas Arnal, Carmen; Salcedo Roca, Carolina; Fernandez Garcia,
                                                                                 Andres;
                                                                                 (31) 200401966            (32) 30 Jul 2004       (33) ES
                                                                                 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                                 Wellington 6011, New Zealand
                                                                                 (57) Disclosed are tyrosine derivatives of formula I, wherein R1 repre-
                                                                                   sents the radical 2-benzoylphenylamino, and the other substituents are
                                                                                   as defined herein. Also disclosed is a pharmaceutical composition which
                                                                                   comprises a therapeutically effective amount of a compound as defined
                                                                                   above together with appropriate amounts of pharmaceutically accept-
                                                                                   able excipients. The use of above compounds of formula I for the manu-
                                                                                   facture of a medicament for the treatment or prevention of diseases me-
                                                                                   diated by PPAR gamma is further disclosed, as is the use of the above
                                                                                   medicaments for the treatment or prevention of metabolic diseases in a
                                                                                   mammal, including a human (diseases such as non-insulin-dependent
                                                                                   diabetes mellitus and obesity, cardiovascular diseases associated with
                                                                                   metabolic syndrome, inflammatory diseases, cancer, bone diseases, skin
                                                                                   wound healing, cutaneous disorders associated with an anomalous dif-
                                                                                   ferentiation of epidermic cells, and other disorders where insulin resist-
                                                                                   ance is a component).




 PATENT OFFICE JOURNAL 1567                                        29 January 2010                                 Page 89 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


                                                                                centroid consists of a weighted average of a value associated with each
                                                                                pixel as a function of the pixel's position in the image for at least a portion
                                                                                of the image. The value associated with each pixel is selected from a
                                                                                portion of a range of values associated with each pixel. The image is
                                                                                translated such that the centroid of the image and the centroid of the
                                                                                same portion of a reference image approximately coincide. The value
                                                                                associated with each pixel is one of a hue and an intensity. The refer-
                                                                                ence image to a subsequent image in the video data stream can be
                                                                                updated. A method for stabilizing an image in a video data stream com-
                                                                                prises dividing the image into at least two regions; calculating a centroid
                                                                                of each region of the image, and transforming the image so that the
                                                                                centroids of the image and the centroids of a reference image approxi-
                                                                                mately coincide. The centroid consists of a weighted average of a value
                                                                                associated with each pixel of the region as a function of the pixel's posi-
(21) 552976      (22) 3 Aug 2005                                                tion in the region.
(54) Vaccine for prevention and treatment of HIV-infection comprising Nef,
p17 Gag and p24 Gag
(86) PCT/EP2005/008434          (87) WO2006/013106                             (21) 553434       (22) 1 Sep 2005
(51) IPC2010.01:A61K39/21,295; C07K14/16; C12N15/49,62                         (54) Prostaglandin derivatives for treating gastrointestinal disorder
(71) GLAXOSMITHKLINE BIOLOGICALS SA                                            (86) PCT/JP2005/016464           (87) WO2006/025599
(72) Abrecht, Helge; Delchambre, Martine; Marchand, Martine; Mathy,            (51) IPC2010.01:A61K31/557,558; A61P1/04,08,14
Nathalie Louise; Voss, Gerald Hermann; Permanne, Philippe Jean Gervais         (71) SUCAMPO AG
Ghislain;                                                                      (72) Ueno, Ryuji;
(31) 0417494 (32) 5 Aug 2004           (33) GB                                 (31) 04 606521 (32) 2 Sep 2004           (33) US
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand              (31) 05 666317 (32) 30 Mar 2005          (33) US
(57) Disclosed is a polypeptide which comprises Nef or an immunogenic          (31) 05 666593 (32) 31 Mar 2005          (33) US
 fragment or derivative thereof, p17 Gag and p24 Gag or immunogenic            (74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
 fragments or derivatives thereof, wherein there is at least one HIV anti-     (57) Disclosed is the use of a prostaglandin compound represented by
 gen or immunogenic fragment between p17 Gag and p24 Gag, the                   Formula (I) and/or its tautomer thereof, wherein the substituents are as
 polypeptide further comprising RT or an immunogenic fragment or de-            defined in the specification, for manufacturing a pharmaceutical compo-
 rivative thereof, wherein the immunogenic fragments or derivatives re-         sition for the long term treatment of gastrointestinal disorders in a human
 main capable of raising an immune response against the native antigen.         subject, wherein the composition is to be administered to the patient in
Divisional filed as 582162                                                      need thereof for over four weeks.


(21) 553149      (22) 11 Aug 2005
(54) Use of inositol hexaphosphate or inositol hexasulphate to complex
biologically active compounds for the preparation of controlled release
pharmaceutical compositions
(86) PCT/US2005/028676           (87) WO2006/017852
(51) IPC2010.01:A61K9/14,20,22,24,26,48,52,54; C07C35/14,16
(71) QUEST PHARMACEUTICAL SERVICES
(72) Yuhua, Li; Chien, Benjamin;
(31) 04 600907 (32) 12 Aug 2004          (33) US
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand
(57) Disclosed is a pharmaceutical composition which comprises: a) a
 complex of a biologically active compound having at least one basic func-
 tional group and a polyanion that is inositol hexaphosphate or inositol
 hexasulphate; and b) a pharmaceutically acceptable carrier comprising
 a biodegradable, water-insoluble polymer. Also disclosed is the use of
 the above pharmaceutical composition in the manufacture of a sustained,
 controlled release medicament for treating warm-blooded animals in need
 of such treatment. Additionally, a process for the preparation of the above
 composition is also disclosed, comprising: a) separately dissolving a bio-
 logically active compound having at least one basic functional group,
 and a polyanion that is inositol hexaphosphate or inositol hexasulphate;
 and b) mixing the dissolved biologically active compound and polyanion
 to produce a complex; and c) dispersing the complex into a
 pharmaceutically acceptable carrier comprising a biodegradable, water-
 insoluble polymer.


(21) 553345      (22) 22 Aug 2005
(54) Real-time image stabilization
(86) PCT/US2005/029816          (87) WO2006/023863                             (21) 553521      (22) 5 Sep 2005
(51) IPC2010.01:G01S3/786; G06T7/20; H04N7/26                                  (54) Improvements relating to meningococcal outer membrane vesicles
                                                                               and their use in vaccines
(71) INTERGRAPH SOFTWARE TECHNOLOGIES COMPANY
                                                                               (86) PCT/IB2005/002801           (87) WO2006/024946
(72) Grindstaff, Gene A; Whitaker, Sheila G;
                                                                               (51) IPC2010.01:A61K39/095; C07K16/12; C07K14/22
(31) 04 603768 (32) 23 Aug 2004        (33) US
                                                                               (71) Novartis Vaccines and Diagnostics SRL
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
                                                                               (72) Oster, Philipp; Rappuoli, Rino; Pizza, Mariagrazia;
(57) A computer-implemented method for stabilizing an image in a video
 data stream is disclosed. A centroid of the image is calculated. The          (31) 04 0419627          (32) 3 Sep 2004        (33) GB




PATENT OFFICE JOURNAL 1567                                      29 January 2010                                  Page 90 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(74) F B RICE & CO, Level 23, 44 Market Street, Sydney, New South                 (57) Disclosed is the use of an antibody polypeptide comprising an anti-
Wales 2000, Australia                                                              body single variable domain polypeptide in the preparation of a medica-
(57) Discloses is a composition comprising an admixture of outer mem-              ment for treating or preventing a symptom of autoimmune disease,
 brane vesicles from two or three of: (i) a serosubtype P1.7b,4 meningo-           wherein said single variable domain polypeptide is monovalent for bind-
 coccus; (ii) a serosubtype P1.7,16 meningococcus; and (iii) a serosubtype         ing to CD40L (gp39) and antagonizes an activity of CD40 or CD40L or
 P1.19,15 meningococcus. Further disclosed is the use of the composi-              both.
 tion in the manufacture of a medicament for use in immunisation against
 meningococcal meningitis and kits comprising said vaccine.
                                                                                  (21) 553848       (22) 22 Sep 2005
                                                                                  (54) Benzoxazine and quinoxaline derivatives and their use in treating
(21) 553621      (22) 9 Aug 2005                                                  diseases associated with the central nervous system
(54) Prevention and treatment of synucleinopathic and amyloidogenic dis-          (86) PCT/EP2005/010238             (87) WO2006/037481
ease                                                                              (51) IPC2010.01:A61K31/536; A61P1/00; A61P25/00; C07D265/36;
(86) PCT/US2005/028166           (87) WO2006/028166                               C07D413/04,06
(51) IPC2010.01:A61K38/17; A61K39/395; C12P21/08                                  (71) F. Hoffmann-La Roche AG
(71) Elan Pharmaceuticals, Inc.; The Regents of the University of Califor-        (72) Bonhaus, Douglas, William; Martin, Renee, Sharon; Sethofer, Steven;
  nia                                                                             Zhang, Li; Zhao, Shu-Hai;
(72) Schenk, Dale B; Masliah, Eliezer; Buttini, Manuel J; Chilcote, Tamie         (31) 04 614705 (32) 30 Sep 2004            (33) US
J; Rockenstein, Edward; Games, Kate Dora;                                         (31) 04 630608 (32) 24 Nov 2004            (33) US
(31) 04 915214 (32) 9 Aug 2004           (33) US                                  (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
(31) 05 185907 (32) 19 Jul 2005          (33) US                                  Wellington 6011, New Zealand
(74) SPRUSON & FERGUSON, St Martins Tower, Level 35, 31 Market                    (57) Disclosed are substituted benzo[1,4]oxazine compounds of the for-
Street, Sydney, New South Wales 2000, Australia                                     mula I, or a pharmaceutically acceptable salt thereof, wherein: Ar is aryl;
(57) Provided is the use of an antibody that specifically binds to an epitope       X is –CH2- or C=O; Y is O or NRa wherein Ra is hydrogen or alkyl; k is 1
  within residues 1-20 of human alpha-synuclein, residues being numbered            or 2; m is from 0 to 3; and the remaining substituents are as defined
  according to a specified sequence, for the manufacture of a medicament            herein; or a compound selected from the group consisting of:            6-
  for prophylaxis or treatment of a disease characterized by Lewy bodies            benzenesulfonyl-4-piperidin-4-yl-3,4-dihydro-2H-benzo[1,4]oxazine, 7-
  or alpha-synuclein aggregation in the brain. Further provided are similar         benzenesulfonyl-4-piperidin-4-yl-3,4-dihydro-2H-benzo[1,4]oxazine,
  uses of variants of the said antibody and methods of producing the anti-          azetidin-3-yl-(7-benzenesulfonyl-2,3-dihydro-benzo[1,4]oxazin-4-yl)-
  body.                                                                             methanone, 4-azelidin-3-ylmethyl-7-benzenesulfonyl-3,4-dihydro-2H-
Divisional filed as 582127                                                          benzo[1,4]oxazine, (7-benzenesulfonyl-2,3-dihydro-benzo[1,4]oxazin-4-
                                                                                    yl)-pyrrolidin-3-yl-methanone, (7-benzenesulfonyl-2,3-dihydro-
                                                                                    benzo[1,4]oxazin-4-yl)-piperidin-3-yl-methanone, (7-benzenesulfonyl-2,3-
(21) 553656       (22) 7 Sep 2005                                                   dihydro-benzo[1,4]oxazin-4-yl)-piperidin-4-yl-methanone, 7-
(54) Injectable composition for animals comprising trace elements and               benzenesulfonyl-4-pyrrolidin-3-yl-3,4-dihydro-2H-benzo[1,4]oxazine,
other components                                                                    7-benzenesulfonyl-2,2-dimethyl-4-pyridin-4-yl-3,4-dihydro-2H-
                                                                                    benzo[1,4]oxazine,             7-benzenesulfonyl-2,2-dimethyl-4-piperidin-
(86) PCT/IB2005/052917           (87) WO2006/027745                                 4-yl-3,4-dihydro-2H-benzo[1,4]oxazine,             7-benzenesulfonyl-2,2-
(51) IPC2010.01:A61K33/04,24,30,32,34                                               dimethyl-4-(1-methyl-piperidin-4-yl)-3,4-dihydro-2H-benzo[1,4]oxazine,
(71) WARBURTON TECHNOLOGY LIMITED                                                   (R)-7-benzenesulfonyl-4-pyrrolidin-3-yl-3,4-dihydro-2H-
(72) Laurie, Robert Naylor; Smith, William Alfred;                                  benzo[1,4]oxazine, (S)-7-benzenesulfonyl-4-pyrrolidin-3-yl-3,4-dihydro-
(31) 04 7201 (32) 9 Sep 2004               (33) ZA                                  2H-benzo[1,4]oxazine, or a pharmaceutically acceptable salt thereof. Also
(74) PIPERS, Level 1, 5A Pacific Rise, Mt Wellington, Auckland, New                 disclosed is a pharmaceutical composition which comprises an effective
Zealand                                                                             amount of a compound as defined above in admixture with a
(57) The disclosure relates to an injectable trace element solution, which          pharmaceutically acceptable carrier. Further disclosed is the use of a
  includes                                                                          compound as defined above for the preparation of a medicament for
(a) 2.5 – 10 mg/ml selenium,                                                        treating a central nervous system disease state in a subject (such as
(b) 20 – 50 mg/ml zinc,                                                             psychoses, schizophrenia, manic depressions. neurological disorders,
                                                                                    memory disorders, attention deficit disorder, Parkinson's disease, amyo-
(c) 5 – 15 mg/ml manganese, and                                                     trophic lateral sclerosis, Alzheimer's disease, food uptake disorders, and
(d) at least one component selected from the group consisting of a vita-            Huntington's disease).
  min, a vaccine, a growth stimulant of the group including zeranol, estradiol,
  testosterone, progesterone and/or trenbolone acetate, a dewormer of
  the group including macrocyclic lactones, leramizoles, benzimidazoles
  and/or
salicylanilides, iron dextran, and an antibiotic;
(e) with at least one of the metals provided in the form of an EDTA com-
  plex and the total metal concentration being at least 60 mg/ml,
(f) the EDTA complex obtained by means of at least one compound se-
  lected from the group comprising sodium EDTA, sodium hydroxide EDTA
  acid and potassium EDTA,
(g) and the solution being prepared in a continuous batch process.


(21) 553847     (22) 16 Sep 2005
(54) Single variable domain monovalent for binding to CD40L (gp39)
(86) PCT/GB2005/003562         (87) WO2006/030220
(51) IPC2010.01:C07K16/28; A61K39/395; A61P37/06
(71) Domantis Limited
                                                                                  (21) 553862     (22) 8 Aug 2005
(72) Grant, Steven; Liu, Haiqun; Moulder, Kevin;
                                                                                  (54) Method for producing sour milk products, method for treating milk
(31) 04 610819 (32) 17 Sep 2004       (33) US                                     therefor, sour milk production line, device for treating milk for said line
(31) 11 102572 (32) 8 Apr 2005(33) US                                             (86) PCT/RU2005/000405           (87) WO2006/025761
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,          (51) IPC2010.01:A01J11/00; A23C3/02,07; A23C9/00,12,13,152
Wellington 6011, New Zealand




 PATENT OFFICE JOURNAL 1567                                         29 January 2010                                 Page 91 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(71) Viktor Vasilievich Marchenko; Valery Alexandrovich Sotnikov                 (21) 554022      (22) 11 Oct 2002
(72) Marchenko, Viktor Vasilievich; Sotnikov, Valery Alexandrovich;              (54) Polypeptide binding agents of human angiopoietin-2
Lutcenko, Alexandr Mikhailovich;                                                 (51) IPC2010.01:C12N5/10; A61K38/04,03; C07K7/06,08; C12N15/63;
(31) 04 04125189          (32) 17 Aug 2004         (33) RU                       A61P9/00; A61P29/00; A61P35/00
(74) WATERMARK PATENT & TRADE MARK ATTORNEYS, Level 2, 302                       (71) AMGEN INC.
Burwood Road, Hawthorn, Victoria 3122, Australia                                 (72) Oliner, Jonathan Daniel; Min, Hosung;
(57) Disclosed is a method for producing sour milk products including            (31) 01 328624 (32) 11 Oct 2001          (33) US
 treating milk with pasteurization and homogenizing, fermenting milk by          (31) 02 414155 (32) 27 Sep 2002          (33) US
 the way of direct applying ferment, bottling and packing, fermenting with       (31) 02 269695 (32) 10 Oct 2002          (33) US
 thermostatic keeping, cooling, ripening, distinguished by the process of        (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
 treating milk and the following operations of producing sour milk prod-         Wellington 6011, New Zealand
 ucts are carried out in the presence of a milk soluble polyphosphoric acid
 derivative of the general formula HO-[PO3X]n wherein X represents ions          (57) Disclosed is a polypeptide capable of binding Ang-2 comprising an
 of sodium, or potassium, or calcium, or magnesium, or hydrogen or am-            amino acid sequence of the formula RPe3e4e5e6e7G (SEQ ID NO: 73)
 monium, 30>or=n>or=1, at a quantitative value 0.4-0.7g per 1 litre, treat-      wherein
 ing milk is carried out with double pasteurization, bottling and packing        e5 is a neutral polar or an acidic amino acid residue;
 are carried out with hermetic sealing at 68-72 degrees Celsius before           e4 is an acidic amino acid residue;
 the second pasteurization, ferment is applied into hermetically sealed          e5 is a neutral polar or an acidic amino acid residue;
 milk at its depressurization, with ultraviolet treating of the area of apply-   e6 is a neutral hydrophobic amino acid residue;
 ing ferment and final hermetic sealing of package afterwards.                   e7 is a neutral hydrophobic amino acid residue;
                                                                                 wherein further, at least two of
                                                                                 e3 is Y or C,
(21) 553879     (22) 15 Mar 2007        (23) 19 Feb 2008                         e4 is E, or
(54) Enhanced plant growth                                                       e6 is M;
(51) IPC2010.01:C05F11/00; C05D1/00; C05G3/00; A01N25/00; A01N65/                or a physiologically acceptable salt thereof.
00
                                                                                 Also      disclosed       are     polypeptides      of  the     formula
(71) Lynda Kay Florey                                                             f1f2f3f4RPf7f8f9f10f11Gf13f14f15f16f17f18f19f20 wherein f1-f4, f7-f11
(72) Florey, Lynda Kay; Munro, Geoffrey Neil;                                     and f13-f20 are as defined. The compounds of the invention are useful
(74) A J PIETRAS & CO, Level 2, Gibson Sheat Centre, 1 Margaret Street,           in the treatment of angiogenesis.
Lower Hutt, New Zealand                                                          (62) Divided Out of 531902
(57) Disclosed is a method of enhancing growth of root crops, tuber crops,
 and/or vine crops (excluding tomatoes) comprising adding to a body of
 soil a humate or humate containing substance pre-mixed with a mineral           (21) 554041       (22) 16 Sep 2005
 or mineral containing substance where the pre-mix comprises an effec-           (54) Novel pyridinone derivatives and their use as positive allosteric modu-
 tive amount of a suitable sugar or sugar containing substance. Also dis-        lators of MGLUR2-receptors
 closed is a plant growth enhancer for use with root crops, tuber crops,
 and/or vine crops (excluding tomatoes) comprising a humate or humate            (86) PCT/EP2005/054636            (87) WO2006/030032
 containing substance mixed with a mineral or mineral containing sub-            (51) IPC2010.01:A61K31/4412; A61P25/00; C07D213/64; C07D401/10;
 stance so that the mixture is able to deliver a synergistic benefit to crop     C07D407/10; C07D409/10; C07D413/10
 soil in terms of enhancing plant growth wherein the mixture comprises           (71) ADDEX PHARMA SA; Ortho-McNeil-Janssen Pharmaceuticals, Inc.
 an effective amount of a suitable sugar or sugar containing substance.          (72) Imogai, Hassan Julien; Cid-Nunez, Jose Maria; Duvey, Guillaume
                                                                                 Albert Jacques; Bolea, Christelle Martine; Nhem, Vanthea; Finn, Terry
                                                                                 Patrick; Le Poul, Emmanuel Christian; Rocher, Jean-Philippe Francois
(21) 553970       (22) 28 Jul 2005                                               Christian; Lutjens, Robert Johannes;
(54) Use of (halobenzyloxy)benzylamino-propanamides for the manufac-             (31) 04 0420722           (32) 17 Sep 2004       (33) GB
ture of medicaments active as sodium and/or calcium channel selective            (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
modulators                                                                       tre, 342 Lambton Quay, Wellington 6011, New Zealand
(86) PCT/EP2005/008200             (87) WO2006/027052                            (57) Disclosed is a compound of formula (I), or a pharmaceutically accept-
(51) IPC2010.01:A61K31/00,165; A61K45/06; A61P1/00; A61P11/00;                     able acid or base addition salt, a stereoisomer, or an N-oxide thereof,
A61P13/00; A61P17/00; A61P25/02,06,08; A61P29/00; A61P3/00; A61P37/                wherein R1 is not H, and is -V1-M1, R2 is H, R3 is -V2-M2, M1 and M2
00; A61P5/00; A61P9/00                                                             are each selected from H or optionally substituted cycloalkyl, aryl, or
(71) NEWRON PHARMACEUTICALS S.P.A.                                                 heteroaryl, and wherein the other substituents are as defined in the speci-
(72) Barbanti, Elena; Thaler, Florian; Caccia, Carla; Fariello, Ruggero;           fication. Also disclosed is the use of the compound for treating diseases
Salvati, Patricia;                                                                 related to the neuromodulatory effect of mGluR2 positive allosteric modu-
                                                                                   lators.
(31) 04021525 (32) 10 Sep 2004             (33) EP
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
(57)        Disclosed         is     the       use      of      (R)-2-[4-(2-
  fluorobenzyloxy)benzylamino]propanamide as a single isomer of 2-[4-
  (2-fluorobenzyloxy)benzylamino]propanamide or (R)-2-[4-5 (2-
  chlorobenzyloxy)benzylamino]-N-methylpropanamide as a single isomer
  of 2-[4-(2-chlorobenzyloxy)benzylamino]-N-propanamide, or a
  pharmaceutically acceptable salts thereof for the manufacture of a medi-
  cament selectively active as sodium and/or calcium channel modulator
  suitable for preventing, alleviating and/or curing pathological diseases or
  conditions listed in the specification, wherein said medicament is sub-
  stantially free from any MAO inhibitory effect or exhibits a significantly
  reduced MAO inhibitory effect at dosages that are therapeutically effec-       (21) 554114    (22) 23 Apr 2007       (23) 23 Apr 2008
  tive in preventing, alleviating and/or curing pathological diseases or con-    (54) Plants with an increased ratio of oleosin to TAG synthesising en-
  ditions where the above said mechanism(s) play(s) a pathological role.         zymes
                                                                                 (51) IPC2010.01:A23D9/00; C11B1/00; C12N15/82; A01H1/00; A01H5/
                                                                                 00,10; A23K1/14; C07H21/00; C12N15/09,29; C12P21/02
                                                                                 (71) AgResearch Limited




PATENT OFFICE JOURNAL 1567                                        29 January 2010                                 Page 92 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(72) Cookson, Ruth Jocelyn; Scott, Richard William; Winichayakul,                (21) 554165       (22) 16 Sep 2005
Somrutai; Roberts, Nicholas John;                                                (54) System and method for creating multiple operating territories within a
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,         meter reading system
Wellington 6011, New Zealand                                                     (86) PCT/US2005/033183            (87) WO06/036594
(57) Disclosed is a construct which includes:                                    (51) IPC2010.01:G08B23/00; G08C15/06
a) at least one promoter;                                                        (71) ELSTER ELECTRICITY LLC
b) a nucleic acid molecule encoding a single oleosin protein; and                (72) Christopher, Russell G; Kelley, Raymond; Rudran, Dileep; Nemecz,
c) at least one nucleic acid molecule encoding an triacylglycerol biosynthetic   Susane K;
 enzyme (TAG synthesising enzyme);                                               (31) 04 949927 (32) 24 Sep 2004          (33) US
wherein the promoter(s) are operatively linked to the nucleic acid mol-          (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
 ecules so as to cause expression of the oleosin and at least one TAG            Wellington 6011, New Zealand
 synthesising enzyme. The construct can be used to produce plants with           (57) A method for creating a number of operating territories within a meter
 an increased ratio of oleosin to TAG synthesising enzymes. These plants          reading system, each operating territory having an assigned set of time
 are useful as animal feed.                                                       of use programs, is provided. The method includes: providing to a con-
                                                                                  figuration database an identification of the number of operating territo-
                                                                                  ries and, for each operating territory, a listing of the set of time of use
(21) 554164       (22) 16 Sep 2005                                                programs assigned to the operating territory; receiving a command to
(54) System and method for automated configuration of meters                      assign a collector at a remote location to a first operating territory; re-
(86) PCT/US2005/033184              (87) WO2006/036595                            sponsive to the command, querying the configuration database to iden-
(51) IPC2010.01:H04M11/00; G01R21/133; G01D4/00; G01R22/10                        tify the set of time of use programs assigned to the first operating terri-
(71) ELSTER ELECTRICITY LLC                                                       tory; and configuring the collector at the remote location with the set of
(72) Scoggins, Sean M; Christopher, Russell G; Garianov, Alexi;                   time of use programs assigned to the first operating territory.
(31) 04 949267 (32) 24 Sep 2004              (33) US                             A method for approving a registered meter for assignment to a selected
                                                                                  time of use program is also provided. The method includes: identifying
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,          an operating territory within which the meter operates; retrieving a set of
Wellington 6011, New Zealand                                                      time of use programs assigned to the operating territory; determining
(57) A method for automated configuration of a meter according to a billing       whether the selected time of use program is a member of the set of time
  rate is provided. The method includes:                                          of use programs assigned to the operating territory; if so, then: assigning
retrieving, from stored data, meter configuration capability information in-      the meter to the selected time of use program; and configuring the meter
  dicating a configuration capability of the meter;                               with an index of the selected time of use program; and if not, then refus-
receiving configuration parameters associated with the billing rate;              ing to assign the meter to the selected time of use program.
prior to configuring or refusing to configure the meter, determining based       A method for attempting to register a meter with a previously assigned
  on the meter configuration capability information whether the meter is          time of use program to a collector is also provided. The method includes:
  capable of implementing the configuration parameters associated with            determining whether the previously assigned time of use program is a
  the billing rate, if not, then refusing to configure the meter to implement     member of a set of at least one time of use program stored at the collec-
  the configuration parameters associated with the billing rate; and if so,       tor; if so, then: registering the meter with the collector; and configuring
  then: translating the billing rate from a meter independent format into a       the meter with an index of the previously assigned time of use program;
  format specific to the meter; and configuring the meter in accordance           and if not then refusing to register the meter with the collector.
  with the meter's particular requirements to implement the configuration        A meter reading system is also provided.
  parameters associated with the billing rate.




 PATENT OFFICE JOURNAL 1567                                        29 January 2010                                Page 93 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(21) 554167      (22) 23 Sep 2005                                                 dispersed in said hydrophilic polymer in an amount in the range of 15%
(54) System for automatically enforcing a demand reset in a fixed network         to 75% by weight of the ibuprofen, said formulation additive comprising
of electricity meters                                                             microcrystalline cellulose, silica, magnesium stearate, stearic acid, lac-
(86) PCT/US2005/034119          (87) WO06/036780                                  tose pre-gelatinized starch, dicalcium phosphate or a combination of any
(51) IPC2010.01:G06F11/32; G08B23/00; G08C15/06; G08C19/20;                       of them, wherein at least 20% of the ibuprofen is released within 2 hours
H03K17/00; H04L12/56                                                              following oral administration or exposure to an agitated aqueous me-
(71) ELSTER ELECTRICITY LLC                                                       dium of a single dosage unit, then thereafter releases ibuprofen at a
                                                                                  relatively constant rate over a period of at least 8 hours, and wherein at
(72) Scoggins, Sean M; Mills, Stuart; Mason Robert T; Borleske, Andrew            least 70% of the ibuprofen is released over a period of not more than 14
J; Smith Kathryn J; Rudran, Dileep;                                               hours following such administration or exposure. The disclosure also
(31) 04 948929 (32) 24 Sep 2004        (33) US                                    relates to use of the dosage form in the preparation of medicaments for
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,          the treatment of inflammation.
Wellington 6011, New Zealand
(57) A system for enforcing a demand reset in a meter operating within a
 wireless metering network is provided. The system includes a network            (21) 554264      (22) 6 Oct 2005
 configuration server that determines a network state; and a data collec-        (54) Milk production method using antibodies to improve product life
 tion server that receives meter data and a counter from the meter. The          (86) PCT/AU2005/001541            (87) WO2006/037183
 data collection server receives the meter data and the counter, the sys-
 tem compares the counter to a second counter, and if the counter is less        (51) IPC2010.01:A23C3/00; A23C9/152; A61D7/00; A23C9/158; A23L1/
 than the second counter, the network configuration server requests the          305
 meter to download the meter data and perform a demand reset.                    (71) Agri-BIOTECH Pty Ltd
                                                                                 (72) Tay, Kwang Guan; Penhale, William John; Geerlings, Peter Michael;
                                                                                 (31) 04 905761 (32) 6 Oct 2004            (33) AU
                                                                                 (74) WRAYS, Ground Floor, 56 Ord Street, West Perth, WA 6005, Aus-
                                                                                 tralia
                                                                                 (57) Disclosed is a method for improving the shelf-life of milk comprising
                                                                                   the step of contacting milk with an antibody raised against at least one of
                                                                                   the following: a lipase, proteinase, or lecithinase molecule of a micro-
                                                                                   organism wherein the antibody, when contacted with the milk, forms an
                                                                                   antibody-antibody interaction with the molecule which depletes, removes
                                                                                   or prevents the activity of the molecule. Also disclosed is a method for
                                                                                   the induction of antibody production in milk comprising implantation of at
                                                                                   least one antigen releasing device adjacent to or within at least one
                                                                                   supramammary lymph node of a non-human mammal wherein the de-
                                                                                   vice stimulates antibody secretion into a mammary gland.


                                                                                 (21) 554332     (22) 12 Sep 2005
                                                                                 (54) Truncated LHRH formulations with T helper cell epitopes
                                                                                 (86) PCT/AU2005/001383          (87) WO06/026834
                                                                                 (51) IPC2010.01:A61K38/24; A61P15/16,18; C07K14/59
                                                                                 (71) The Council of the Queensland Institute of Medical Research (QIMR)
                                                                                 (72) Jackson, David Charles; Walker, John; Zeng, Weiguang;
                                                                                 (31) 04 905194 (32) 10 Sep 2004        (33) AU
                                                                                 (74) DAVIES COLLISON CAVE - MELBOURNE, 1 Nicholson Street, Mel-
                                                                                 bourne, Victoria, Australia
                                                                                 (57) Provided is a peptide comprising a truncated LHRH consisting of the
                                                                                  sequence SYGLRPG linked to a sequence of less than 60 amino acids
                                                                                  which comprises at least one T helper cell epitope. Further provided is
                                                                                  the use of the peptide in the preparation of medicaments to induce an
                                                                                  anti LHRH response in an animal.

(21) 554213        (22) 30 Sep 2005                                              (21) 554353      (22) 4 Oct 2005
(54) Modified release ibuprofen dosage form                                      (54) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2
(86) PCT/US2005/035630             (87) WO2006/039692                            and angiogenesis, and for the treatment of breast, colon, lung and pros-
(51) IPC2010.01:A61K9/14,20,22                                                   tate cancer
(71) SCOLAR PHARMA, INC.                                                         (86) PCT/EP2005/010653          (87) WO2006/040036
(72) Hite, Michael; Federici, Cathy; Brunelle, Alan; Turner, Stephen;            (51) IPC2010.01:A61K31/5517; A61P35/00; C07D487/04; C07D243/06,10
(31) 04 614932 (32) 30 Sep 2004             (33) US                              (71) F. Hoffmann-La Roche AG
(31) 05 689631 (32) 10 Jun 2005             (33) US                              (72) Liu, Jin-Jun; Luk, Kin-Chun; Pizzolato, Giacomo; Ren, Yi; Thakkar,
(31) 05 238802 (32) 29 Sep 2005             (33) US                              Kshitij Chhabilbhai; Wovkulich, Peter Michael; Zhang, Zhuming;
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,         (31) 04 618174 (32) 13 Oct 2004          (33) US
Wellington 6011, New Zealand                                                     (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
(57) The disclosure relates to a solid dosage form for modified oral admin-      Wellington 6011, New Zealand
   istration of ibuprofen comprising:                                            (57) Disclosed are 7,8-disubstituted pyrazolo[3,4-b][1,4]benzodiazepines
i) a hydrophilic polymer;                                                          of formula IV or a pharmaceutically acceptable salt thereof, wherein the
ii) 300 to 800 mg of ibuprofen in the solid dosage form uniformly dispersed        substituents are as defined herein. Also disclosed is the use of a com-
   in said polymer;                                                                pound of formula IV as defined above or a pharmaceutically acceptable
iii) a dissolution additive dispersed in said hydrophilic polymer in an amount     salt thereof for the manufacture of a medicament for the treatment of
   in the range of 10% to 35% by weight of the ibuprofen, said dissolution         cancer, particular breast cancer, prostate cancer, colon cancer and lung
   additive comprising an alkali metal salt, an amino acid having a neutral        cancer. Additionally disclosed are processes for the preparation of the
   to alkaline side chain, croscarmellose or a salt thereof, or a combination      compounds of formula IV, and pharmaceutical compositions which com-
   of any two of such dissolution additives; and an inert formulation additive     prise a compound as defined above together with pharmaceutically ac-
                                                                                   ceptable adjuvants.



PATENT OFFICE JOURNAL 1567                                        29 January 2010                                 Page 94 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


.                                                                               (72) Hashimoto, Noriaki; Takahashi, Keiji; Nakama, Chisato; Ogino, Yoshio;
                                                                                Sakai, Fumiko; Nishimura, Teruyuki; Eiki, Jun-ichi;
                                                                                (31) 04 319339 (32) 2 Nov 2004            (33) JP
                                                                                (31) 05 178628 (32) 17 Jun 2005           (33) JP
                                                                                (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                                Wellington 6011, New Zealand
                                                                                (57) Disclosed is a glucokinase activator compound of formula (I) or a
                                                                                  pharmaceutically acceptable salt thereof, wherein Q represents a car-
                                                                                  bon atom, a nitrogen atom or a sulfur atom optionally substituted with
                                                                                  one or two oxo groups, X represents a carbon atom, ring A represents a
                                                                                  5-or 6-membered nitrogen-containing heteroaromatic group and wherein
                                                                                  the rest of the substituents are disclosed within the specification.


(21) 554385      (22) 20 Sep 2005
(54) 2-Acylaminothiazole derivatives having affinity for the adenosine 2A
(86) PCT/DK2005/000591           (87) WO2006/032273
(51) IPC2010.01:A61K31/47; A61P25/02,16,18,24,28; C07D417/04,14
(71) H Lundbeck A/S
(72) Larsen, Mogens; Sams, Anette Graven; Mikkelsen, Gitte; Bang-
Anderson, Benny;
(31) 04 0401441          (32) 22 Sep 2004        (33) DK
(74) WATERMARK PATENT & TRADE MARK ATTORNEYS, Level 2, 302
Burwood Road, Hawthorn, Victoria 3122, Australia
(57) The disclosure relates to 2-acylamino-thiazole derivative compounds
  of the formula (I), wherein the variables are as defined in the specifica-    (21) 554458       (22) 6 Oct 2005
  tion, for use as a medicament. The compounds are A2A-receptor leg-            (54) Method of formation of the shape-retentive aggregates of gel parti-
  ends and are useful in the treatment of neurological and psychiatric dis-     cles and their uses
  orders where an A2A-receptor is implicated, particularly diseases such        (86) PCT/US2005/035905             (87) WO2006/041967
  as Parkinson's Disease (PD), Alzheimer's Disease, Huntington's disease,
                                                                                (51) IPC2010.01:A61K9/14
  cerebral ischemia, haemorrhagic stroke, neonatal ischemia and hypoxia,
  subarachnoid haemorrhage, traumatic brain injury, cardiac arrest, Multi-      (71) ULURU Inc.
  ple Sclerosis, depression and psychosis.                                      (72) Moro, Daniel G; St. John, John V; Shannon, Kevin F; Ponder, Bill C;
                                                                                (31) 04 960461 (32) 6 Oct 2004             (33) US
                                                                                (74) Pizzeys Patent and Trade Mark Attorneys, Level 2, Woden Plaza
(21) 554388       (22) 5 Oct 2005                                               Offices, Woden Town Square, Woden, ACT 2606, Australia
(54) VLP-Antigen conjugates and their uses as vaccines                          (57) Disclosed is a suspension system for forming a shape-retentive ag-
(86) PCT/EP2005/055009            (87) WO06/037787                                gregate of gel particles, comprising:
(51) IPC2010.01:A61K39/00,39                                                     a plurality of gel particles dispersed in a polar liquid or a mixture of two or
(71) Cytos Biotechnology AG                                                       more polar liquid(s), wherein the polar liquid or at least one of the two or
                                                                                  more polar liquids comprise(s) one or more hydroxyl groups and; wherein
(72) Bachmann, Martin; Meijerink, Edwin; Proba, Karl; Schwarz, Katrin;
                                                                                  the gel particles have an average diameter of less than 955 nanometers
Maurer, Patrik;
                                                                                  and a first absolute zeta potential; and, wherein the plurality of gel parti-
(31) 04 615637 (32) 5 Oct 2004             (33) US                                cles are formed from the suspension polymerization of a monomer or
(31) 05 05105228          (32) 14 Jun 2005         (33) EP                        two or monomers, wherein the monomer(s) are selected from the group
(74) WATERMARK PATENT & TRADE MARK ATTORNEYS, Level 2, 302                        consisting of a 2-alkenoic acid, a hydroxy(2C - 4C)alkyl 2-alkenoate, a
Burwood Road, Hawthorn, Victoria 3122, Australia                                  hydroxy(2C - 4C)alkoxy(2C - 4C)alkyl 2-alkenoate, a (1 C - 4C)alkoxy(2C
(57) Disclosed is a composition comprising: (a) a virus-like particle (VLP)       4C)alkoxy(2C - 4C)alkyl 2-alkenoate and a vicinyl epoxy(1C - 4C)alkyl 2-
  comprising coat proteins, mutants or fragments thereof, of an RNA-bac-          alkenoate and a combination of two or more thereof in the presence of
  teriophage with at least one first attachment site, wherein said VLP is         from 0.01 to 10 mol percent of a surfactant; and wherein the suspension
  recombinantly produced by a host, and said VLP is essentially free of           system is suitable to be introduced at a selected introduction rate into a
  host RNA, and wherein said mutant or said fragment of said coat protein         receiving medium wherein the gel particles acquire a second absolute
  of said RNA-bacteriophage is capable of assembling into a VLP, and              zeta potential which is lower (closer to zero) than the first absolute zeta
  wherein said mutant of said coat protein of said RNA-bacteriophage has          potential whereupon the gel particles coalesce into a shape-retentive
  an amino acid sequence identity of at least 80% with the amino acid             aggregate held together by non-covalent bond physical forces compris-
  sequence of said coat protein, and wherein said fragment of said coat           ing hydrophobic-hydrophilic interactions and hydrogen bonds. The dis-
  protein of said RNA-bacteriophage is a polypeptide of at least 70% of the       closure also relates to the application of the shape-retentive aggregates
  length of said coat protein (b) at least one antigen with at least one sec-     in orthopedic applications such as tissue scaffolding, cartilage and bone
  ond attachment site; wherein said at least one antigen (b) is linked to         repair, meniscus repair/replacement, artificial spinal discs, artificial ten-
  said VLP (a) through said at least one first attachment site and said at        dons and ligaments, and bone defect filler.
  least one second attachment site, and wherein said composition further
  comprises at least one polyanionic macromolecule packaged inside said
  VLP, and wherein said polyanionic macromolecule is selected from the          (21) 554518    (22) 1 Nov 2005
  group consisting of: (a) polyanionic polypeptides; (b) polyanionic            (54) Cushioning device for a compression plate of an x-ray machine and
  saccharides; (c) polyanionic organic polymers; and (d) nucleic acids,         method for using such eg in mammography
  wherein said nucleic acid is not a toll-like receptor ligand.                 (86) PCT/US2005/039849         (87) WO06/050466
                                                                                (51) IPC2010.01:G03B42/04; A61B6/04
                                                                                (71) BIOLUCENT, LLC.
(21) 554440    (22) 1 Nov 2005
                                                                                (72) Hermann, George D; Lebovic, Gail S;
(54) Aryloxy-substituted benzimidazole derivatives
                                                                                (31) 04 624683 (32) 2 Nov 2004        (33) US
(86) PCT/JP2005/020483         (87) WO2006/049304
                                                                                (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
(51) IPC2010.01:A61K31/155,4439,444,4545,497,506; A61K38/22,26;
                                                                                Wellington 6011, New Zealand
A61K45/00; A61P3/04,10; A61P43/00; C07D401/04
(71) BANYU PHARMACEUTICAL CO., LTD




    PATENT OFFICE JOURNAL 1567                                    29 January 2010                                  Page 95 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(57) A compression device includes a frame mountable to a mammogra-             (21) 554717       (22) 24 Apr 2007        (23) 24 Apr 2008
 phy unit that includes a window disposed within an x-ray field of the mam-     (54) A movement assembly with work articles movable on threaded drive
 mography unit when the frame is mounted to the mammography unit,               shaft by shaft rotation
 and a radiolucent compressible member connectable to the frame across          (51) IPC2010.01:B65B25/02; B65G37/00
 the window for providing a compression surface within the x-ray field.         (60) 554717
 For example, the compressible member may include a rigid backing               (71) Peter Owen Davies
 member and a radiolucent pad, e.g., a gel pad, on the backing member.
 The backing member and frame may include tongue and groove or other            (72) Davies, Peter Owen; Menhinick, Michael Edward; Maxton, Steve;
 connectors for connecting the compressible member to the frame. Op-            Unger, Walter; Brooks, Murray Peter;
 tionally, one or more thin, radiolucent films may be removable from the        (74) JAMES & WELLS, Level 2, Regency House, 1 Elizabeth Street,
 compressible member, e.g., after obtaining x-rays from successive indi-        Tauranga, New Zealand
 vidual patients.                                                               (57) A movement assembly including a drive axle (21); a number of threaded
                                                                                  drive portions (22) operativeIy associated with the axle; two or more work
                                                                                  articles (12) positioned in a row aligned with the longitudinal axis of the
                                                                                  drive axle; at least one work article having a complimentary thread (18)
                                                                                  engaged with an associated drive portion; characterised in that the move-
                                                                                  ment assembly is configured such that rotation of the drive axle causes
                                                                                  the threaded drive portions to turn and alter the spacing between the
                                                                                  engaged work articles along the row. At least one threaded drive portion
                                                                                  is also coupled to a work article adjacent to that which it is associated.




(21) 554551      (22) 17 Nov 2005
(54) Pharmaceutical compositions comprising a camptothecin derivate
(86) PCT/EP2005/012334          (87) WO2006/053755
(51) IPC2010.01:A61K9/107; A61K31/4745; A61P35/00
(71) Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
(72) Ottinger, Isabel;
(31) 04 629757 (32) 19 Nov 2004        (33) US
(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
tre, 342 Lambton Quay, Wellington 6011, New Zealand
                                                                                (21) 554761       (22) 12 Oct 2005
(57) Disclosed is a pharmaceutical composition comprising 7-t-
                                                                                (54) Formulations comprising ecteinascidin and a disaccharide
  butoxyiminomethyl camptothecin, wherein the pharmaceutical composi-
  tion is a microemulsion preconcentrate, that is useful for the treatment      (86) PCT/GB2005/050184            (87) WO2006/046079
  for the treatment for and prevention of proliferative diseases including      (51) IPC2010.01:A61K31/4995; A61K47/26; A61P31/00
  cancer.                                                                       (71) Pharma Mar S.A., Sociedad Unipersonal
                                                                                (72) Calvo Salve, Pilar; Nuijen, Bastiaan; Beijnen, Jacob Hendrick; Tobio
                                                                                Barreira, Maria;
(21) 554672      (22) 20 Apr 2007         (23) 18 Apr 2008                      (31) 04 623813 (32) 29 Oct 2004            (33) US
(54) An improved edge lifting anchor                                            (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
(51) IPC2010.01:E04C5/12; B66C1/10; E04C2/04; E04G21/14                         tre, 342 Lambton Quay, Wellington 6011, New Zealand
(71) ITW New Zealand Limited                                                    (57) Disclosed are compositions comprising of Ecteinascidin and disac-
(72) Gilmour, Roydon John;                                                        charide and methods of preparing the same. Also disclosed are methods
(74) JAMES & WELLS, Level 9, James and Wells Tower, 56 Cawley Street,             of treating proliferative diseases with the same compositions.
Ellerslie, Auckland, New Zealand
(57) An edge lifting anchor for casting into concrete elements is disclosed.
 The edge lifting anchor includes: a lifting portion that receives edge lift-   (21) 554765       (22) 26 Oct 2005
 ing forces; two or more substantially elongate and separated force trans-      (54) Pegylated Liposomal Doxorubicin In Combination With Ecteinescidin
 fer portions that extend from the lifting portion; one or more concrete        743
 engaging projections extending from the one or more force transfer por-        (86) PCT/GB2005/050189            (87) WO2006/046080
 tions; and one or more shear resisting portions projecting transversely to     (51) IPC2010.01:A61K47/48; A61K31/4995; A61P35/00
 a direction defined by shear forces imparted to the edge lifting anchor in     (71) Pharma Mar S.A.
 use.                                                                           (72) Gilles, Erard; Sternas, Lars-Axel; Trifan, Ovid; Van De Velde, Helgi;
                                                                                Teitelbaum, April;
                                                                                (31) 04 622163 (32) 26 Oct 2004            (33) US
                                                                                (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
                                                                                tre, 342 Lambton Quay, Wellington 6011, New Zealand
                                                                                (57) Disclosed is the use of ET-743 in the preparation of a medicament for
                                                                                  an effective treatment of cancer of the human body by combination therapy
                                                                                  employing an effective therapeutic amount of ET-743 with an effective
                                                                                  therapeutic amount of Pegylated Liposomal form of the anthracycline
                                                                                  Doxorubicin ("PLD").




PATENT OFFICE JOURNAL 1567                                       29 January 2010                                 Page 96 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(21) 554780       (22) 1 Dec 2005
(54) Spectrophotometer
(86) PCT/EP2005/012820             (87) WO2006/058741
(51) IPC2010.01:G01N21/03,31
(71) Foss Analytical A/S
(72) Juhl, Henrik Vilstrup;
(31) PA 2004 01883        (32) 2 Dec 2004          (33) DK
(74) F B RICE & CO, Level 23, 44 Market Street, Sydney, New South
Wales 2000, Australia
(57) A spectrophotometer is provided, including a sample holder adapted
  to present internally several different path lengths to radiation of several
  wavelengths emitted from a source; a detection arrangement for detect-
  ing a wavelength dependent intensity of emitted radiation after it has
  traversed one of the path lengths and for providing an output indicative
  thereof; and an arithmetic unit operably connected to receive the output
  and to generate therefrom one or both a quantitative and a qualitative
  indication of a substance of interest within a sample. The arithmetic unit
  is adapted to calculate a value dependent on the ratio of received out-
  puts at two of the different path lengths for a same one of the emitted
  wavelengths and to generate by means of a multivariate statistical analysis
  of the calculated value at each of the wavelengths one or both the quan-
  titative and the qualitative indications.




                                                                                 (21) 554794      (22) 6 Oct 2005
                                                                                 (54) Mutated amyloid protein
                                                                                 (86) PCT/JP2005/018896            (87) WO2006/038729
                                                                                 (51) IPC2010.01:C12N15/09; A01K67/027; A61K31/7088; A61K38/00;
                                                                                 A61K39/395; A61K45/00; A61K48/00; A61P25/28; A61P43/00; C07K14/
                                                                                 47; C07K16/18; C07K7/06,08; C12N5/10; C12Q1/02; G01N33/15,50,68
                                                                                 (71) Hiroshi Mori
                                                                                 (72) Mori, Hiroshi; Tomiyama, Takami; Shimada, Hiroyuki;
                                                                                 (31) 04 294292 (32) 6 Oct 2004            (33) JP
                                                                                 (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
                                                                                 tre, 342 Lambton Quay, Wellington 6011, New Zealand
                                                                                 (57) Provided is a human variant amyloid protein, which consists of a speci-
                                                                                   fied amino acid sequence comprising: (1) the 39 amino acids from posi-
                                                                                   tion 597 to position 636 with the deletion of glutamic acid at position 618;
                                                                                   (2) the 41 amino acids from position 597 to position 638 with the deletion
                                                                                   of glutamic acid at position 618; or (3) the 42 amino acids from position
                                                                                   597 to position 639 with the deletion of glutamic acid at position 618.
                                                                                   Further provided are corresponding DNAs, antibodies, transgenic ani-
                                                                                   mals having the protein, and uses of the composition in the manufacture
(21) 554781      (22) 16 Dec 2005                                                  of a medicament for vaccine therapy in amyloid disease.
(54) A method for standardising a spectrometer
(86) PCT/DK2005/000798           (87) WO2006/066581
(51) IPC2010.01:G01J3/453,28                                                     (21) 554861      (22) 4 Oct 2005
(71) Foss Analytical A/S                                                         (54) Plate for producing an electroluminescent number plate
(72) Juhl, Henrik Vilstrup;                                                      (86) PCT/EP2005/010675            (87) WO2006/037607
(31) 2004 01965          (32) 21 Dec 2004         (33) DK                        (51) IPC2010.01:B60R13/10
(74) F B RICE & CO, Level 23, 44 Market Street, Sydney, New South                (71) Arno Martin Sauer; Bernd Moderegger; Adolf Sievers
Wales 2000, Australia                                                            (72) Sauer, Arno, Martin; Moderegger, Bernd; Sievers, Adolf;
(57) A computer-implemented method for adjusting the wavelength scale            (31) 04 04023583          (32) 4 Oct 2004         (33) EP
 of an optical spectrum of a sample of interest recorded by a spectrometer       (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
 is provided. The method includes: providing an optical spectrum recorded        tre, 342 Lambton Quay, Wellington 6011, New Zealand
 by the spectrometer and comprising spectral patterns originating from           (57) Disclosed is a plate for producing an electroluminescent number plate.
 atmospheric air in the spectrometer; selecting from the provided optical          The plate has an inscription area and a border area which lies outside
 spectrum a spectral pattern originating from a constituent of the atmos-          the inscription area. The plate includes a board and a film. The film has
 pheric air; determining a wavelength dependent position value associ-             an electroluminescent coating and extends at least partially over the in-
 ated with the selected spectral pattern; and adjusting a wavelength scale         scription area and the border area. The film includes metallic conductor
 of the optical spectrum of a sample of interest recorded by the                   tracks which are electrically insulated from the board.
 spectrometer based on a difference between the determined value and
 a corresponding reference value of the selected spectral pattern. An
 infrared spectrometer implementing this method is also provided.




 PATENT OFFICE JOURNAL 1567                                        29 January 2010                                 Page 97 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


                                                                                (72) Chanwa, Nguy; Lin, Pei-Ying;
                                                                                (31) 04 93132336         (32) 26 Oct 2004             (33) TW
                                                                                (74) PHILLIPS ORMONDE FITZPATRICK, 367 Collins Street, Melbourne,
                                                                                Victoria 3000, Australia
                                                                                (57) Disclosed is a vertical tool rack storage device which includes a hol-
                                                                                 low upright pivot shaft, a plurality of flat tool racks for holding tool bits and
                                                                                 parts, and a plurality of connectors for pivotally coupling tool racks to the
                                                                                 hollow upright pivot shaft for enabling the tool racks to be arranged in a
                                                                                 stack and individually turnable about the hollow upright pivot shaft.




(21) 554892      (22) 20 Oct 2005
(54) Stable metal/conductive polymer composite colloids and methods for
making and using the same
(86) PCT/US2005/038099          (87) WO2006/047371
(51) IPC2010.01:C12Q1/68
(71) ENGLEBIENNE & ASSOCIATES
(72) Englebienne, Patrick; Van Hoonacker, Anne;
(31) 04 621258 (32) 21 Oct 2004          (33) US
(74) Pizzeys Patent and Trade Mark Attorneys, Level 2, Woden Plaza
Offices, Woden Town Square, Woden, ACT 2606, Australia
(57) Disclosed is a method of producing a metal/conductive polymer com-
 posite colloid, said method comprising combining a metal colloid and a
 water-soluble conductive polymer under conditions sufficient for said
 water-soluble conductive polymer to adsorb to metal particles of said
 colloid to produce a metal/conductive polymer composite colloid. Also
 disclosed is the composite colloid produced by this method.
Also disclosed is a method for screening a sample for the presence of an
 analyte, said method comprising contacting said sample with a stable
 metal/conductive polymer composite colloid to produce an assay mix-
 ture, wherein said colloid metal particles are surface coated with a con-
 ductive polymer layer and displaying a ligand for said analyte, and then
 detecting an optical parameter of said assay mixture to screen said sam-
 ple for the presence of said analyte.


(21) 554917      (22) 5 Jan 2006
(54) Use of cyanine dyes for the diagnosis of proliferative diseases
(86) PCT/EP2006/000058            (87) WO2006/072580
(51) IPC2010.01:A61K49/00; A61K31/404,185
(71) BAYER SCHERING PHARMA AKTIENGESELLSCHAFT                                   (21) 555068      (22) 21 Nov 2005
(72) Licha, Kai; Pessel, Martin; Bahner, Malte; Schirner, Michael;              (54) Total patient input monitoring
(31) 05 05000276         (32) 7 Jan 2005         (33) EP                        (86) PCT/US2005/042592            (87) WO2006/058151
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand               (51) IPC2010.01:G06F19/00
(57) Disclosed is the use of a compound according to formula (I) or a           (71) CARDINAL HEALTH 303, INC.
 pharmaceutically acceptable salt thereof, for the preparation of a diag-       (72) Russell, Claudia, J.;
 nostic composition for the detection of a proliferative disease (such as a     (31) 04 999095 (32) 29 Nov 2004            (33) US
 tumor, a precancerosis, a dysplasia, a metaplasia. psoriasis, psoriatic        (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
 arthritis, rheumatoid arthritis, endometriosis and/or an ocular disease),      Wellington 6011, New Zealand
 wherein the proliferative disease is related to detectable proliferative le-   (57) A system for monitoring medication delivery to a patient while the
 sion having a diameter smaller than 7mm, wherein the diagnostic com-            patient is in a healthcare facility is provided. The monitoring system in-
 position comprises the compound in an amount of less than 0.5 and               cludes:
 more than 0.001 mg/kg body weight per diagnostic application.                  an infusion pump for delivering medication to a patient;
                                                                                a memory in which is stored identification data about the patient and medi-
                                                                                 cation delivery data about the patient;
                                                                                a display on which identification data and medication delivery data about a
                                                                                 patient is displayed; and
                                                                                a processor that programmatically retrieves patient identification data and
                                                                                 medication delivery data about the patient from multiple sources in the
                                                                                 healthcare facility while the patient is in the healthcare facility and stores
                                                                                 the identification data and medication delivery data in the memory.
                                                                                The processor also retrieves the patient identification data and medica-
                                                                                 tion delivery data from the memory in response to a request therefor,
                                                                                 formats the retrieved data in accordance with a format request, and dis-
(21) 555033     (22) 26 Oct 2005                                                 plays the retrieved and formatted data on the display.
(54) Vertical Tool Rack Storage Device
(86) PCT/US2005/039402         (87) WO2006/047785
(51) IPC2010.01:A47B73/00
(71) Steelworks Hardware, LLC




PATENT OFFICE JOURNAL 1567                                       29 January 2010                                   Page 98 |BACK TO CONTENT
                                     INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND




                                                                                   (21) 555178      (22) 27 Oct 2005
                                                                                   (54) Pharmaceutical preparation comprising EPO for the treatment of Frie-
                                                                                   dreich’s ataxia
                                                                                   (86) PCT/EP2005/011510            (87) WO2006/050819
(21) 555076       (22) 16 Dec 2005                                                 (51) IPC2010.01:A61K38/18; A61P21/00; A61P9/00
(54) Antibiotic combinations for providing total solution to the treatment of      (71) MEDIZINISCHE UNIVERSITAT WIEN
infections                                                                         (72) Scheiber-Mojdehkar, Barbara; Sturm, Brigitte, Nina;
(86) PCT/IN2005/000415              (87) WO2006/064516                             (31) 04 1869 (32) 9 Nov 2004              (33) AT
(51)                                                  IPC2010.01:A61K31/           (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
7036,165,4025,427,43,431,496,5377,545,546,57,65,7004,7016,7048                     Wellington 6011, New Zealand
(71) VENUS REMEDIES LIMITED                                                        (57) Disclosed is the use of human erythropoietin or a derivative thereof
(72) Chaudhary, Manu;                                                                having the biological activity of human erythropoietin of increasing the
(31) 04DEL 2510            (32) 17 Dec 2004         (33) IN                          expression of frataxin for the production of a pharmaceutical preparation
(74) A.P.T. PATENT AND TRADE MARK ATTORNEYS, 383 Goodwood                            for the treatment of Friedreich's ataxia or a disease associated therewith
Road, Westbourne Park, SA 5041, Australia                                            in a patient suffering from Friedreich's ataxia.
(57) The disclosure relates to a new pharmaceutical composition com-
  prising:
Two different antibiotics and a stabilizing agent suitable for parenteral in-      (21) 555184     (22) 1 Dec 2005
  jection as antimicrobial fixed dose combination therapy for mammals, in          (54) Malonamide derivatives as inhibitors of gamma-secretase for the treat-
  dry powder form ready after reconstitution with a suitable solvent for           ment of Alzheimer’s disease
  injection, wherein:                                                              (86) PCT/EP2005/012834          (87) WO2006/061136
(a) a first of the antibiotics is a protein synthesis inhibiting antibiotic, se-   (51) IPC2010.01:C07D267/14; A61K31/553; A61P25/28
  lected from a group of aminoglycoside consisting of netilmicin, kanamy-          (71) F. HOFFMANN-LA ROCHE AG
  cin, gentamycin, streptomycin, amikacin, and tobramycin.                         (72) Flohr, Alexander; Jakob-Roetne, Roland; Wostl, Wolfgang;
(b) a second of the antibiotics is not a protein synthesis inhibiting antibiotic   (31) 04 04106395        (32) 8 Dec 2004          (33) EP
  and is selected from a group of beta lactam cephalosporin consisting of          (31) 05 05100816        (32) 7 Feb 2005          (33) EP
  cefepime, ceftazidime, cefotaxime, cefuroxime, cefaclor, and cetriaxone,         (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
(c) the stabilizing agent comprising L- arginine, the first and second antibi-     Wellington 6011, New Zealand
  otics being present in a weight ratio of 1:5 to 5:1. Also disclosed is a         (57) Disclosed are 8-oxo-6,7,8,9-tetrahydro-5-oxa-9-aza-
  process to prepare the composition. The present disclosure additionally            benzocyclohepten-7-yl-malonamide compounds of the general Formula
  provides a therapy for control of multiresistant P. aeruginosa, or                 I, wherein the substituents are as defined in the specification,
  Acinetobacter spp. and / or methicillin - resistant S. aureus, and is useful       pharmaceutically suitable acid addition salts thereof, and optically pure
  for intramuscular or intravenous administration as antibiotics for hospi-          enantiomers, recemates or diastereomers and diastereomeric mixtures
  talized patients with acute or serious infections. The pharmaceutical com-         thereof. The compounds are useful for the treatment of Alzheimer's dis-
  positions described here have better efficacy and safety of cefepime               ease.
  plus amikacin combination.


(21) 555128       (22) 10 May 2007          (23) 29 May 2008
(54) Inductive power transfer pad and system
(51) IPC2010.01:H02J7/00
(60) 555128
(71) AUCKLAND UNISERVICES LIMITED
(72) Covic, Grant Anthony; Boys, John Talbot;
(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
tre, 342 Lambton Quay, Wellington 6011, New Zealand
(57) An inductive power transfer pad is disclosed which comprises: a coil
  having at least one turn of a conductor; one or more ferromagnetic slabs;
  and a shield member arranged around both the coil and the ferromagnetic
  slabs for channelling electromagnetic flux. When the inductive power             (21) 555187     (22) 15 May 2007       (23) 15 May 2008
  transfer pad is in use, the coil is arranged in a plane substantially parallel   (54) Weight estimation for excavator payloads
  to that of the ferromagnetic slabs.                                              (51) IPC2010.01:B60P5/00; G01G19/08,14; G01G23/01; E02F9/26
Divisional filed as 579313                                                         (71) ACTRONIC LIMITED




 PATENT OFFICE JOURNAL 1567                                          29 January 2010                                Page 99 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(72) Hsu, Hsin Pai; King, Jennifer Carol; Corder, Paul John;
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand
(57) A method for estimating weight of a payload held by a load lifting
 machine, where the load lifting machine comprises a lifting linkage with a
 boom pivotably connected to a machine chassis, a stick pivotably con-
 nected to the boom and a load holder for a payload pivotably connected
 to the stick, the boom, stick and load holder being moveable into a range
 of boom, stick and load holder angles, is disclosed. The method com-
 prises the steps of:
a) determining first, second, and third torque parameters, which are in-
 dicative of torque between the boom and the chassis during boom move-
 ment, torque generated by acceleration of the centre of mass of the lift-
 ing linkage when the load holder has a first payload, and torque gener-
 ated by acceleration of the centre of mass of the lifting linkage when the
 load holder has a second payload respectively,
b) determining a current boom angle, a current stick angle, and a current
 load holder angle,
c) estimating a payload weight by determining a relationship between the
 first torque parameter and at least two corresponding calibration torque
 parameters determined during a calibration process, where each corre-           (21) 555297       (22) 24 Nov 2005
 sponding calibration torque parameter is a torque or a parameter indica-        (54) Dental handpiece with air guide surrounding turbine housing
 tive of torque between the boom and the chassis at the current boom,            (86) PCT/CA2005/001782             (87) WO2006/056059
 stick and load holder angles, and
                                                                                 (51) IPC2010.01:A61C1/05; A61B17/16
d) using the relationship and a mass of a calibration payload to calculate a
 payload weight estimation.                                                      (71) TTI TURNER TECHNOLOGY INSTRUMENTS INC.
                                                                                 (72) Turner, Derek;
                                                                                 (31) 04 2488454           (32) 24 Nov 2004          (33) CA
                                                                                 (74) PIPERS, Level 1, 5A Pacific Rise, Mt Wellington, Auckland, New Zea-
                                                                                 land
                                                                                 (57) A dental handpiece is disclosed including a turbine construction cre-
                                                                                   ating a radial in flow of air onto the impeller blades about the whole cir-
                                                                                   cumference of the turbine. An air guide inserted into the turbine housing
                                                                                   and extending about the turbine defines a drive air supply chamber sepa-
                                                                                   rated from the turbine housing and communicating with a drive air supply
                                                                                   conduit, the air guide having a plurality of inlet openings for radially in-
                                                                                   wardly directing pressurized air from the drive air supply chamber into
                                                                                   the turbine housing onto the turbine.




(21) 555285      (22) 21 May 2007          (23) 14 Jul 2008
(54) Data switch
(51) IPC2010.01:H04L12/22; H01H23/00; H01H9/02; H01H1/38
(71) MICHEAL PADRAIC CREEL
(72) Creel, Micheal Padraic;
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,         (21) 555303     (22) 22 Dec 2005
Wellington 6011, New Zealand                                                     (54) 2,5 and 2,6-disubstituted benzazole analogues useful as protein ki-
(57) Disclosed is a data switch comprising of a first port, adapted for con-     nase inhibitors
 nection to a data source; a second port, adapted for connection to an           (86) PCT/EP2005/013922          (87) WO2006/069740
 electronic device; a third port, adapted for connection to a data storage       (51) IPC2010.01:C07D413/12; A61K31/505,52; A61P35/00; C07D403/12;
 device; and a switch device connected to the first port, the second port,       C07D417/12,14; C07D473/34; C07D277/82; C07D263/58; A61K31/
 and the third port. The switch has a first switch position and a second         423,428
 switch position, wherein the first port is connected to the third port. When    (71) 4SC AG
 the switch device is in the first switch position the first port is connected   (72) Herz, Thomas; Krauss, Rolf; Kubbutat, Michael; Lang, Martin;
 to the second port, and when the switch device is in the second switch          Schachtele, Christoph; Tasler, Stefan; Totzke, Frank;
 position the first port is isolated from the second port.



PATENT OFFICE JOURNAL 1567                                        29 January 2010                                 Page 100 |BACK TO CONTENT
                                         INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(31) 04 04030819         (32) 27 Dec 2004      (33) EP                                       ating handle 12 of polypropylene. A screw hole 28 goes through the edge
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand                            of the handle to intersect the square cavity, the cavity having a slot 32A
(57) Disclosed are benzoxazole and benzothiazole derivatives as repre-                       extending into side opposite the entry of the screw hole. A screw with
 sented by the general formula (I), wherein the substituent –Y-R1 is at-                     head 22, unthreaded shank 22a, threaded portion 22b, and lead in end
 tached to the 5- or 6-position of the benzazole moiety; X independently                     22b is inserted into the screw hole so that the thread engages and threads
 represents S, O, SO, or SO--2; Y independently represents S, O, NR2,                        the aperture in the rod end and into the plastic of the slot on the other
 SO, or SO2; and the other substituents are as defined herein. Also dis-                     side, the leading end of the screw being within the slot, and the shoulder
 closed is a composition containing a compound as defined above (which                       29 between the shank 36 and the threaded portion of the screw is screwed
 may additionally include an adjuvant and/or an additive). Further dis-                      up tight against the shoulder 28a in the hole.
 closed is the use of a compound as defined above for the preparation of
 a pharmaceutical composition for treating, relieving, and/or preventing
 cancer, or for the treatment of diseases which are cured or relieved by
 the inhibition of one or several kinases.




(21) 555326        (22) 6 Dec 2005
(54) Novel anthranilic acid derivative or salt thereof
(86) PCT/JP2005/022367                 (87) WO2006/062093
(51)                    IPC2010.01:C07C233/55;                               A61K31/
18,196,341,343,357,36,381,40,42,426,427,428,433,44,4402,4406,4409,4436,4439,451,455,5377;
A61P19/02; A61P35/00; A61P43/00; C07C233/63,81; C07C235/24;
C07C311/13,21; C07C317/50; C07C323/63; C07D207/327; C07D209/
08,34; C07D211/14,32,70; C07D213/55,56,81,82; C07D249/18; C07D257/
04; C07D261/18; C07D277/66,68; C07D285/10; C07D307/54,68,79,81;
C07D317/62,68; C07D319/18; C07D333/38,60,68; C07D401/04;                                    (21) 555458      (22) 27 Dec 2005
C07D407/12; C07D409/04,14; C07D417/12                                                       (54) A device for total spinal disc replacement
(71) TOYAMA CHEMICAL CO., LTD.                                                              (86) PCT/CH2005/000776             (87) WO2006/069464
(72) Yokotani, Junichi; Taniguchi, Yoichi; Hara, Eiji; Akitsu, Hitoshi; Tada,               (51) IPC2010.01:A61F2/46,44
Yukie;                                                                                      (71) SYNTHES GMBH
(31) 04 353725 (32) 7 Dec 2004                   (33) JP                                    (72) Lechmann, Beat; Frigg, Robert; Pavlov, Paul, W.; Buerki, Roger;
(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-                                Feigenwinter, Gregor; Appenzeller, Andreas;
tre, 342 Lambton Quay, Wellington 6011, New Zealand                                         (31) 04 2160 (32) 28 Dec 2004               (33) CH
(57) The disclosure relates to an anthranilic acid derivative of the general                (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
  formula (I), wherein the substituents are defined in the specification or a               tre, 342 Lambton Quay, Wellington 6011, New Zealand
  salt of the derivative. Also disclosed is the derivative or salt’s usefulness
                                                                                            (57) Provided is an intervertebral prosthesis comprising: A) a first pros-
  as a MMP-13 production inhibitor and its usefulness as a therapeutic
                                                                                              thetic component having a first apposition surface disposed transversely
  agent for articular rheumatism, osteoarthritis and cancer.
                                                                                              to the central axis for contacting the end plate of a first adjoining verte-
                                                                                              bral body; B) a second prosthetic component having a second apposi-
                                                                                              tion surface disposed transversely to the central axis for contacting the
                                                                                              end plate of a second adjoining vertebral body; whereby C) said first and
                                                                                              second prosthetic components are connected by means of an articula-
                                                                                              tion; whereby D) when viewed parallel to said central axis said first and
                                                                                              second prosthetic components have an elongated shape with a major
                                                                                              axis and a transverse minor axis; E) said central axis, major axis and
                                                                                              transverse minor axis intersecting each other and said central axis and
                                                                                              transverse minor axis defining a middle plane; F) said first and second
                                                                                              prosthetic component have a cross-sectional area orthogonal to said
                                                                                              central axis, which is substantially oval or elliptical; whereby G) said cross-
                                                                                              sectional area comprises at least two concavities lying on different sides
                                                                                              of said middle plane and on the same side of said major axis


                                                                                            (21) 555491     (22) 2 Jan 2006
(21) 555429      (22) 5 Jan 2006                                                            (54) Aryl piperazine derivatives for the treatment of neuropsychiatric dis-
(54) Polypropylene recliner handle with locking means                                       orders
(86) PCT/US2006/000387           (87) WO2006/081050                                         (86) PCT/EP2006/050001           (87) WO2006/072608
(51) IPC2010.01:G05G1/04; A47C7/00                                                          (51) IPC2010.01:C07D401/12; A61K31/44,47; A61P25/00; C07D403/14;
(71) LA-Z-BOY INCORPORATED                                                                  C07D405/12; C07D487/04
(72) Lapointe, Larry, P.;                                                                   (71) UNIVERSITA DEGLI STUDI DI SIENA
(31) 05 041615 (32) 24 Jan 2005          (33) US                                            (72) Campiani, Giuseppe; Butini, Stefania; Fattorusso, Caterina; Trotta,
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand                           Francesco; Franceschini, Silvia; De Angelis, Meri; Nielsen, Karin Sandager;
(57) The squared end of a drive rod 20 of a reclining chair operating mecha-                (31) 05 00004 (32) 3 Jan 2005            (33) DK
  nism is inserted into a square cavity 30 in the side of an end 16 of oper-                (31) 05 641006 (32) 4 Jan 2005           (33) US




 PATENT OFFICE JOURNAL 1567                                                  29 January 2010                                   Page 101 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand                  ber for being accelerated in a longitudinal direction to accrue kinetic en-
(57) Disclosed is an aryl piperazine derivative represented by Formula (I)         ergy for transfer of the kinetic energy to the elongate object to be driven
 an enantiomer thereof or a mixture of its enantiomers, or a                       as an impact force, a force transfer assembly for locating with the end of
 pharmaceutically acceptable salt thereof, wherein the substituents are            the elongate object and allow for effective transfer of energy from the
 described in the specification. Also disclosed is the use of formula I for        impactor member to the object being driven, and an angle compensation
 the manufacture of a pharmaceutical composition for the treatment, pre-           arrangement for compensating for the oblique angle between the impact
 vention or alleviation of a disease or a disorder or a condition of a mam-        surface of the elongate object and the normal to the longitudinal axis of
 mal, including a human, which disease, disorder or condition is respon-           the elongate object to facilitate transfer of the kinetic energy of the impactor
 sive to modulation of the dopamine and serotonin receptors.                       member to the elongate object in order to drive the elongate object in a
                                                                                   direction parallel to the direction of its longitudinal axis. The angle com-
                                                                                   pensation arrangement is an angle joint which allows the force transfer
                                                                                   assembly to be abutted against the impact surface of the elongate ob-
                                                                                   ject. Other arrangements are also disclosed.




(21) 555501     (22) 22 Nov 2005
(54) Compositions comprising azelastine and methods of use thereof
(86) PCT/US2005/042362          (87) WO2006/058022
(51) IPC2010.01:A61K47/32
(71) MEDPOINTE HEALTHCARE INC.
(72) Dang, Phuong Grace; Lawrence, Brian D.; Balwani, Gul; D’Addio,
Alexander D.;
(31) 04 630274 (32) 24 Nov 2004         (33) US
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand
(57) Provided is a pharmaceutical composition comprising azelastine hy-
 drochloride, at a concentration of about 0.005% to about 5.0% by weight,
 and one of more pharmaceutically acceptable carriers or excipients com-
 prising sucralose at a concentration of from about 0.001% to about 1%
 (w/v), Further provided are uses of such formulations in the production
 of medicaments for the treatment of snoring, rhinitis and allergic con-
 junctivitis.


(21) 555503     (22) 12 Dec 2005
(54) Therapeutic formulations of keratinocyte growth factor
(86) PCT/US2005/045169           (87) WO2006/065861
(51) IPC2010.01:A61K38/18; A61K47/18,26                                           (21) 555595      (22) 31 May 2007        (23) 16 May 2008
(71) BIOVITRUM AB (publ)                                                          (54) Orchid sleeving apparatus
(72) Treuheit, Michael, J.; Dharmavaram, Vasumathi; Purtell, Judith; Roy,         (51) IPC2010.01:A01G5/00; B65B25/02
Suzanne, E.;                                                                      (71) AIRBORNE CYMBIDIUM LIMITED
(31) 04 636210 (32) 15 Dec 2004         (33) US                                   (72) Floyd, Ian Ronald;
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,          (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand                                                      Wellington 6011, New Zealand
(57) Provided is a lyophilized keratinocyte growth factor (KGF) composi-          (57) Apparatus suitable for or for assisting the sleeving or bagging of cut
 tion comprising KGF in a concentration between 3 mg/mL and 15 mg/                 flowers such as, for example, orchids. The apparatus includes a slide, a
 mL, mannitol at a concentration of about 2% to about 5% w/v, sucrose at           mount for the sleeve or bag at or adjacent one end of the slide, and a
 a concentration of about 1% to about 3% w/v, polysorbate 20 at a con-             drive operable to move a cut flower stem first, by acting on the stem and/
 centration within a range of about 0.1% to about 0.004% w/v and histi-            or any apparatus (e.g. vial) engaged to the stem (whether on a mat or
 dine buffer, wherein the pH is in a range of about 6.0 to about 8.0. Fur-         not), from the slide into the sleeve or bag attached to the mount so that
 ther provided is the use of the formulation in the manufacture of a medi-         the bloom of the flower is in the sleeve or bag. The mount is or includes
 cament for treatment of diseases related to KGF mediated epithelial cell          at least one of an expandable lip arrangement and/or expandable iris
 growth.                                                                           arrangement.
                                                                                  Divisional filed as 582212
(21) 555515       (22) 29 May 2007         (23) 26 May 2008
(54) Post driver hammer assembly
(51) IPC2010.01:E04H17/26; E02D7/00
(71) Ramet Holdings Limited
(72) Jowitt, William Alan; Glasson, Anthony Victor; Kennett, David;
(74) Ramet Holdings Limited, c/- Bertelsen Harry Waters Limited, 139 Great
South Road, Greenlane, Auckland, New Zealand
(57) A post driver hammer assembly for driving an elongate object into
  matter, the elongate object including an impact end having an impact
  surface that is obliquely aligned with the normal to the longitudinal axis of
  the elongate object. The hammer assembly comprises: an impactor mem-




PATENT OFFICE JOURNAL 1567                                         29 January 2010                                  Page 102 |BACK TO CONTENT
                                    INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND




                                                                                 (21) 555737      (22) 22 Dec 2005
                                                                                 (54) Heteroaromatic quinoline compounds and their use as PDE10 inhibi-
                                                                                 tors
                                                                                 (86) PCT/IB2005/003937            (87) WO2006/072828
                                                                                 (51) IPC2010.01:C07D401/14; A61K31/14; A61P25/18; C07D413/14
                                                                                 (71) Pfizer Products Inc.
                                                                                 (72) Verhoest, Patrick Robert; Helal, Christopher John; Hoover, Dennis
                                                                                 Jay; Humphrey, John Michael;
                                                                                 (31) 05 642058 (32) 7 Jan 2005            (33) US
                                                                                 (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Cen-
                                                                                 tre, 342 Lambton Quay, Wellington 6011, New Zealand
                                                                                 (57) Disclosed are heteroaromatic compounds of formula I, wherein Z is
                                                                                   as pictured and the remaining substituents are as defined in the specifi-
(21) 555694       (22) 7 Dec 2005                                                  cation. The compounds are effective phosphodiesterase (PDE) inhibi-
(54) Cellulosic staple fiber and its use as a filling material                     tors, and in particular, the compounds are selective inhibitors of PDE10.
(86) PCT/AT2005/000493              (87) WO2006/060835                             Also disclosed are intermediates for preparation of said compounds; phar-
(51) IPC2010.01:D01F2/06; B68G1/00; D01D5/253; D01F2/10                            maceutical compositions comprising said compounds; and the use of
(71) LENZING AKTIENGESELLSCHAFT                                                    said compounds in a method for treating certain central nervous system
(72) Kroner, Gert; Firgo, Heinrich; Manner, Johann; Sulek, Peter;                  (CNS) or other disorders.
(31) 04 2083 (32) 10 Dec 2004               (33) AT
(31) 05 256       (32) 17 Feb 2005          (33) AT
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand
(57) The disclosure relates to the use of a multilobal cellulosic staple
 fiber as a filling fiber. Furthermore, the disclosure relates to a cellulosic
 staple fiber which is characterized in that
 - the cross-section of the fiber has three or more lobes,
 - the cross-section of the fibers is substantially the same throughout
 the plurality of the fibers,
 - the titer of the fiber is 1.0 to 30 dtex, preferably more than 3.0 dtex,
 especially more than 5.0 dtex, preferably 5.6 to 10 dtex, especially
 preferred more than 6.0 dtex, especially 6.3 to 10 dtex,
 - the wet modulus of the fiber fulfils the following formula: Wet modulus
 (cN/tex) is greater or equal to 0.5*square root of T wherein T is the titer
 of the fiber in dtex,
 - the breaking strength of the fiber in the conditioned state fulfils the
 following formula: Breaking Strength (cN/tex) is greater or equal to
 1.3*square root of T + 2*T wherein T is the titer of the fiber in dtex.
 This multilobal cellulosic staple fiber is suitable as a filling material for
 duvets, cushions, pillows, mattresses, clothing and fleeces for
 upholstery.


(21) 555695      (22) 21 Dec 2005                                                (21) 555748      (22) 2 Dec 2005
(54) Improved structural sandwich plate members                                  (54) Self-sealing male luer connector with multiple seals
(86) PCT/GB2005/004965           (87) WO06/067433                                (86) PCT/US2005/043973          (87) WO2006/062912
(51) IPC2010.01:B32B15/08                                                        (51) IPC2010.01:A61M39/10,04,26
(71) INTELLIGENT ENGINEERING (BAHAMAS) LIMITED                                   (71) CARDINAL HEALTH 303, INC.
(72) Kennedy, Stephen John;                                                      (72) Whitley, Kenneth;
(31) 04 0428251          (32) 23 Dec 2004         (33) GB                        (31) 04 9444 (32) 10 Dec 2004            (33) US
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,         (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand                                                     Wellington 6011, New Zealand
(57) A structural sandwich plate member 10 comprising first and second           (57) A self-sealing male connector 10 for connection with a female con-
  outer plates 11 12 with perimeter members 14 between the first and               nector , the male connector 10 comprising a rigid housing 12 having a
  second outer plates 11 12 forming a cavity, sealant strips or gaskets 17         distal end 54 and a proximal end, the housing 12 comprising at the distal
  18 between the perimeter members 14 and the first and second outer               end 54 a rigid tubular male portion having a shape selected for engage-
  plates 11 12, and a core of compact plastics or polymer material 13 in the       ment with a female connector, a distal valve located at the distal end of
  cavity and bonded to the outer plates 11 12 so as to transfer shear forces       the housing 12, the distal valve comprising an internal valve seat dis-
  there between, wherein the sealant strips or gaskets 17 18 have adhe-            posed in the tubular male portion, a proximal valve located at the proxi-
  sive on one side only so as to be adhered to only one of either (i) the          mal end of the housing 12, and a rigid actuator 36 movably disposed
  perimeter members 14, or (ii) the first or second outer plates 11 12.
Divisional filed as 582147



 PATENT OFFICE JOURNAL 1567                                        29 January 2010                                Page 103 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


 within the housing 12 for movement toward the proximal end of the hous-        (21) 555843      (22) 16 Dec 2005
 ing 12 to open both the distal and proximal valves, the actuator 36 com-       (54) Methods and models for cholesterol metabolism
 prising a rigid actuator arm disposed adjacent and wholly outside the          (86) PCT/US2005/045520            (87) WO2006/066051
 tubular male portion and extending axially in a proximal to distal direction   (51) IPC2010.01:G06F17/10; G06F7/60; G06F19/00
 wherein movement of the actuator arm towards the proximal end of the           (71) ENTELOS, INC.
 housing 12 will cause the actuator 36 to move towards the proximal end
 of the housing 12 and open both the distal and proximal valves, whereby        (72) Balgi, Ganesh; Kadambi, Ananth; Paterson, Thomas S;
 as a female connector is engaged with the tubular male portion, the            (31) 04 637106 (32) 16 Dec 2004            (33) US
 female connector will move the actuator arm towards the proximal end           (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
 of the housing 12 thereby opening both the distal and proximal valves,         Wellington 6011, New Zealand
 and wherein the actuator 36 comprises a distal end and a proximal end,         (57) A system comprising a processor; computer-readable instructions that,
 the proximal end comprising a piercing element 50 located so as to pierce        upon execution by the processor, cause the processor to simulate cho-
 the proximal valve upon movement of the actuator 36 in the proximal              lesterol metabolism in an animal; a first user terminal; and a second user
 direction.                                                                       terminal is provided. The computer readable instructions include: i) math-
                                                                                  ematically representing one or more biological processes associated with
                                                                                  lipoprotein particles; ii) mathematically representing one or more biologi-
                                                                                  cal processes associated with lipid flux; and iii) defining a set of math-
                                                                                  ematical relationships between the representations of biological proc-
                                                                                  esses associated with lipoprotein particles and representations of bio-
                                                                                  logical processes associated with lipid flux; iv) applying a virtual protocol
                                                                                  to the set of mathematical relationships to generate a set of outputs. The
                                                                                  first user terminal is operable to receive a user input specifying one or
                                                                                  more parameters associated with one or more mathematical represen-
                                                                                  tations defined by the computer readable instructions. The second user
                                                                                  terminal is operable to provide the set of outputs to a second user.


                                                                                (21) 555852      (22) 17 Jan 2006
                                                                                (54) Use of oxycodone for treating visceral pain
                                                                                (86) PCT/EP2006/050252            (87) WO2006/077212
                                                                                (51) IPC2010.01:A61K31/485; A61K9/20; A61P25/04
                                                                                (71) EURO-CELTIQUE S.A.
                                                                                (72) Drewes, Asbjorn Mohr; Nielsen, Lars Arendt;
                                                                                (31) 05 645490 (32) 18 Jan 2005           (33) US
                                                                                (74) F B RICE & CO, Level 23, 200 Queen Street, Melbourne, Victoria
                                                                                3000, Australia
                                                                                (57) Disclosed is the use of oxycodone or a pharmaceutically acceptable
                                                                                 salt thereof for the manufacture of a medicament for treating visceral
                                                                                 pain, wherein oxycodone or its pharmaceutically acceptable salt alone is
                                                                                 suitable for effectively treating visceral pain. It is possible to effectively
                                                                                 treat moderate to severe visceral pain by administering analgesic medi-
                                                                                 cations comprising the opioid oxycodone or pharmaceutically accept-
                                                                                 able salts thereof. Visceral pain and especially acute (i.e. non-chronic)
                                                                                 visceral pain can be effectively treated by administering oxycodone at a
(21) 555769      (22) 22 Dec 2005                                                dosage which is lower than the corresponding dosage of other opioids
(54) Process for preparing rosuvastatin                                          like morphine.
(86) PCT/GB2005/004999           (87) WO2006/067456
(51) IPC2010.01:C07D239/36,42
(71) ASTRAZENECA UK LIMITED                                                     (21) 556034      (22) 14 Nov 2005
(72) Butters, Michael; Lenger, Steven Robert; Murray, Paul Michael; Snape,      (54) Wind-air engine, namely engine using wind and air pressure as en-
Evan William;                                                                   ergy to replace fuel
(31) 04 0428328          (32) 24 Dec 2004         (33) GB                       (86) PCT/CN2005/001911          (87) WO2006/053484
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand               (51) IPC2010.01:F03D9/00,02
(57) A process for formation of a compound of formula (I) or a                  (71) Yang Cong
  pharmaceutically acceptable salt thereof, via a Heck reaction is disclosed,   (72) Cong, Yang;
  wherein the variables shown in formula (I) are as defined in the specifi-     (31) 04 0410091154 (32) 22 Nov 2004            (33) CN
  cation. Intermediates useful in the process and processes for making          (31) 05 0510090760 (32) 16 Aug 2005            (33) CN
  said intermediates are also described.                                        (31) 05 0510117451 (32) 2 Nov 2005             (33) CN
                                                                                (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
                                                                                Wellington 6011, New Zealand
                                                                                (57) A wind-air engine and a motor vehicle including a wind-air engine, is
                                                                                 disclosed. The wind-air engine comprises at least one impeller chamber,
                                                                                 at least one impeller disposed in the impeller chamber, and an air-jet
                                                                                 system for jetting high-pressure compressed air (HPCA) into the impeller
                                                                                 chamber. The impeller chamber comprises an air inlet for receiving ex-
                                                                                 ternal wind resistance airflow. The HPCA jetted by the air-jet system in
                                                                                 conjunction with the external wind resistance airflow enters the air inlet
                                                                                 and drives the impeller to generate power output.




PATENT OFFICE JOURNAL 1567                                       29 January 2010                                  Page 104 |BACK TO CONTENT
                                 INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


                                                                            (21) 556103      (22) 22 Jun 2007         (23) 20 Jun 2008
                                                                            (54) Adjustable work surface with slippable belt drive
                                                                            (51) IPC2010.01:A47B21/00
                                                                            (71) Dexion Commercial (New Zealand) Limited
                                                                            (72) McGowan, Neil Dwayne; Curd, Mitchell James; Couch, Simon Ashley;
                                                                            Jones, David Matthew; Roberts, Dean Andrews; Billing, Todd David;
                                                                            (74) ELLIS TERRY, Level 12, 45 Johnston Street, Wellington 6011, New
                                                                            Zealand
                                                                            (57) The position of the working surface of a work desk or table is adjust-
                                                                              able by one or more adjusting arrangements which are driven via a belt
                                                                              transmission by a drive mechanism. The belt transmission includes a
                                                                              preferably toothed belt 28 connecting a drive gear or pulley 21 receiving
                                                                              power from the drive mechanism and one or more adjustment gears
                                                                              and/or pulleys 30, 31, 32 of the adjustment mechanism. The belt is
                                                                              configured to slip on at least one of the gears and/or pulleys, preferably
                                                                              on the drive gear 21, when overloaded so that the mechanisms are not
                                                                              damaged. The tension of the belt can be adjusted by a tensioning ar-
                                                                              rangement such as being able to move the position of the idler pulleys.




(21) 556087      (22) 1 Dec 2005
(54) An automated window system with an overcentre drive mechanism
(86) PCT/AU2005/001811          (87) WO2006/058376
(51) IPC2010.01:E06B7/096,08
(71) Breezway Australia Pty Ltd
(72) Alexander, Edwin John;
(31) 05 901980 (32) 20 Apr 2005         (33) AU
(31) 04 906883 (32) 2 Dec 2004          (33) AU
(74) CULLEN & CO, Level 32, 239 George Street, Brisbane, QLD 4001,
Australia
(57) Disclosed is a drive mechanism for a louvre window system. The
  drive mechanism includes an operating bar adapted to open and close
  the louvres by its movement, a drive wheel means and at least one link
  member associated with the wheel means and the operating bar. The
  link member is attached such that linear movement of the operating bar
  decreases for a unit radial movement of the wheel means during a pe-
  riod when increase load is experienced in the louvre opening or closing
  sequence.                                                                 (21) 556147        (22) 9 Jan 2006
Divisional filed as 580229                                                  (54) Novel process for the preparation of substituted indoles
                                                                            (86) PCT/GB2006/000060             (87) WO2006/075139
                                                                            (51) IPC2010.01:C07D209/30
                                                                            (71) ASTRAZENECA AB
                                                                            (72) Keegan, Philip; Gill, Duncan; Merifield, Eric;
                                                                            (31) 05 0500604            (32) 13 Jan 2005        (33) GB
                                                                            (74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
                                                                            (57) Disclosed is a process which comprises reaction of a compound of
                                                                              formula (VIII), in which R is hydrogen or an ester forming group, with a
                                                                              compound of formula (VII), in which R1 is chloro or a group that can be
                                                                              converted to chloro.
                                                                            Also disclosed is a process which comprises reaction of a compound of
                                                                              formula (IX), in which R is hydrogen or an ester forming group, with a
                                                                              compound of formula (VII).
                                                                            Also disclosed is a process which comprises reducing a compound of
                                                                              formula (III) with sodium dithionite or by hydrogenation followed by amide
(21) 556095     (22) 15 Jun 2005                                              formation.
(54) Fixed dosing of her antibodies
(86) PCT/US2005/021287         (87) WO2006/078307
(51) IPC2010.01:A61K39/395; C07K16/32
(71) GENENTECH, INC.
(72) Allison, David E; Bruno, Rene; Lu, Jian-Feng; Ng, Chee M;
(31) 05 645697 (32) 21 Jan 2005         (33) US
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand
(57) Provided is a use of at least one fixed dose of pertuzumab in the
 preparation of a medicament for the treatment of cancer in a human
 patient, wherein the fixed dose is selected from the group consisting of
 approximately 420mg, approximately 525mg, approximately 840mg, and
 approximately 1050mg of pertuzumab. Further provided are correspond-
 ing pharmaceutical formulations and kits.




 PATENT OFFICE JOURNAL 1567                                    29 January 2010                               Page 105 |BACK TO CONTENT
                                   INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND


                                                                               (72) Coates, Michael John; Watt, Mark; Kloss, Guy Kristoffer; Johnson,
                                                                               Martin;
                                                                               (74) JAMES & WELLS, Level 12, KPMG Centre, 85 Alexandra Street,
                                                                               Hamilton, New Zealand
                                                                               (57) A method of tracking objects within an object transportation system
                                                                                comprises a) providing an object identification code for an object; b) cap-
                                                                                turing visual identification information for the object at a first location
                                                                                within the system; c) relating the visual identification information cap-
                                                                                tured at the first location with the object identification code; d) capturing
                                                                                visual identification information at a second location within the system;
                                                                                e) comparing the visual identification information captured at the second
                                                                                location to the visual identification information captured at the first loca-
                                                                                tion; and f) relating the visual identification information captured at the
                                                                                second location to the object identification code if the visual identification
                                                                                information captured at the first and second locations meet predefined
                                                                                comparison criteria. A baggage tracking apparatus comprises a conveyer
                                                                                to convey the object; a first camera (16a) to capture visual identification
                                                                                information for the object at a first location of the conveyer; a second
                                                                                camera (16b) to capture visual identification information for the object at
                                                                                a second location of the conveyer; a scanner (21) to provide an object
                                                                                identification code for the object; and a computer server adapted to carry
                                                                                out the above described method of tracking objects.



(21) 556191     (22) 11 Jan 2006
(54) Improvements to tubular electrical generators
(86) PCT/GB2006/000082           (87) WO2006/075147
(51) IPC2010.01:H02K41/03; H02K35/00
(71) TRIDENT ENERGY LIMITED
(72) Kelly, Hugh-Peter Granville;
(31) 05 0500507          (32) 11 Jan 2005        (33) GB
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square,
Wellington 6011, New Zealand
(57) A linear generator having an annular armature containing coils and a
 translator containing permanent magnets is provided. The translator is
 located concentrically through the armature and which armature and trans-
 lator are movable relative to one another along a longitudinal axis. A
 magnetically permeable sleeve is affixed to and circumferentially sur-
 rounds the armature. The permeability of one or both ends of the sleeve
 is contoured around its circumference such that the variation of the lon-
 gitudinal cogging force on the sleeve in its travel with the armature rela-   (21) 556259       (22) 29 Nov 2005
 tive to the translator is reduced. The contouring of the permeability is      (54) Digital image collector for x-ray systems
 achieved by a variation in the amount of material around the circumfer-
                                                                               (86) PCT/CA2005/001804              (87) WO2006/058420
 ence of the sleeve end at one or both ends of the sleeve. Such variation
 is in the form of varying absence of sleeve material at locations around      (51) IPC2010.01:H04N5/32; A61B6/00; G01N23/04; G01T1/16,29
 the circumference of the armature. The sleeve includes or is constructed      (71) IMASCOPE INC.
 from a number of individual ferromagnetic elements for drawing out lines      (72) Caseault, Jean; Wang, Min; Thibault, Simon;
 of flux from the translator, each being of a shape and individually insu-     (31) 04 000533 (32) 1 Dec 2004              (33) US
 lated such as to eliminate substantially the circulation of eddy currents     (74) PIPERS, Level 1, 5A Pacific Rise, Mt Wellington, Auckland, New Zea-
 around and/or along the circumference sleeve.                                 land
                                                                               (57) A digital image capturer for receiving X-rays and providing digital im-
                                                                                 age data corresponding to the received X-rays is provided. The digital
                                                                                 image capturer includes a light generator for receiving the X-rays and for
                                                                                 emitting light in response to the received X-rays; a first planar reflector
                                                                                 for reflecting the emitted light; a second planar reflector positioned for
                                                                                 receiving the emitted light from the first planar reflector, and reflecting
                                                                                 the emitted light; and, a fast relay-optics system for receiving the emitted
                                                                                 light from the second planar reflector and for focusing the emitted light
                                                                                 onto a digital imaging device. The digital imaging device generates the
                                                                                 digital image data.




(21) 556253     (22) 29 Jun 2007     (23) 9 Jun 2008
(54) Object tracking method and apparatus
(51) IPC2010.01:B07C5/00; B65G43/08; B64F1/36; B65G47/50
(71) Baggage Sortation Management Limited




PATENT OFFICE JOURNAL 1567                                      29 January 2010                                  Page 106 |BACK TO CONTENT

								
To top